{"PMC7123331": [["IntroductionRegarding the global impact of public health emergencies at the international level, communicable diseases are a top priority and countries need to develop a modern system of surveillance and control of outbreaks.", [["communicable diseases", "DISEASE", 97, 118], ["communicable diseases", "PROBLEM", 97, 118], ["surveillance", "TEST", 187, 199], ["outbreaks", "PROBLEM", 215, 224], ["global", "OBSERVATION_MODIFIER", 26, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39]]], ["This has also been a priority of the public health authorities in Romania in the last 10 years and important steps have been taken in order to develop an epidemiological surveillance system based on EU standards, integrated in a national emergency system [2].OverviewRomania is a medium sized EU member state, with the ninth largest territory, and the seventh largest population.", [["OverviewRomania", "DISEASE", 259, 274], ["medium sized", "OBSERVATION_MODIFIER", 280, 292], ["largest", "OBSERVATION_MODIFIER", 360, 367], ["population", "OBSERVATION", 368, 378]]], ["The country has an area of 238,391 km2and an estimated population of 21.5 million people (2009) with a density of 90 people per km2.OverviewFrom the administrative point of view the country is divided in 41 counties and the capital Bucharest.", [["people", "ORGANISM", 82, 88], ["people", "ORGANISM", 117, 123], ["people", "SPECIES", 82, 88], ["people", "SPECIES", 117, 123], ["area", "OBSERVATION_MODIFIER", 19, 23], ["population", "OBSERVATION_MODIFIER", 55, 65]]], ["Each county has its own administrative structures including those for health and emergencies.OverviewDemographic indicators from 2008 showed a negative growth of population and a relatively high infant mortality, compared to other EU member states.", [["a negative growth of population", "PROBLEM", 141, 172], ["a relatively high infant mortality", "PROBLEM", 177, 211], ["negative growth", "OBSERVATION_MODIFIER", 143, 158]]], ["The birth rate is 10.3 per 1,000 inhabitants, the general mortality is 11.8 per 1,000 inhabitants.", [["The birth rate", "TEST", 0, 14]]], ["The infant mortality is 11 per 1,000 live births, but with a decreasing trend.", [["infant", "ORGANISM", 4, 10], ["infant", "SPECIES", 4, 10], ["a decreasing trend", "PROBLEM", 59, 77]]], ["Life expectancy is 73.3 years (69.7 years for men and 77.4 years for women).", [["men", "ORGANISM", 46, 49], ["women", "ORGANISM", 69, 74], ["men", "SPECIES", 46, 49], ["women", "SPECIES", 69, 74]]], ["The main diseases as causes of death are listed in Table 15.1.", [["death", "DISEASE", 31, 36], ["The main diseases", "PROBLEM", 0, 17], ["death", "PROBLEM", 31, 36], ["main", "OBSERVATION_MODIFIER", 4, 8], ["diseases", "OBSERVATION", 9, 17]]]], "67e0237592a7c1f41f0d7e6939ced99e270a34c1": [["v200603.1DisclaimersThe findings and conclusions in this report have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy.DisclaimersThe protocols described here are for research purposes only and should not be used in place of approved diagnostic testing.Disclaimersv200603.1Application NotesValidation specimen submission extraction, and quantitation v200603.1Singleplex nested RT-PCR Protocol NotesTo complete this protocol, 190 uL of extracted template is needed.", [["v200603.1", "CHEMICAL", 0, 9], ["Disease Control", "TREATMENT", 119, 134], ["research purposes", "TEST", 274, 291], ["diagnostic testing", "TEST", 341, 359], ["specimen submission extraction", "TEST", 408, 438], ["quantitation", "TEST", 444, 456], ["this protocol", "TREATMENT", 517, 530], ["extracted template", "TREATMENT", 542, 560]]], ["For samples between Ct 27 and 35, two rounds of nested RT-PCR are recommended; for samples up to Ct 27, one round of RT-PCR is recommended.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 83, 90], ["Ct", "TEST", 20, 22], ["nested RT-PCR", "TREATMENT", 48, 61], ["samples", "TEST", 83, 90], ["Ct", "TEST", 97, 99], ["RT-PCR", "TEST", 117, 123]]], ["The resulting PCR products can be individually proceeded with Sanger sequencing, or they can be pooled for Oxford Nanopore or Illumina sequencing, depending on the number of samples and availability of sequencing platforms.Generate consensus sequences from MinION dataThere are many considerations for generating high-quality consensus data from the MinION.", [["samples", "ANATOMY", 174, 181], ["PCR products", "DNA", 14, 26], ["consensus sequences", "DNA", 232, 251], ["MinION", "DNA", 350, 356], ["The resulting PCR products", "TREATMENT", 0, 26], ["Sanger sequencing", "TEST", 62, 79], ["Oxford Nanopore", "TREATMENT", 107, 122], ["Illumina sequencing", "TREATMENT", 126, 145], ["sequencing platforms", "TEST", 202, 222]]], ["Here are some suggestions for basecalling based on our experience.Filter on quality and lengthFiltering out low quality sequence, as well as unexpectedly long and short reads helps tremendously on off-target mapping affecting consensus quality.", [["Filter", "TREATMENT", 66, 72]]], ["BAMClipper by default will output at file with the suffix \"primerclipped.bam.\"", [["BAMClipper", "CHEMICAL", 0, 10], ["BAMClipper", "SIMPLE_CHEMICAL", 0, 10]]], ["Clipping by position allows only primers near the beginning of a read to be trimmed (rather than genuine sequence in the middle of a read), and it is faster than sequence-based trimming (e.g. Porechop).", [["Clipping", "TREATMENT", 0, 8], ["primers", "TREATMENT", 33, 40], ["genuine sequence", "TEST", 97, 113]]], ["(3, 9, 15, 33bp, 384bp, etc) , so keep in mind the difference between a potential real indel and missing amplicon or nanopore error.", [["bp", "TEST", 13, 15], ["bp", "TEST", 20, 22], ["a potential real indel", "PROBLEM", 70, 92], ["missing amplicon or nanopore error", "PROBLEM", 97, 131]]], ["IGV can be useful for examining the \"believability\" of variants However, some of these 1-2bp indels appear in the reads, but they cannot be confirmed by Illumina or Sanger sequencing.", [["Sanger sequencing", "TEST", 165, 182]]], ["These are either unlucky PCR bias or systematic sequencing error.Filter on quality and lengthv200603.1Illumina Library Preparation and Sequencing Protocol NotesStarting Material: 100 pg-250 ng DNA.", [["DNA", "CELLULAR_COMPONENT", 193, 196], ["systematic sequencing error", "PROBLEM", 37, 64], ["Illumina Library Preparation", "TREATMENT", 102, 130], ["Material", "TEST", 169, 177]]], ["We recommend that the DNA be in 1X TE (10 mM Tris pH 8.0, 1 mM EDTA), however, 10 mM Tris pH 7.5-8, low EDTA TE or water are also acceptable.", [["EDTA", "CHEMICAL", 63, 67], ["Tris", "CHEMICAL", 85, 89], ["EDTA", "CHEMICAL", 104, 108], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["EDTA TE", "SIMPLE_CHEMICAL", 104, 111], ["water", "SIMPLE_CHEMICAL", 115, 120], ["the DNA", "TEST", 18, 25], ["mM Tris pH", "TEST", 42, 52], ["1 mM EDTA", "TEST", 58, 67], ["mM Tris pH", "TEST", 82, 92], ["low EDTA TE", "TREATMENT", 100, 111]]], ["If the input DNA is less than 26 \u00b5l, add TE (provided) to a final volume of 26 \u00b5l.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["the input DNA", "TEST", 3, 16], ["a final volume", "TEST", 58, 72]]], ["This protocol is adapted from the NEBNext Ultra II FS protocol, which can be found in its entirety at http://www.neb.com.Illumina Library Preparation and Sequencing Protocol NotesFor sizing, other devices, such as the 2100 BioAnalyzer, 5200 FragmentAnalyzer, QIAxcel, or LabChipGX may also be used.", [["This protocol", "TREATMENT", 0, 13], ["the NEBNext Ultra II FS protocol", "TREATMENT", 30, 62], ["Library Preparation", "TREATMENT", 130, 149], ["FragmentAnalyzer", "TEST", 241, 257], ["QIAxcel", "TREATMENT", 259, 266], ["LabChipGX", "TREATMENT", 271, 280]]], ["These vary in quantitation accuracy, so fluorometric quantitation with Qubit (or similar instrument) or qPCR is recommended.", [["quantitation accuracy", "TEST", 14, 35], ["fluorometric quantitation", "TEST", 40, 65], ["qPCR", "TEST", 104, 108]]], ["Primers are added to each PCR reaction (PCR1-PCR38) prior to adding RNA.", [["PCR1", "DNA", 40, 44], ["PCR38", "DNA", 45, 50], ["each PCR reaction", "TEST", 21, 38], ["PCR1", "TEST", 40, 44]]], ["The layout stays the same until sequencing reactions are run.Required ReagentsWe recommend making PCR primer plates (R1 and R2) in the same format so that primers may be added by multichannel pipetting. *This amplicon is intentionally doubled due to its reduced efficiency-add 2 parts of this primer set to the pool.Appendix D -Multiplex PCR PrimersPool 1 Pool 2 PCR Name Sequence PCR Name Sequence 1 SC2M1-1_LEFT_31 ACCAACCAACTTTCGATCTCTTGT 2 SC2M1-2_LEFT_445 TTTGCCTCAACTTGAACAGCCC SC2M1-1_RIGHT_574 TGTCTCACCACTACGACCGTAC SC2M1-2_RIGHT_965 GTTCACGGCAGCAGTATACACC 5 SC2M1-5_LEFT_1706 TCTGCTTCCACAAGTGCTTTTGT 6 SC2M1-6_LEFT_2138 AAACCCGTCCTTGATTGGCTTG SC2M1-5_RIGHT_2266 ACAGGTGACAATTTGTCCACCG SC2M1-6_RIGHT_2642 TTTCGAGCAACATAAGCCCGTT 9 SC2M1-9_LEFT_3306 TGGAACTTACACCAGTTGTTCAGAC 10 SC2M1-10_LEFT_3715 AGCTGGTATTTTTGGTGCTGACC SC2M1-9_RIGHT_3878 CAGCGATCTTTTGTTCAACTTGCT SC2M1-10_RIGHT_4262 CCTGACCCGGGTAAGTGGTTAT 13 SC2M1-13_LEFT_4885 TCCTACCACATTCCACCTAGATGG 14 SC2M1-14_LEFT_5258 ACTTCTATTAAATGGGCAGATAACAACTGT SC2M1-13_RIGHT_5400 GCACAAAAGTTAGCAGCTTCACC SC2M1-14_RIGHT_5818 AGCACCGTCTATGCAATACAAAGT 17 SC2M1-17_LEFT_6408 CTGAAGAAGTAGTGGAAAATCCTACCA 18 SC2M1-18_LEFT_6748 AAACCGTGTTTGTACTAATTATATGCCTT SC2M1-17_RIGHT_6903 GCCTCTAGACAAAATTTACCGACACT SC2M1-18_RIGHT_7255 TGCCAAAAACCACTCTGCAACT 21 SC2M1-21_LEFT_8004 TTGGTGATAGTGCGGAAGTTGC 22 SC2M1-22_LEFT_8407 CGTTAAAGATTTCATGTCATTGTCTGAACA SC2M1-21_RIGHT_8553 CCACCCTTAAGTGCTATCTTTGTTGT SC2M1-22_RIGHT_8913 TGCAAAAAGTCACCATTAGTTGTGC 25 SC2M1-25_LEFT_9551 CCAGTTTACTCATTCTTACCTGGTGT 26 SC2M1-26_LEFT_9903 AGTACAAGTATTTTAGTGGAGCAATGGA SC2M1-25_RIGHT_10061 AACCACTCTGCAAAACAGCTGA SC2M1-26_RIGHT_10451 TGGGCCTCATAGCACATTGGTA 29 SC2M1-29_LEFT_11047 AGTCCAGAGTACTCAATGGTCTTTGT 30 SC2M1-30_LEFT_11400 TGAATGTCTTGACACTCGTTTATAAAGTT SC2M1-29_RIGHT_11541 ACAATACCTCTGGCCAAAAACATGA SC2M1-30_RIGHT_11944 CTGGACACATTGAGCCCACAAT 33 SC2M1-33_LEFT_12557 ATCCAACAGGTTGTAGATGCAGAT 34 SC2M1-34_LEFT_13006 TGCCACAGTACGTCTACAAGCT SC2M1-33_RIGHT_13136 TTGGTTGTCCCCCACTAGCTAG SC2M1-34_RIGHT_13501 GTGTAAGACGGGCTGCACTTAC 37 SC2M1-37_LEFT_14103 TTTCATACAAACCACGCCAGGT 38 SC2M1-38_LEFT_14480 ACTTCAGAGAGCTAGGTGTTGTACA SC2M1-37_RIGHT_14641 GTGCAGCTACTGAAAAGCACGT SC2M1-38_RIGHT_15027 TGCGAAAAGTGCATCTTGATCCT 41 SC2M1-41_LEFT_15637 AGAAATAGAGATGTTGACACAGACTTTGT 42 SC2M1-42_LEFT_16065 GGAGTATGCTGATGTCTTTCATTTGTAC SC2M1-41_RIGHT_16208 GCCTCATAAAACTCAGGTTCCCA SC2M1-42_RIGHT_16648 GCGTTTCTGCTGCAAAAAGCTT 45 SC2M1-45_LEFT_17317 AATGCATTGCCTGAGACGACAG 46 SC2M1-46_LEFT_17752 TGGAGAAAAGCTGTCTTTATTTCACCT SC2M1-45_RIGHT_17903 CAAGAGTGAGCTGTTTCAGTGGT SC2M1-46_RIGHT_18275 GCTTCTTCGCGGGTGATAAACA 49 SC2M1-49_LEFT_18897 TGTTAAGCGTGTTGACTGGACT 50 SC2M1-50_LEFT_19311 TGCATTCCACACACCAGCTTTT SC2M1-49_RIGHT_19484 GCACCACCTAAATTGCAACGTG SC2M1-50_RIGHT_19866 ATTAGCAGCAATGTCCACACCC 53 SC2M1-53_LEFT_20554 TCTGTAGTTTCTAAGGTTGTCAAAGTGA 54 SC2M1-54_LEFT_20990 TGATTGGTGATTGTGCAACTGTACA SC2M1-53_RIGHT_21144 AGCTAGCTTTTGTTGTATAAACCCACA SC2M1-54_RIGHT_21562 TGTTCGTTTAGTTGTTAACAAGAACATCA 57 SC2M1-57_LEFT_22203 GTGATCTCCCTCAGGGTTTTTCG 58 SC2M1-58_LEFT_22563 ACTTGTGCCCTTTTGGTGAAGT SC2M1-57_RIGHT_22697 ACTTAAAAGTGGAAAATGATGCGGAA SC2M1-58_RIGHT_23128 TGCTGGTGCATGTAGAAGTTCA 61 SC2M1-61_LEFT_23737 AATTCTACCAGTGTCTATGACCAAGAC 62 SC2M1-62_LEFT_24095 GCTGCTAGAGACCTCATTTGTGC SC2M1-61_RIGHT_24231 GCACCAAAGGTCCAACCAGAAG SC2M1-62_RIGHT_24623 AAGCTCTGATTTCTGCAGCTCT 65 SC2M1-65_LEFT_25214 CTAGGTTTTATAGCTGGCTTGATTGC 66 SC2M1-66_LEFT_25665 CTCACACCTTTTGCTCGTTGCT SC2M1-65_RIGHT_25790 CATTTCCAGCAAAGCCAAAGCC SC2M1-66_RIGHT_26224 GTGCTTACAAAGGCACGCTAGT 69 SC2M1-69_LEFT_26877 CTTCTCAACGTGCCACTCCATG 70 SC2M1-70_LEFT_27254 TTATGAGGACTTTTAAAGTTTCCATTTGGA SC2M1-69_RIGHT_27432 AGCGAGTGTTATCAGTGCCAAG SC2M1-70_RIGHT_27808 AGCAGAAAGGCTAAAAAGCACAAA 73 SC2M1-73_LEFT_28525 TGGCTACTACCGAAGAGCTACC 74 SC2M1-74_LEFT_28918 TGATGCTGCTCTTGCTTTGCTG SC2M1-73_RIGHT_29045 GCTTCTTAGAAGCCTCAGCAGC SC2M1-74_RIGHT_29469 TCTGCAGCAGGAAGAAGAGTCA 78 SC2M1-52_LEFT2_20349 AGTCAGTTAGGTGGTTTACATCTACTGA SC2M1-52_RIGHT2_20798 TTTTGCGACATTCATCATTATGCCT v200603.1 Pool 3 Pool 4 PCR Name Sequence PCR Name Sequence 3 SC2M1-3_LEFT_827 AACAACTTCTGTGGCCCTGATG 4 SC2M1-4_LEFT_1262 ACGGGCGATTTTGTTAAAGCCA SC2M1-3_RIGHT_1395 TCTGAATTGTGACATGCTGGACA SC2M1-4_RIGHT_1840 TCACCAATATTCCAGGCACCTTT 11 SC2M1-11_LEFT_4126 GGGTGATGTTGTTCAAGAGGGT 8 SC2M1-8_LEFT_2932 ACTTACACCACTGGGCATTGATT SC2M1-11_RIGHT_4658 ACCGAGCAGCTTCTTCCAAATT SC2M1-8_RIGHT_3461 CTGCAACACCTCCTCCATGTTT 15 SC2M1-15_LEFT_5677 TGTTATGATGTCAGCACCACCTG 12 SC2M1-12_LEFT_4519 TGGTGCTAGATTTTACTTTTACACCAGT SC2M1-15_RIGHT_6172 AGCCACCACATCACCATTTAAGT SC2M1-12_RIGHT_5017 CACAACTTGCGTGTGGAGGTTA 19-2 SC2M1-19b_LEFT_7235 TGCAGAGTGGTTTTTGGCATATATTCT 16 SC2M1-16_LEFT_6030 ACGCAAGCTTCGATAATTTTAAGTTTGT SC2M1-19_RIGHT_7694 ACTGTAGTGACAAGTCTCTCGCA SC2M1-16_RIGHT_6544 TGTGTGGCCAACCTCTTCTGTA 23 SC2M1-23_LEFT_8778 TTAGCCAGCGTGGTGGTAGTTA 20 SC2M1-20_LEFT_7560 GGTCCTTTTATGTCTATGCTAATGGAGG SC2M1-23_RIGHT_9330 TCTACACCACAGAAAACTCCTGGT SC2M1-20_RIGHT_8128 TGCAAGTTCAGCTTCTGCAGTT 27 SC2M1-27_LEFT_10318 GCTTAAGGTTGATACAGCCAATCCT 24 SC2M1-24_LEFT_9203 GATTCTGAGTACTGTAGGCACGG SC2M1-27_RIGHT_10837 AACGGCAATTCCAGTTTGAGCA SC2M1-24_RIGHT_9734 AGAACCAATAGAAATGCTTTGTGGAAA 31 SC2M1-31_LEFT_11810 GGCAAACCTTGTATCAAAGTAGCC 28 SC2M1-28_LEFT_10697 GGAGACAGGTGGTTTCTCAATCG SC2M1-31_RIGHT_12335 TTGCCCTCTTGTCCTCAGATCT SC2M1-28_RIGHT_11209 AGCTACAGTGGCAAGAGAAGGT 35 SC2M1-35_LEFT_13366 AAACACAGTCTGTACCGTCTGC 32 SC2M1-32_LEFT_12201 AGTTGAAGAAGTCTTTGAATGTGGCT SC2M1-35_RIGHT_13861 TGTCACAATTACCTTCATCAAAATGCC SC2M1-32_RIGHT_12719 TCTGTCGTAGTGCAACAGGACT 39 SC2M1-39_LEFT_14888 ACGATGGTGGCTGTATTAATGCT 36 SC2M1-36_LEFT_13727 GCTGTTGCTAAACATGACTTCTTTAAGT SC2M1-39_RIGHT_15391 GGTGTGACAAGCTACAACACGT SC2M1-36_RIGHT_14232 AGGCTTTGTTAAGTCAGTGTCAACA 43 SC2M1-43_LEFT_16518 AAATACATGTGTTGGTAGCGATAATGTT 40 SC2M1-40_LEFT_15264 TGTAGAAAACCCTCACCTTATGGG SC2M1-43_RIGHT_17087 GGTGGTCCCTGGAGTGTAGAAT SC2M1-40_RIGHT_15771 AGCCACTAGACCTTGAGATGCA 47 SC2M1-47_LEFT_18148 GGTTTATGTGTTGACATACCTGGCA 44 SC2M1-44_LEFT_16948 CCTACACTAGTGCCACAAGAGC SC2M1-47_RIGHT_18668 CATAGACAACAGGTGCGCTCAG SC2M1-44_RIGHT_17458 GTGCAGGTAATTGAGCAGGGTC 51 SC2M1-51_LEFT_19725 TGATGGTGTTGATGTAGAATTGTTTGAA 48 SC2M1-48_LEFT_18506 GACTTCCTTGGAATGTAGTGCGT SC2M1-51_RIGHT_20255 TCAATTTCCATTTGACTCCTGGGT SC2M1-48_RIGHT_19038 ACCAATGTCGTGAAGAACTGGG 55 SC2M1-55_LEFT_21421 AGGGGTACTGCTGTTATGTCTTTAAA 52 SC2M1-52_LEFT_20124 TGGAGAAGCCGTAAAAACACAGT SC2M1-55_RIGHT_21916 AAGTAGGGACTGGGTCTTCGAA SC2M1-52_RIGHT_20698 GATTAGGCATAGCAACACCCGG 59 SC2M1-59_LEFT_22986 CCGGTAGCACACCTTGTAATGG 56 SC2M1-56_LEFT_21775 TGGGACCAATGGTACTAAGAGGT SC2M1-59_RIGHT_23519 CCCCTATTAAACAGCCTGCACG SC2M1-56_RIGHT_22345 ACCAGCTGTCCAACCTGAAGAA 63 SC2M1-63_LEFT_24493 AAATGATATCCTTTCACGTCTTGACAAA 60 SC2M1-60_LEFT_23379 ACCAGGTTGCTGTTCTTTATCAGG SC2M1-63_RIGHT_25003 TGAGTCTAATTCAGGTTGCAAAGGA SC2M1-", [["PCR primer plates", "DNA", 98, 115], ["R1", "DNA", 117, 119], ["R2", "DNA", 124, 126], ["Sequence 1 SC2M1-1_LEFT_31 ACCAACCAACTTTCGATCTCTTGT 2 SC2M1-2_LEFT_445 TTTGCCTCAACTTGAACAGCCC SC2M1-1_RIGHT_574 TGTCTCACCACTACGACCGTAC SC2M1-2_RIGHT_965 GTTCACGGCAGCAGTATACACC 5 SC2M1-5_LEFT_1706 TCTGCTTCCACAAGTGCTTTTGT 6 SC2M1-6_LEFT_2138 AAACCCGTCCTTGATTGGCTTG SC2M1-5_RIGHT_2266 ACAGGTGACAATTTGTCCACCG SC2M1-6_RIGHT_2642 TTTCGAGCAACATAAGCCCGTT 9 SC2M1-9_LEFT_3306 TGGAACTTACACCAGTTGTTCAGAC 10 SC2M1-10_LEFT_3715 AGCTGGTATTTTTGGTGCTGACC SC2M1-9_RIGHT_3878 CAGCGATCTTTTGTTCAACTTGCT SC2M1-10_RIGHT_4262 CCTGACCCGGGTAAGTGGTTAT 13 SC2M1-13_LEFT_4885 TCCTACCACATTCCACCTAGATGG 14 SC2M1-14_LEFT_5258 ACTTCTATTAAATGGGCAGATAACAACTGT SC2M1-13_RIGHT_5400 GCACAAAAGTTAGCAGCTTCACC SC2M1-14_RIGHT_5818 AGCACCGTCTATGCAATACAAAGT 17 SC2M1-17_LEFT_6408 CTGAAGAAGTAGTGGAAAATCCTACCA 18 SC2M1-18_LEFT_6748 AAACCGTGTTTGTACTAATTATATGCCTT SC2M1-17_RIGHT_6903 GCCTCTAGACAAAATTTACCGACACT SC2M1-18_RIGHT_7255 TGCCAAAAACCACTCTGCAACT 21 SC2M1-21_LEFT_8004 TTGGTGATAGTGCGGAAGTTGC 22 SC2M1-22_LEFT_8407 CGTTAAAGATTTCATGTCATTGTCTGAACA SC2M1-21_RIGHT_8553 CCACCCTTAAGTGCTATCTTTGTTGT SC2M1-22_RIGHT_8913 TGCAAAAAGTCACCATTAGTTGTGC 25 SC2M1-25_LEFT_9551 CCAGTTTACTCATTCTTACCTGGTGT 26 SC2M1-26_LEFT_9903 AGTACAAGTATTTTAGTGGAGCAATGGA SC2M1-25_RIGHT_10061 AACCACTCTGCAAAACAGCTGA SC2M1-26_RIGHT_10451 TGGGCCTCATAGCACATTGGTA 29 SC2M1-29_LEFT_11047 AGTCCAGAGTACTCAATGGTCTTTGT 30 SC2M1-30_LEFT_11400 TGAATGTCTTGACACTCGTTTATAAAGTT SC2M1-29_RIGHT_11541 ACAATACCTCTGGCCAAAAACATGA SC2M1-30_RIGHT_11944 CTGGACACATTGAGCCCACAAT 33 SC2M1-33_LEFT_12557 ATCCAACAGGTTGTAGATGCAGAT 34 SC2M1-34_LEFT_13006 TGCCACAGTACGTCTACAAGCT SC2M1-33_RIGHT_13136 TTGGTTGTCCCCCACTAGCTAG SC2M1-34_RIGHT_13501 GTGTAAGACGGGCTGCACTTAC 37 SC2M1-37_LEFT_14103 TTTCATACAAACCACGCCAGGT 38 SC2M1-38_LEFT_14480 ACTTCAGAGAGCTAGGTGTTGTACA SC2M1-37_RIGHT_14641 GTGCAGCTACTGAAAAGCACGT SC2M1-38_RIGHT_15027 TGCGAAAAGTGCATCTTGATCCT 41 SC2M1-41_LEFT_15637 AGAAATAGAGATGTTGACACAGACTTTGT 42 SC2M1-42_LEFT_16065 GGAGTATGCTGATGTCTTTCATTTGTAC SC2M1-41_RIGHT_16208 GCCTCATAAAACTCAGGTTCCCA SC2M1-42_RIGHT_16648 GCGTTTCTGCTGCAAAAAGCTT 45 SC2M1-45_LEFT_17317", "DNA", 390, 2452], ["SC2M1", "PROTEIN", 3371, 3376], ["SC2M1-19_RIGHT_7694 ACTGTAGTGACAAGTCTCTCGCA SC2M1-16_RIGHT_6544 TGTGTGGCCAACCTCTTCTGTA 23 SC2M1-23_LEFT_8778 TTAGCCAGCGTGGTGGTAGTTA 20 SC2M1-20_LEFT_7560 GGTCCTTTTATGTCTATGCTAATGGAGG SC2M1-23_RIGHT_9330 TCTACACCACAGAAAACTCCTGGT SC2M1-20_RIGHT_8128 TGCAAGTTCAGCTTCTGCAGTT 27 SC2M1-27_LEFT_10318 GCTTAAGGTTGATACAGCCAATCCT 24 SC2M1-24_LEFT_9203 GATTCTGAGTACTGTAGGCACGG SC2M1-27_RIGHT_10837 AACGGCAATTCCAGTTTGAGCA SC2M1-24_RIGHT_9734 AGAACCAATAGAAATGCTTTGTGGAAA 31 SC2M1-31_LEFT_11810 GGCAAACCTTGTATCAAAGTAGCC 28 SC2M1-28_LEFT_10697 GGAGACAGGTGGTTTCTCAATCG SC2M1-31_RIGHT_12335 TTGCCCTCTTGTCCTCAGATCT SC2M1-28_RIGHT_11209 AGCTACAGTGGCAAGAGAAGGT 35 SC2M1-35_LEFT_13366 AAACACAGTCTGTACCGTCTGC 32 SC2M1-32_LEFT_12201 AGTTGAAGAAGTCTTTGAATGTGGCT SC2M1-35_RIGHT_13861 TGTCACAATTACCTTCATCAAAATGCC SC2M1-32_RIGHT_12719 TCTGTCGTAGTGCAACAGGACT 39 SC2M1-39_LEFT_14888 ACGATGGTGGCTGTATTAATGCT 36 SC2M1-36_LEFT_13727 GCTGTTGCTAAACATGACTTCTTTAAGT SC2M1-39_RIGHT_15391 GGTGTGACAAGCTACAACACGT SC2M1-36_RIGHT_14232 AGGCTTTGTTAAGTCAGTGTCAACA 43 SC2M1-43_LEFT_16518 AAATACATGTGTTGGTAGCGATAATGTT 40 SC2M1-40_LEFT_15264 TGTAGAAAACCCTCACCTTATGGG SC2M1-43_RIGHT_17087 GGTGGTCCCTGGAGTGTAGAAT SC2M1-40_RIGHT_15771 AGCCACTAGACCTTGAGATGCA 47 SC2M1-47_LEFT_18148 GGTTTATGTGTTGACATACCTGGCA 44 SC2M1-44_LEFT_16948 CCTACACTAGTGCCACAAGAGC SC2M1-47_RIGHT_18668 CATAGACAACAGGTGCGCTCAG SC2M1-44_RIGHT_17458 GTGCAGGTAATTGAGCAGGGTC 51 SC2M1-51_LEFT_19725 TGATGGTGTTGATGTAGAATTGTTTGAA 48 SC2M1-48_LEFT_18506 GACTTCCTTGGAATGTAGTGCGT SC2M1-51_RIGHT_20255 TCAATTTCCATTTGACTCCTGGGT SC2M1-48_RIGHT_19038 ACCAATGTCGTGAAGAACTGGG 55 SC2M1-55_LEFT_21421 AGGGGTACTGCTGTTATGTCTTTAAA 52 SC2M1-52_LEFT_20124 TGGAGAAGCCGTAAAAACACAGT SC2M1-55_RIGHT_21916 AAGTAGGGACTGGGTCTTCGAA SC2M1-52_RIGHT_20698 GATTAGGCATAGCAACACCCGG 59 SC2M1-59_LEFT_22986 CCGGTAGCACACCTTGTAATGG 56 SC2M1-56_LEFT_21775 TGGGACCAATGGTACTAAGAGGT SC2M1-59_RIGHT_23519 CCCCTATTAAACAGCCTGCACG SC2M1-56_RIGHT_22345 ACCAGCTGTCCAACCTGAAGAA 63 SC2M1-63_LEFT_24493 AAATGATATCCTTTCACGTCTTGACAAA 60 SC2M1-60_LEFT_23379 ACCAGGTTGCTGTTCTTTATCAGG SC2M1-63_RIGHT_25003 TGAGTCTAATTCAGGTTGCAAAGGA SC2M1-", "DNA", 4716, 6815], ["ReagentsWe", "TREATMENT", 70, 80], ["PCR primer plates", "TREATMENT", 98, 115], ["primers", "TREATMENT", 155, 162], ["This amplicon", "TREATMENT", 204, 217], ["its reduced efficiency", "PROBLEM", 250, 272], ["this primer", "TREATMENT", 288, 299], ["Appendix D", "TEST", 316, 326], ["Multiplex PCR", "TEST", 328, 341], ["Name Sequence PCR", "TEST", 367, 384], ["TCTGCTTCCACAAGTGCTTTTGT", "TEST", 586, 609], ["AAACCCGTCCTTGATTGGCTTG", "TEST", 630, 652], ["ACAGGTGACAATTTGTCCACCG", "TEST", 672, 694], ["TTTCGAGCAACATAAGCCCGTT", "TEST", 714, 736], ["TGGAACTTACACCAGTTGTTCAGAC", "TEST", 757, 782], ["AGCTGGTATTTTTGGTGCTGACC", "TEST", 805, 828], ["CAGCGATCTTTTGTTCAACTTGCT", "TEST", 848, 872], ["CCTGACCCGGGTAAGTGGTTAT", "TEST", 893, 915], ["TCCTACCACATTCCACCTAGATGG", "TEST", 938, 962], ["ACTTCTATTAAATGGGCAGATAACAACTGT", "TEST", 985, 1015], ["GCACAAAAGTTAGCAGCTTCACC", "TEST", 1036, 1059], ["AGCACCGTCTATGCAATACAAAGT", "TEST", 1080, 1104], ["CTGAAGAAGTAGTGGAAAATCCTACCA", "TEST", 1127, 1154], ["AAACCGTGTTTGTACTAATTATATGCCTT", "TEST", 1177, 1206], ["GCCTCTAGACAAAATTTACCGACACT", "TEST", 1227, 1253], ["TGCCAAAAACCACTCTGCAACT", "TEST", 1274, 1296], ["TTGGTGATAGTGCGGAAGTTGC", "TEST", 1319, 1341], ["CGTTAAAGATTTCATGTCATTGTCTGAACA", "TEST", 1364, 1394], ["CCACCCTTAAGTGCTATCTTTGTTGT", "TEST", 1415, 1441], ["TGCAAAAAGTCACCATTAGTTGTGC", "TEST", 1462, 1487], ["CCAGTTTACTCATTCTTACCTGGTGT", "TEST", 1510, 1536], ["AGTACAAGTATTTTAGTGGAGCAATGGA", "TEST", 1559, 1587], ["AACCACTCTGCAAAACAGCTGA", "TEST", 1609, 1631], ["TGGGCCTCATAGCACATTGGTA", "TEST", 1653, 1675], ["AGTCCAGAGTACTCAATGGTCTTTGT", "TEST", 1699, 1725], ["TGAATGTCTTGACACTCGTTTATAAAGTT", "TEST", 1749, 1778], ["ACAATACCTCTGGCCAAAAACATGA", "TEST", 1800, 1825], ["CTGGACACATTGAGCCCACAAT", "TEST", 1847, 1869], ["ATCCAACAGGTTGTAGATGCAGAT", "TEST", 1893, 1917], ["TGCCACAGTACGTCTACAAGCT", "TEST", 1941, 1963], ["TTGGTTGTCCCCCACTAGCTAG", "TEST", 1985, 2007], ["GTGTAAGACGGGCTGCACTTAC", "TEST", 2029, 2051], ["TTTCATACAAACCACGCCAGGT", "TEST", 2075, 2097], ["TGCGAAAAGTGCATCTTGATCCT", "TEST", 2212, 2235], ["AGAAATAGAGATGTTGACACAGACTTTGT", "TEST", 2259, 2288], ["GCGTTTCTGCTGCAAAAAGCTT", "TEST", 2407, 2429], ["AATGCATTGCCTGAGACGACAG", "TEST", 2453, 2475], ["TGGAGAAAAGCTGTCTTTATTTCACCT", "TEST", 2499, 2526], ["GCTTCTTCGCGGGTGATAAACA", "TEST", 2593, 2615], ["TGTTAAGCGTGTTGACTGGACT", "TEST", 2639, 2661], ["ACTTAAAAGTGGAAAATGATGCGGAA", "TEST", 3111, 3137], ["TGCTGGTGCATGTAGAAGTTCA", "TEST", 3159, 3181], ["AATTCTACCAGTGTCTATGACCAAGAC", "TEST", 3205, 3232], ["GCTGCTAGAGACCTCATTTGTGC", "TEST", 3256, 3279], ["AAGCTCTGATTTCTGCAGCTCT", "TEST", 3345, 3367], ["SC2M1", "TEST", 3371, 3376], ["CTAGGTTTTATAGCTGGCTTGATTGC", "TEST", 3391, 3417], ["CATTTCCAGCAAAGCCAAAGCC", "TEST", 3485, 3507], ["GTGCTTACAAAGGCACGCTAGT", "TEST", 3529, 3551], ["CTTCTCAACGTGCCACTCCATG", "TEST", 3575, 3597], ["TTATGAGGACTTTTAAAGTTTCCATTTGGA", "TEST", 3621, 3651], ["AGCGAGTGTTATCAGTGCCAAG", "TEST", 3673, 3695], ["AGCAGAAAGGCTAAAAAGCACAAA", "TEST", 3717, 3741], ["TGGCTACTACCGAAGAGCTACC", "TEST", 3765, 3787], ["TGATGCTGCTCTTGCTTTGCTG", "TEST", 3811, 3833], ["GCTTCTTAGAAGCCTCAGCAGC", "TEST", 3855, 3877], ["TCTGCAGCAGGAAGAAGAGTCA", "TEST", 3899, 3921], ["SC2M1-", "TEST", 3925, 3931], ["AGTCAGTTAGGTGGTTTACATCTACTGA", "TEST", 3946, 3974], ["TTTTGCGACATTCATCATTATGCCT", "TEST", 3997, 4022], ["Sequence PCR", "TEST", 4056, 4068], ["AACAACTTCTGTGGCCCTGATG", "TEST", 4102, 4124], ["ACGGGCGATTTTGTTAAAGCCA", "TEST", 4145, 4167], ["TCTGAATTGTGACATGCTGGACA", "TEST", 4187, 4210], ["TCACCAATATTCCAGGCACCTTT", "TEST", 4230, 4253], ["GGGTGATGTTGTTCAAGAGGGT", "TEST", 4276, 4298], ["ACTTACACCACTGGGCATTGATT", "TEST", 4319, 4342], ["ACCGAGCAGCTTCTTCCAAATT", "TEST", 4363, 4385], ["CTGCAACACCTCCTCCATGTTT", "TEST", 4405, 4427], ["TGTTATGATGTCAGCACCACCTG", "TEST", 4450, 4473], ["TGGTGCTAGATTTTACTTTTACACCAGT", "TEST", 4496, 4524], ["AGCCACCACATCACCATTTAAGT", "TEST", 4545, 4568], ["CACAACTTGCGTGTGGAGGTTA", "TEST", 4589, 4611], ["TGCAGAGTGGTTTTTGGCATATATTCT", "TEST", 4637, 4664], ["ACTGTAGTGACAAGTCTCTCGCA", "TEST", 4736, 4759], ["TGTGTGGCCAACCTCTTCTGTA", "TEST", 4780, 4802], ["TTAGCCAGCGTGGTGGTAGTTA", "TEST", 4825, 4847], ["TCTACACCACAGAAAACTCCTGGT", "TEST", 4919, 4943], ["TGCAAGTTCAGCTTCTGCAGTT", "TEST", 4964, 4986], ["GCTTAAGGTTGATACAGCCAATCCT", "TEST", 5010, 5035], ["GATTCTGAGTACTGTAGGCACGG", "TEST", 5058, 5081], ["AACGGCAATTCCAGTTTGAGCA", "TEST", 5103, 5125], ["AGAACCAATAGAAATGCTTTGTGGAAA", "TEST", 5146, 5173], ["GGCAAACCTTGTATCAAAGTAGCC", "TEST", 5197, 5221], ["GGAGACAGGTGGTTTCTCAATCG", "TEST", 5245, 5268], ["TTGCCCTCTTGTCCTCAGATCT", "TEST", 5290, 5312], ["AGCTACAGTGGCAAGAGAAGGT", "TEST", 5334, 5356], ["AAACACAGTCTGTACCGTCTGC", "TEST", 5380, 5402], ["AGTTGAAGAAGTCTTTGAATGTGGCT", "TEST", 5426, 5452], ["TGTCACAATTACCTTCATCAAAATGCC", "TEST", 5474, 5501], ["TCTGTCGTAGTGCAACAGGACT", "TEST", 5523, 5545], ["ACGATGGTGGCTGTATTAATGCT", "TEST", 5569, 5592], ["AGGCTTTGTTAAGTCAGTGTCAACA", "TEST", 5710, 5735], ["AAATACATGTGTTGGTAGCGATAATGTT", "TEST", 5759, 5787], ["AGCCACTAGACCTTGAGATGCA", "TEST", 5901, 5923], ["GGTTTATGTGTTGACATACCTGGCA", "TEST", 5947, 5972], ["GTGCAGGTAATTGAGCAGGGTC", "TEST", 6084, 6106], ["TGATGGTGTTGATGTAGAATTGTTTGAA", "TEST", 6130, 6158], ["TCAATTTCCATTTGACTCCTGGGT", "TEST", 6227, 6251], ["ACCAATGTCGTGAAGAACTGGG", "TEST", 6273, 6295], ["AGGGGTACTGCTGTTATGTCTTTAAA", "TEST", 6319, 6345], ["AAGTAGGGACTGGGTCTTCGAA", "TEST", 6414, 6436], ["GATTAGGCATAGCAACACCCGG", "TEST", 6458, 6480], ["CCGGTAGCACACCTTGTAATGG", "TEST", 6504, 6526], ["TGGGACCAATGGTACTAAGAGGT", "TEST", 6550, 6573], ["CCCCTATTAAACAGCCTGCACG", "TEST", 6595, 6617], ["ACCAGCTGTCCAACCTGAAGAA", "TEST", 6639, 6661], ["AAATGATATCCTTTCACGTCTTGACAAA", "TEST", 6685, 6713], ["ACCAGGTTGCTGTTCTTTATCAGG", "TEST", 6737, 6761]]]], "a9e9067237fae176fdf6341862f5ddd693ad527a": [["tests are insensitive during the window period before seroconversion of an infected donor.", [["tests", "TEST", 0, 5], ["an infected donor", "PROBLEM", 72, 89], ["infected", "OBSERVATION", 75, 83]]], ["2 Collection of blood during the window period is likely the most important source of residual human immunodeficiency virus (HIV) infections.", [["blood", "ANATOMY", 16, 21], ["human immunodeficiency virus (HIV) infections", "DISEASE", 95, 140], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["human immunodeficiency virus", "ORGANISM", 95, 123], ["HIV", "ORGANISM", 125, 128], ["human immunodeficiency virus", "SPECIES", 95, 123], ["human immunodeficiency virus", "SPECIES", 95, 123], ["HIV", "SPECIES", 125, 128], ["residual human immunodeficiency virus (HIV) infections", "PROBLEM", 86, 140], ["blood", "ANATOMY", 16, 21], ["likely the", "UNCERTAINTY", 50, 60], ["most important", "OBSERVATION_MODIFIER", 61, 75], ["residual human immunodeficiency virus", "OBSERVATION", 86, 123]]], ["3 Nucleic acid testing (NAT) of minipools (MPs) has reduced, although not eliminated, the window period for newly infected donors, but may not detect those with low HIV viral burdens during the acute phase.", [["Nucleic acid", "CHEMICAL", 2, 14], ["HIV viral burdens", "DISEASE", 165, 182], ["MPs", "GENE_OR_GENE_PRODUCT", 43, 46], ["donors", "ORGANISM", 123, 129], ["HIV", "SPECIES", 165, 168], ["Nucleic acid testing", "TEST", 2, 22], ["minipools", "PROBLEM", 32, 41], ["newly infected donors", "PROBLEM", 108, 129], ["low HIV viral burdens", "PROBLEM", 161, 182], ["infected", "OBSERVATION", 114, 122]]], ["4 Furthermore, some potential donors with silent chronic viral infections, such as hepatitis B virus (HBV), may have very low viral burdens without detectable antiviral antibodies and thus remain undetected by MP NAT.", [["chronic viral infections", "DISEASE", 49, 73], ["hepatitis B", "DISEASE", 83, 94], ["donors", "ORGANISM", 30, 36], ["hepatitis B virus", "ORGANISM", 83, 100], ["HBV", "ORGANISM", 102, 105], ["antiviral antibodies", "PROTEIN", 159, 179], ["hepatitis B virus", "SPECIES", 83, 100], ["hepatitis B virus", "SPECIES", 83, 100], ["HBV", "SPECIES", 102, 105], ["silent chronic viral infections", "PROBLEM", 42, 73], ["hepatitis B virus", "PROBLEM", 83, 100], ["HBV", "PROBLEM", 102, 105], ["very low viral burdens", "PROBLEM", 117, 139], ["detectable antiviral antibodies", "PROBLEM", 148, 179], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infections", "OBSERVATION", 63, 73], ["antiviral antibodies", "OBSERVATION", 159, 179]]], ["5 With a combination of serologic and MP NAT in place, the residual risk of contamination for selected viruses has decreased to less than 1:2,000,000 for HIV-1 and -2 and human T-lymphotropic virus (HTLV)-I and -II, less than 1:1,000,000 for hepatitis C virus (HCV), and less than 1:200,000 for HBV.", [["hepatitis C", "DISEASE", 242, 253], ["HIV-1", "ORGANISM", 154, 159], ["-2", "ORGANISM", 164, 166], ["human T-lymphotropic virus (HTLV)-I", "ORGANISM", 171, 206], ["hepatitis C virus", "ORGANISM", 242, 259], ["HCV", "ORGANISM", 261, 264], ["HBV", "ORGANISM", 295, 298], ["HIV-1", "SPECIES", 154, 159], ["human", "SPECIES", 171, 176], ["T-lymphotropic virus", "SPECIES", 177, 197], ["hepatitis C virus", "SPECIES", 242, 259], ["HIV-1", "SPECIES", 154, 159], ["human T-lymphotropic virus", "SPECIES", 171, 197], ["HTLV", "SPECIES", 199, 203], ["hepatitis C virus", "SPECIES", 242, 259], ["HCV", "SPECIES", 261, 264], ["HBV", "SPECIES", 295, 298], ["serologic and MP NAT", "TREATMENT", 24, 44], ["contamination", "PROBLEM", 76, 89], ["selected viruses", "PROBLEM", 94, 110], ["HIV", "TEST", 154, 157], ["human T-lymphotropic virus", "TEST", 171, 197], ["hepatitis C virus", "PROBLEM", 242, 259], ["HCV", "PROBLEM", 261, 264], ["HBV", "PROBLEM", 295, 298], ["contamination", "OBSERVATION", 76, 89]]], ["1, 2 Despite improving the safety of blood components, testing remains a reactive approach to blood safety.", [["blood", "ANATOMY", 37, 42], ["blood", "ANATOMY", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["blood components", "TEST", 37, 53], ["testing", "TEST", 55, 62], ["blood safety", "TEST", 94, 106]]], ["The contaminating organisms must be identified before sensitive tests can be developed.", [["The contaminating organisms", "PROBLEM", 0, 27], ["sensitive tests", "TEST", 54, 69]]], ["New pathogens, such as West Nile virus (WNV), continue to enter the donor population and may be transmitted before a sensitive test is in place.", [["West Nile virus", "ORGANISM", 23, 38], ["WNV", "ORGANISM", 40, 43], ["West Nile virus", "SPECIES", 23, 38], ["West Nile virus", "SPECIES", 23, 38], ["WNV", "SPECIES", 40, 43], ["New pathogens", "PROBLEM", 0, 13], ["West Nile virus (WNV", "PROBLEM", 23, 43], ["the donor population", "TREATMENT", 64, 84], ["a sensitive test", "TEST", 115, 131], ["pathogens", "OBSERVATION", 4, 13]]], ["6 The recent emergence of new strains of pathogenic viruses, such as severe acute respiratory syndromehuman coronavirus (SARS-HCoV), demonstrates once again the susceptibility of the world's blood supply to previously unknown viruses that can spread globally in a short amount of time.", [["blood", "ANATOMY", 191, 196], ["acute respiratory syndromehuman coronavirus", "DISEASE", 76, 119], ["SARS-HCoV)", "DISEASE", 121, 131], ["severe acute respiratory syndromehuman coronavirus", "ORGANISM", 69, 119], ["SARS-HCoV", "ORGANISM", 121, 130], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["respiratory syndromehuman coronavirus", "SPECIES", 82, 119], ["severe acute respiratory syndromehuman coronavirus", "SPECIES", 69, 119], ["HCoV", "SPECIES", 126, 130], ["pathogenic viruses", "PROBLEM", 41, 59], ["severe acute respiratory syndromehuman coronavirus", "PROBLEM", 69, 119], ["previously unknown viruses", "PROBLEM", 207, 233], ["new", "OBSERVATION_MODIFIER", 26, 29], ["pathogenic viruses", "OBSERVATION", 41, 59], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory syndromehuman coronavirus", "OBSERVATION", 82, 119], ["viruses", "OBSERVATION", 226, 233]]], ["7, 8 In addition, cytomegalovirus (CMV) exposure is a significant risk for immunocompromised patients receiving blood component therapy; however, testing and leukoreduction may fail to reach a zero-risk level for prevalent pathogens such as CMV.", [["blood", "ANATOMY", 112, 117], ["cytomegalovirus (CMV) exposure", "DISEASE", 18, 48], ["cytomegalovirus", "ORGANISM", 18, 33], ["CMV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 93, 101], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["CMV", "ORGANISM", 241, 244], ["patients", "SPECIES", 93, 101], ["CMV", "SPECIES", 35, 38], ["CMV", "SPECIES", 241, 244], ["cytomegalovirus (CMV) exposure", "PROBLEM", 18, 48], ["blood component therapy", "TREATMENT", 112, 135], ["testing", "TEST", 146, 153], ["leukoreduction", "TREATMENT", 158, 172], ["prevalent pathogens", "PROBLEM", 213, 232], ["CMV", "PROBLEM", 241, 244], ["cytomegalovirus", "OBSERVATION", 18, 33], ["significant risk for", "UNCERTAINTY", 54, 74], ["immunocompromised", "OBSERVATION", 75, 92]]], ["9, 10 In contrast, pathogen inactivation technologies offer a proactive approach and the potential to further improve blood safety.", [["blood", "ANATOMY", 118, 123], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["pathogen inactivation technologies", "TREATMENT", 19, 53], ["a proactive approach", "TREATMENT", 60, 80], ["blood safety", "TEST", 118, 130]]], ["To reduce the risks associated with PLT transfusions, a photochemical treatment (PCT) process utilizing a combination of the psoralen amotosalen-HCl and long-wavelength ultraviolet light (UVA) has been developed and introduced into clinical practice in Europe.", [["psoralen amotosalen-HCl", "CHEMICAL", 125, 148], ["UVA", "CHEMICAL", 188, 191], ["psoralen", "CHEMICAL", 125, 133], ["HCl", "CHEMICAL", 145, 148], ["PLT", "CELL", 36, 39], ["psoralen", "SIMPLE_CHEMICAL", 125, 133], ["HCl", "SIMPLE_CHEMICAL", 145, 148], ["PLT transfusions", "TREATMENT", 36, 52], ["a photochemical treatment (PCT) process", "TREATMENT", 54, 93], ["the psoralen amotosalen", "TREATMENT", 121, 144], ["HCl", "TREATMENT", 145, 148], ["long-wavelength ultraviolet light (UVA", "TREATMENT", 153, 191]]], ["11 In vitro studies and extensive clinical testing have demonstrated that PCT inactivates a variety of pathogens while preserving the hemostatic properties of PLTs.", [["PLTs", "ANATOMY", 159, 163], ["PCT", "SIMPLE_CHEMICAL", 74, 77], ["PLTs", "CELL", 159, 163], ["PCT", "PROTEIN", 74, 77], ["PLTs", "CELL_TYPE", 159, 163], ["vitro studies", "TEST", 6, 19], ["extensive clinical testing", "TEST", 24, 50], ["PCT", "TEST", 74, 77], ["pathogens", "PROBLEM", 103, 112], ["PLTs", "TEST", 159, 163]]], ["[12] [13] [14] [15] [16] [17] [18] A recent report provided a summary of the broad-spectrum bacterial inactivation data in PLTs with the PCT process.", [["PLTs", "ANATOMY", 123, 127], ["[12] [13] [14] [15] [16] [17] [18] A", "SIMPLE_CHEMICAL", 0, 36], ["PLTs", "CELL", 123, 127], ["PLTs", "CELL_TYPE", 123, 127], ["the broad-spectrum bacterial inactivation data", "TREATMENT", 73, 119], ["PLTs", "TEST", 123, 127], ["the PCT process", "TREATMENT", 133, 148], ["bacterial inactivation", "OBSERVATION", 92, 114]]], ["19 This report summarizes the viral inactivation data obtained to date.PLT concentratesEarly experiments were conducted with single-donor PLT concentrates (SDP) collected with a blood cell separator (CS3000, Baxter Healthcare, Deerfield, IL) with an A35 col-lection chamber.", [["blood cell", "ANATOMY", 178, 188], ["PLT", "GENE_OR_GENE_PRODUCT", 71, 74], ["blood cell", "CELL", 178, 188], ["PLT concentrates", "PROTEIN", 71, 87], ["the viral inactivation data", "TEST", 26, 53], ["PLT concentrates", "TEST", 71, 87], ["single-donor PLT concentrates", "TREATMENT", 125, 154], ["a blood cell separator", "TREATMENT", 176, 198], ["an A35 col-lection chamber", "TREATMENT", 247, 273]]], ["Later experiments were conducted with SDP collected with another cell separator (Amicus, Baxter Healthcare).", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69], ["another cell separator", "TREATMENT", 57, 79]]], ["Each SDP contained 3.0 \u00a5 10 11 to 6.0 \u00a5 10 11 PLTs suspended in approximately 300 mL of 35 percent plasma and 65 percent PLT additive solution (InterSol, Baxter Healthcare) in a 1-L plastic container (PL-2410, Baxter Healthcare).PCT and UVA illumination devicesPCT was performed with amotosalen-HCl (150 m mol/L) and UVA (320-400 nm).", [["PLTs", "ANATOMY", 46, 50], ["plasma", "ANATOMY", 99, 105], ["PL-2410", "CHEMICAL", 201, 208], ["UVA", "CHEMICAL", 237, 240], ["amotosalen-HCl", "CHEMICAL", 284, 298], ["UVA", "CHEMICAL", 317, 320], ["amotosalen", "CHEMICAL", 284, 294], ["HCl", "CHEMICAL", 295, 298], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["PLT", "SIMPLE_CHEMICAL", 121, 124], ["UVA", "SIMPLE_CHEMICAL", 237, 240], ["amotosalen-HCl", "SIMPLE_CHEMICAL", 284, 298], ["UVA", "SIMPLE_CHEMICAL", 317, 320], ["Each SDP", "TEST", 0, 8], ["PLTs", "TEST", 46, 50], ["65 percent PLT additive solution", "TREATMENT", 110, 142], ["PCT", "TEST", 229, 232], ["UVA illumination devicesPCT", "TEST", 237, 264], ["amotosalen-HCl", "TREATMENT", 284, 298], ["UVA", "TREATMENT", 317, 320]]], ["The processing device utilizes a closed system consisting of a series of plastic containers and illumination source (Fig. 1) .", [["The processing device", "TREATMENT", 0, 21], ["a closed system", "TREATMENT", 31, 46], ["a series of plastic containers", "TREATMENT", 61, 91]]], ["Early experiments were conducted with a prototype UVA illumination device capable of processing one PLT unit at a time (Model 4R4440, Baxter Healthcare).", [["UVA", "CHEMICAL", 50, 53], ["PLT unit", "DNA", 100, 108], ["a prototype UVA illumination device", "TREATMENT", 38, 73]]], ["The output of this device was approximately 15 to 20 mW per cm 2 permitting delivery of a 3 J per cm 2 UVA treatment dose in approximately 3 to 4 minutes.", [["UVA", "CHEMICAL", 103, 106], ["this device", "TREATMENT", 14, 25], ["a 3 J per cm 2 UVA treatment dose", "TREATMENT", 88, 121], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["Later experiments used a microprocessor-controlled UV illumination system capable of processing 2 PLT units at a time (Model FTX 1116, Baxter Healthcare).", [["a microprocessor-controlled UV illumination system", "TREATMENT", 23, 73], ["processing 2 PLT units", "TREATMENT", 85, 107]]], ["The UV illumination system delivers a 3 J per cm 2 UVA treatment dose to each PLT unit in approximately 3 to 6 minutes.", [["UVA", "CHEMICAL", 51, 54], ["PLT unit", "DNA", 78, 86], ["The UV illumination system", "TREATMENT", 0, 26], ["a 3 J per cm 2 UVA treatment dose", "TREATMENT", 36, 69], ["PLT unit", "TREATMENT", 78, 86]]], ["Both illumination devices use F15T12-BL fluorescent lamps mounted above and below the illumination tray and are air-cooled for temperature control.", [["Both illumination devices", "TREATMENT", 0, 25], ["BL fluorescent lamps", "TREATMENT", 37, 57], ["temperature control", "TREATMENT", 127, 146], ["illumination devices", "OBSERVATION", 5, 25]]], ["The 3 J per cm 2 UVA treatment doses delivered by the two illuminators are equivalent as measured by photodegradation of amotosalen.", [["UVA", "CHEMICAL", 17, 20], ["amotosalen", "CHEMICAL", 121, 131], ["amotosalen", "CHEMICAL", 121, 131], ["amotosalen", "SIMPLE_CHEMICAL", 121, 131], ["The 3 J per cm 2 UVA treatment doses", "TREATMENT", 0, 36]]], ["PLT concentrates were illuminated in both devices while being agitated with reciprocal shaking.General design of inactivation experimentsThe viruses evaluated in this report represent the most relevant blood-borne viruses in transfusion medicine, including all viruses routinely screened for and model viruses representing a spectrum of enveloped and nonenveloped viruses ( Table 1 ).", [["blood", "ANATOMY", 202, 207], ["PLT", "CELL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["PLT concentrates", "TEST", 0, 16], ["being agitated", "PROBLEM", 56, 70], ["reciprocal shaking", "PROBLEM", 76, 94], ["inactivation experiments", "PROBLEM", 113, 137], ["The viruses", "PROBLEM", 137, 148], ["transfusion medicine", "TREATMENT", 225, 245], ["all viruses", "TREATMENT", 257, 268], ["model viruses", "PROBLEM", 296, 309], ["agitated", "OBSERVATION", 62, 70], ["viruses", "OBSERVATION", 141, 148]]], ["The guidelines issued by CPMP and the FDA were considered in selecting viruses of various genome type and/or size and resistance to inactivation.", [["genome type", "OBSERVATION", 90, 101], ["size", "OBSERVATION_MODIFIER", 109, 113]]], ["20 For each experiment, a full-sized SDP unit (300 mL, unless otherwise specified) was spiked with approximately 10 6 infectious units of a virus per milliliter of PLT concentrate.", [["PLT", "CELL", 164, 167], ["a full-sized SDP unit", "TREATMENT", 24, 45], ["a virus", "TREATMENT", 138, 145], ["PLT concentrate", "TREATMENT", 164, 179]]], ["For some viruses, by use of the highest possible achievable titer resulted in spikes of lower infectious units per milliliter.", [["some viruses", "PROBLEM", 4, 16], ["viruses", "OBSERVATION", 9, 16]]], ["An aliquot was drawn for determination of the pretreatment viral infectivity titer.", [["An aliquot", "TEST", 0, 10], ["the pretreatment viral infectivity titer", "PROBLEM", 42, 82], ["viral infectivity", "OBSERVATION", 59, 76]]], ["The spiked PLT mixture was treated with 150 m mol per L amotosalen and 3 J per cm 2 UVA.", [["UVA", "CHEMICAL", 84, 87], ["PLT", "CELL", 11, 14], ["The spiked PLT mixture", "TREATMENT", 0, 22]]], ["After treatment, a sample was withdrawn for measurement of the posttreatment viral infectivity titer.", [["sample", "ANATOMY", 19, 25], ["treatment", "TREATMENT", 6, 15], ["a sample", "TEST", 17, 25], ["the posttreatment viral infectivity titer", "PROBLEM", 59, 100], ["viral infectivity", "OBSERVATION", 77, 94]]], ["Four replicate experiments (unless otherwise specified) with four independent units of SDP were performed for each virus.", [["SDP", "PROBLEM", 87, 90], ["each virus", "PROBLEM", 110, 120]]], ["The infectious viral titer was measured with cell culture methods or animal systems.", [["cell", "ANATOMY", 45, 49], ["cell", "CELL", 45, 49], ["The infectious viral titer", "TEST", 0, 26], ["cell culture methods", "TEST", 45, 65], ["infectious", "OBSERVATION_MODIFIER", 4, 14]]], ["In the cell culture assay, most PLT samples were first diluted with tissue culture medium and incubated at approximately 37 \u221e C for at least 1 hour to allow time for clot formation, which was then removed.", [["cell", "ANATOMY", 7, 11], ["PLT samples", "ANATOMY", 32, 43], ["tissue", "ANATOMY", 68, 74], ["clot", "ANATOMY", 166, 170], ["cell", "CELL", 7, 11], ["PLT samples", "CELL", 32, 43], ["clot", "ORGANISM_SUBSTANCE", 166, 170], ["the cell culture assay", "TEST", 3, 25], ["most PLT samples", "TEST", 27, 43], ["tissue culture", "TEST", 68, 82], ["clot formation", "PROBLEM", 166, 180], ["clot", "OBSERVATION", 166, 170]]], ["In some experiments, as indicated, heparin sulfate (15 U/mL) was added to prevent clotting.", [["heparin sulfate", "CHEMICAL", 35, 50], ["sulfate", "CHEMICAL", 43, 50], ["heparin sulfate", "SIMPLE_CHEMICAL", 35, 50], ["heparin sulfate", "TREATMENT", 35, 50], ["clotting", "PROBLEM", 82, 90], ["clotting", "OBSERVATION", 82, 90]]], ["The clot-free supernatant was used for viral assay.", [["clot", "ANATOMY", 4, 8], ["supernatant", "ANATOMY", 14, 25], ["clot", "ORGANISM_SUBSTANCE", 4, 8], ["The clot", "PROBLEM", 0, 8], ["viral assay", "TEST", 39, 50], ["clot", "OBSERVATION", 4, 8], ["free supernatant", "OBSERVATION", 9, 25]]], ["The inoculum and infectivity assay for each virus are briefly described below.Cell-free and cell-associated HIV-1Both cell-free and cell-associated HIV-1, strain IIIB, were evaluated.", [["Cell", "ANATOMY", 78, 82], ["cell", "ANATOMY", 92, 96], ["cell", "ANATOMY", 118, 122], ["cell", "ANATOMY", 132, 136], ["Cell", "CELL", 78, 82], ["cell", "CELL", 92, 96], ["HIV-1Both", "ORGANISM", 108, 117], ["cell", "CELL", 118, 122], ["cell", "CELL", 132, 136], ["HIV-1", "ORGANISM", 148, 153], ["strain IIIB", "ORGANISM", 155, 166], ["HIV", "SPECIES", 108, 111], ["HIV-1", "SPECIES", 148, 153], ["HIV-1Both", "SPECIES", 108, 117], ["HIV-1", "SPECIES", 148, 153], ["The inoculum", "TREATMENT", 0, 12], ["infectivity assay", "TEST", 17, 34], ["each virus", "PROBLEM", 39, 49], ["Cell", "TEST", 78, 82], ["HIV", "TEST", 108, 111], ["HIV", "PROBLEM", 148, 151], ["strain IIIB", "PROBLEM", 155, 166], ["inoculum", "OBSERVATION", 4, 12], ["free", "OBSERVATION_MODIFIER", 83, 87], ["cell", "OBSERVATION", 92, 96], ["1Both cell", "OBSERVATION_MODIFIER", 112, 122], ["free", "OBSERVATION_MODIFIER", 123, 127], ["cell", "OBSERVATION", 132, 136], ["HIV", "OBSERVATION", 148, 151], ["strain IIIB", "OBSERVATION_MODIFIER", 155, 166]]], ["22 Cell-associated HIV-1 was produced by harvesting chronically infected H9 cells (gift from C.V. Hanson) and adding these directly to the PLT unit.", [["Cell", "ANATOMY", 3, 7], ["H9 cells", "ANATOMY", 73, 81], ["Cell", "CELL", 3, 7], ["HIV-1", "ORGANISM", 19, 24], ["H9 cells", "CELL", 73, 81], ["gift", "ORGANISM", 83, 87], ["chronically infected H9 cells", "CELL_LINE", 52, 81], ["PLT unit", "DNA", 139, 147], ["HIV-1", "SPECIES", 19, 24], ["HIV-1", "SPECIES", 19, 24], ["chronically infected H9 cells", "PROBLEM", 52, 81], ["the PLT unit", "TREATMENT", 135, 147], ["chronically", "OBSERVATION_MODIFIER", 52, 63], ["infected", "OBSERVATION", 64, 72], ["H9 cells", "OBSERVATION", 73, 81]]], ["Cell-free HIV-1 was produced by vigorous vortexing of the infected H9 cells to release virus from the cell surface.", [["Cell", "ANATOMY", 0, 4], ["H9 cells", "ANATOMY", 67, 75], ["cell surface", "ANATOMY", 102, 114], ["Cell", "CELL", 0, 4], ["HIV-1", "ORGANISM", 10, 15], ["H9 cells", "CELL", 67, 75], ["cell surface", "CELLULAR_COMPONENT", 102, 114], ["infected H9 cells", "CELL_LINE", 58, 75], ["HIV-1", "SPECIES", 10, 15], ["HIV-1", "SPECIES", 10, 15], ["Cell-free HIV", "TEST", 0, 13], ["the infected H9 cells", "PROBLEM", 54, 75], ["infected H9 cells", "OBSERVATION", 58, 75], ["cell surface", "OBSERVATION", 102, 114]]], ["CellularCell-free HIV-1 and HIV-2 clinical isolateThe low-passage, clinical viral stocks were harvested from culture supernatant from infected peripheral blood mononuclear cells (PBMNCs) and provided by Tektagen (Malvern, PA).", [["supernatant", "ANATOMY", 117, 128], ["peripheral blood mononuclear cells", "ANATOMY", 143, 177], ["PBMNCs", "ANATOMY", 179, 185], ["HIV-1", "ORGANISM", 18, 23], ["HIV-2", "ORGANISM", 28, 33], ["peripheral blood mononuclear cells", "CELL", 143, 177], ["PBMNCs", "CELL", 179, 185], ["infected peripheral blood mononuclear cells", "CELL_TYPE", 134, 177], ["PBMNCs", "CELL_TYPE", 179, 185], ["HIV-1", "SPECIES", 18, 23], ["HIV-2", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 18, 23], ["HIV-2", "SPECIES", 28, 33], ["CellularCell", "TEST", 0, 12], ["free HIV", "TEST", 13, 21], ["HIV", "TEST", 28, 31], ["The low-passage", "PROBLEM", 50, 65], ["clinical viral stocks", "TREATMENT", 67, 88], ["culture supernatant", "TEST", 109, 128], ["infected peripheral blood mononuclear cells", "TREATMENT", 134, 177], ["PBMNCs", "TEST", 179, 185], ["low", "OBSERVATION_MODIFIER", 54, 57], ["-passage", "OBSERVATION_MODIFIER", 57, 65], ["viral stocks", "OBSERVATION", 76, 88], ["peripheral", "ANATOMY_MODIFIER", 143, 153], ["blood", "ANATOMY", 154, 159], ["mononuclear cells", "OBSERVATION", 160, 177]]], ["The cell-free, clinical isolate HIV-1, strain Z84, was diluted 1:10 (vol/vol) into PLT concentrates to achieve the highest possible titer of approximately 10 3 to 10 4 tissue culture infectious dose (TCID 50 ) per mL.", [["cell", "ANATOMY", 4, 8], ["tissue", "ANATOMY", 168, 174], ["cell", "CELL", 4, 8], ["HIV-1", "ORGANISM", 32, 37], ["PLT", "CELL", 83, 86], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["Z84", "SPECIES", 46, 49], ["clinical isolate HIV", "TEST", 15, 35], ["strain Z84", "TEST", 39, 49], ["PLT concentrates", "TREATMENT", 83, 99]]], ["The cell-free, clinical isolate HIV-2, strain CBL20, was similarly diluted into PLT concentrates to achieve a highest possible titer of approximately 10 2 to 10 3 TCID 50 per mL.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["HIV-2", "ORGANISM", 32, 37], ["CBL20", "ORGANISM", 46, 51], ["PLT", "CELL", 80, 83], ["HIV-2", "SPECIES", 32, 37], ["HIV-2", "SPECIES", 32, 37], ["clinical isolate HIV", "TEST", 15, 35], ["strain CBL20", "TEST", 39, 51], ["PLT concentrates", "TEST", 80, 96]]], ["PLT concentrate samples before treatment were titrated for viable virus on freshly prepared, phytohemagglutinin-stimulated PBMNCs in RPMI.", [["samples", "ANATOMY", 16, 23], ["PBMNCs", "ANATOMY", 123, 129], ["phytohemagglutinin", "CHEMICAL", 93, 111], ["PLT", "GENE_OR_GENE_PRODUCT", 0, 3], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 93, 111], ["PBMNCs", "CELL", 123, 129], ["phytohemagglutinin-stimulated PBMNCs", "CELL_LINE", 93, 129], ["PLT concentrate samples", "TREATMENT", 0, 23], ["treatment", "TREATMENT", 31, 40], ["viable virus", "PROBLEM", 59, 71], ["phytohemagglutinin-stimulated PBMNCs in RPMI", "TREATMENT", 93, 137]]], ["24 After treatment, 2 mL of PLT samples was assayed in 40 mL of PBMNCs.", [["PLT samples", "ANATOMY", 28, 39], ["PBMNCs", "ANATOMY", 64, 70], ["PBMNCs", "CELL", 64, 70], ["PBMNCs", "CELL_TYPE", 64, 70], ["treatment", "TREATMENT", 9, 18], ["PLT samples", "TEST", 28, 39], ["PBMNCs", "TREATMENT", 64, 70]]], ["Inoculated PBMNCs were incubated at 37 \u221e C and split two to three times weekly for the duration of the study.", [["PBMNCs", "ANATOMY", 11, 17], ["PBMNCs", "CELL", 11, 17], ["PBMNCs", "CELL_TYPE", 11, 17], ["Inoculated PBMNCs", "PROBLEM", 0, 17], ["the study", "TEST", 99, 108]]], ["On Day 11, the cultures were cocultivated with uninfected, phytohemagglutinin-stimulated PBMNCs at a cell ratio of 1:1.", [["cultures", "ANATOMY", 15, 23], ["PBMNCs", "ANATOMY", 89, 95], ["cell", "ANATOMY", 101, 105], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 59, 77], ["PBMNCs", "CELL", 89, 95], ["cell", "CELL", 101, 105], ["phytohemagglutinin", "PROTEIN", 59, 77], ["PBMNCs", "CELL_TYPE", 89, 95], ["the cultures", "TEST", 11, 23], ["phytohemagglutinin", "TEST", 59, 77], ["stimulated PBMNCs", "TREATMENT", 78, 95], ["a cell ratio", "TEST", 99, 111]]], ["Supernatants were harvested on Days 7 and 16 for detection of viral replication with a 32 P-reverse transcriptase assay.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["reverse transcriptase", "PROTEIN", 92, 113], ["viral replication", "PROBLEM", 62, 79], ["harvested", "OBSERVATION", 18, 27]]], ["25 Titer was expressed as TCID 50 per mL.Cell-associated HTLV-I and -IIHTLV-I, as infected cells 2060, 26 or HTLV-II, as infected C-19 cells (California Department of Health Services, Richmond, CA), were inoculated into PLT concentrates to a titer of approximately 10 5 focus-forming units (FFU) per mL.", [["Cell", "ANATOMY", 41, 45], ["cells", "ANATOMY", 91, 96], ["C-19 cells", "ANATOMY", 130, 140], ["PLT", "ANATOMY", 220, 223], ["Cell", "CELL", 41, 45], ["HTLV-I", "ORGANISM", 57, 63], ["-IIHTLV-I", "ORGANISM", 68, 77], ["cells", "CELL", 91, 96], ["HTLV-II", "ORGANISM", 109, 116], ["C-19 cells", "CELL", 130, 140], ["PLT", "CELL", 220, 223], ["infected C-19 cells", "CELL_LINE", 121, 140], ["PLT", "PROTEIN", 220, 223], ["HTLV-I", "SPECIES", 57, 63], ["HTLV-II", "SPECIES", 109, 116], ["C-19", "SPECIES", 130, 134], ["Cell", "TEST", 41, 45], ["HTLV", "TEST", 57, 61], ["infected cells", "PROBLEM", 82, 96], ["HTLV", "TEST", 109, 113], ["PLT concentrates", "TEST", 220, 236], ["a titer", "TEST", 240, 247], ["HTLV", "OBSERVATION", 57, 61]]], ["The infectivity of HTLV-I and -II was measured with the BHK21pA18G indicator cell line, which carries a bgalactosidase gene under the control of the long-terminal repeat region of the HTLV-I genome.", [["cell line", "ANATOMY", 77, 86], ["HTLV-I", "ORGANISM", 19, 25], ["-II", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell line", "CELL", 77, 86], ["bgalactosidase", "GENE_OR_GENE_PRODUCT", 104, 118], ["long-terminal repeat region", "CELLULAR_COMPONENT", 149, 176], ["HTLV-I", "ORGANISM", 184, 190], ["BHK21pA18G indicator cell line", "CELL_LINE", 56, 86], ["bgalactosidase gene", "DNA", 104, 123], ["long-terminal repeat region", "DNA", 149, 176], ["HTLV-I genome", "DNA", 184, 197], ["HTLV-I", "SPECIES", 19, 25], ["HTLV-I", "SPECIES", 184, 190], ["the BHK21pA18G indicator cell line", "TREATMENT", 52, 86], ["a bgalactosidase gene", "TREATMENT", 102, 123], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["cell line", "OBSERVATION", 77, 86], ["HTLV", "OBSERVATION", 184, 188]]], ["27 Trans-activating ( tax ) protein, produced as a result of infection with viable HTLV-I or HTLV-II, binds to the long-terminal repeat and initiates production of b -galactosidase, which can be detected by staining with an appropriate substrate.", [["long-terminal repeat", "ANATOMY", 115, 135], ["infection", "DISEASE", 61, 70], ["Trans-activating ( tax )", "GENE_OR_GENE_PRODUCT", 3, 27], ["HTLV-I", "ORGANISM", 83, 89], ["HTLV-II", "ORGANISM", 93, 100], ["b -galactosidase", "GENE_OR_GENE_PRODUCT", 164, 180], ["Trans-activating ( tax ) protein", "PROTEIN", 3, 35], ["long-terminal repeat", "DNA", 115, 135], ["b -galactosidase", "PROTEIN", 164, 180], ["HTLV-I", "SPECIES", 83, 89], ["HTLV-II", "SPECIES", 93, 100], ["infection", "PROBLEM", 61, 70], ["b -galactosidase", "PROBLEM", 164, 180], ["infection", "OBSERVATION", 61, 70]]], ["Foci of infected cells can be enumerated visually in a manner similar to plaques.Cell-associated HTLV-I and -IIHeparin sulfate was added to all samples to a final concentration of 15 U per mL to prevent clotting during subsequent manipulations.", [["cells", "ANATOMY", 17, 22], ["plaques", "ANATOMY", 73, 80], ["Cell", "ANATOMY", 81, 85], ["samples", "ANATOMY", 144, 151], ["plaques", "DISEASE", 73, 80], ["sulfate", "CHEMICAL", 119, 126], ["cells", "CELL", 17, 22], ["plaques", "PATHOLOGICAL_FORMATION", 73, 80], ["Cell", "CELL", 81, 85], ["HTLV-I", "ORGANISM", 97, 103], ["-IIHeparin sulfate", "SIMPLE_CHEMICAL", 108, 126], ["infected cells", "CELL_TYPE", 8, 22], ["HTLV-I", "SPECIES", 97, 103], ["infected cells", "PROBLEM", 8, 22], ["plaques", "PROBLEM", 73, 80], ["Cell", "TEST", 81, 85], ["HTLV", "PROBLEM", 97, 101], ["IIHeparin sulfate", "TREATMENT", 109, 126], ["clotting", "PROBLEM", 203, 211], ["subsequent manipulations", "TREATMENT", 219, 243], ["infected cells", "OBSERVATION", 8, 22], ["plaques", "OBSERVATION", 73, 80], ["clotting", "OBSERVATION", 203, 211]]], ["Serial 10-fold dilutions were performed as necessary, and samples were inoculated into 24-well plates containing a monolayer of BHK21pA18G cells.", [["samples", "ANATOMY", 58, 65], ["monolayer", "ANATOMY", 115, 124], ["BHK21pA18G cells", "ANATOMY", 128, 144], ["monolayer", "CELL", 115, 124], ["BHK21pA18G cells", "CELL", 128, 144], ["BHK21pA18G cells", "CELL_LINE", 128, 144], ["Serial 10-fold dilutions", "TEST", 0, 24], ["samples", "TEST", 58, 65], ["a monolayer of BHK21pA18G cells", "TREATMENT", 113, 144], ["A18G cells", "OBSERVATION", 134, 144]]], ["The plates were incubated at 37 \u221e C in a humidified 5 percent CO 2 environment for 6 days to allow for the stimulation of b -galactosidase production induced by viral infection.", [["viral infection", "DISEASE", 161, 176], ["CO 2", "CHEMICAL", 62, 66], ["b -galactosidase", "GENE_OR_GENE_PRODUCT", 122, 138], ["a humidified 5 percent CO 2 environment", "TREATMENT", 39, 78], ["b -galactosidase production", "TREATMENT", 122, 149], ["viral infection", "PROBLEM", 161, 176], ["viral", "OBSERVATION_MODIFIER", 161, 166], ["infection", "OBSERVATION", 167, 176]]], ["The presence of HTLV-I or HTLV-II in each well was determined by staining with X-Gal (Sigma Chemical Co., St. Louis, MO) and enumerating HTLV-I-or HTLV-II-induced foci.", [["foci", "ANATOMY", 163, 167], ["HTLV-I", "ORGANISM", 16, 22], ["HTLV-II", "ORGANISM", 26, 33], ["X-Gal", "GENE_OR_GENE_PRODUCT", 79, 84], ["St. Louis", "ORGANISM", 106, 115], ["HTLV-I-or HTLV-II", "ORGANISM", 137, 154], ["foci", "CELL", 163, 167], ["HTLV-II", "PROTEIN", 26, 33], ["HTLV-I", "SPECIES", 16, 22], ["HTLV-II", "SPECIES", 26, 33], ["HTLV", "PROBLEM", 16, 20], ["enumerating HTLV", "TEST", 125, 141], ["induced foci", "PROBLEM", 155, 167], ["HTLV", "OBSERVATION", 16, 20], ["foci", "OBSERVATION", 163, 167]]], ["Titer was expressed in FFU per mL.DHBVDHBV served as a model for HBV infection.", [["HBV infection", "DISEASE", 65, 78], ["FFU", "SIMPLE_CHEMICAL", 23, 26], ["HBV", "ORGANISM", 65, 68], ["HBV", "SPECIES", 65, 68], ["HBV infection", "PROBLEM", 65, 78], ["infection", "OBSERVATION", 69, 78]]], ["DHBV was isolated from infected duck serum (gift from P. Marian).", [["serum", "ANATOMY", 37, 42], ["DHBV", "ORGANISM", 0, 4], ["duck", "ORGANISM", 32, 36], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["gift", "ORGANISM_SUBSTANCE", 44, 48], ["P. Marian", "ORGANISM", 54, 63], ["duck", "SPECIES", 32, 36], ["DHBV", "SPECIES", 0, 4], ["duck", "SPECIES", 32, 36], ["DHBV", "PROBLEM", 0, 4], ["infected duck serum", "PROBLEM", 23, 42], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["duck", "OBSERVATION_MODIFIER", 32, 36]]], ["To measure viral titer, samples were serially diluted with PLT concentrate.", [["samples", "ANATOMY", 24, 31], ["PLT", "SIMPLE_CHEMICAL", 59, 62], ["viral titer", "TEST", 11, 22], ["PLT concentrate", "TREATMENT", 59, 74]]], ["Three-to 5-day-old Legarth Pekin hybrid ducklings (Metzer Farm, Gonzales, CA) were inoculated with samples by intravenous injection into the jugular vein.", [["samples", "ANATOMY", 99, 106], ["intravenous", "ANATOMY", 110, 121], ["jugular vein", "ANATOMY", 141, 153], ["Legarth", "ORGANISM", 19, 26], ["Pekin", "ORGANISM", 27, 32], ["ducklings", "ORGANISM", 40, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 121], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 141, 153], ["Pekin", "SPECIES", 27, 32], ["ducklings", "SPECIES", 40, 49], ["Legarth Pekin hybrid ducklings", "SPECIES", 19, 49], ["Legarth Pekin hybrid ducklings", "TREATMENT", 19, 49], ["jugular vein", "ANATOMY", 141, 153]]], ["For each PLT preparation, six ducks were inoculated with 0.5 mL of the negative control and 12 ducks were inoculated with 6 mL of the undiluted PCT PLTs.", [["PLTs", "ANATOMY", 148, 152], ["ducks", "ORGANISM", 30, 35], ["ducks", "ORGANISM", 95, 100], ["PLTs", "CELL", 148, 152], ["PCT PLTs", "CELL_TYPE", 144, 152], ["ducks", "SPECIES", 30, 35], ["ducks", "SPECIES", 95, 100], ["ducks", "SPECIES", 30, 35], ["ducks", "SPECIES", 95, 100], ["each PLT preparation", "TREATMENT", 4, 24], ["the undiluted PCT PLTs", "TREATMENT", 130, 152]]], ["All animals had been screened for congenital infection with DHBV.", [["congenital infection", "DISEASE", 34, 54], ["DHBV", "ORGANISM", 60, 64], ["DHBV", "SPECIES", 60, 64], ["congenital infection", "PROBLEM", 34, 54], ["DHBV", "PROBLEM", 60, 64], ["infection", "OBSERVATION", 45, 54]]], ["Nineteen days after inoculation, ducks were euthanized, and liver samples were collected for analysis.", [["liver samples", "ANATOMY", 60, 73], ["ducks", "ORGANISM", 33, 38], ["liver samples", "CANCER", 60, 73], ["ducks", "SPECIES", 33, 38], ["ducks", "SPECIES", 33, 38], ["inoculation", "TREATMENT", 20, 31], ["liver samples", "TEST", 60, 73], ["analysis", "TEST", 93, 101], ["liver", "ANATOMY", 60, 65]]], ["DNA was released from hepatocytes by mechanical homogenization in the presence of sodium dodecyl sulfate.", [["hepatocytes", "ANATOMY", 22, 33], ["sodium dodecyl sulfate", "CHEMICAL", 82, 104], ["sodium dodecyl sulfate", "CHEMICAL", 82, 104], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["hepatocytes", "CELL", 22, 33], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 82, 104], ["hepatocytes", "CELL_TYPE", 22, 33], ["DNA", "PROBLEM", 0, 3], ["mechanical homogenization", "TREATMENT", 37, 62], ["sodium dodecyl sulfate", "TREATMENT", 82, 104], ["hepatocytes", "ANATOMY", 22, 33], ["mechanical homogenization", "OBSERVATION", 37, 62]]], ["Lysates were blotted onto a nitrocellulose membrane, and viral DNA was detected by hybridization with a radiolabeled DNA probe synthesized from cloned DHBV DNA on plasmid pD1.5G.", [["Lysates", "ANATOMY", 0, 7], ["membrane", "ANATOMY", 43, 51], ["nitrocellulose", "CHEMICAL", 28, 42], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["DHBV", "ORGANISM", 151, 155], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["viral DNA", "DNA", 57, 66], ["radiolabeled DNA probe", "DNA", 104, 126], ["DHBV DNA", "DNA", 151, 159], ["DHBV", "SPECIES", 151, 155], ["Lysates", "TEST", 0, 7], ["a nitrocellulose membrane", "TREATMENT", 26, 51], ["viral DNA", "PROBLEM", 57, 66], ["a radiolabeled DNA probe", "TREATMENT", 102, 126], ["cloned DHBV DNA", "PROBLEM", 144, 159], ["DHBV DNA", "OBSERVATION", 151, 159]]], ["28 Autoradiograms were scored by comparing the hybridization signal of test samples with the intensity from samples containing known amounts of cloned viral DNA.", [["samples", "ANATOMY", 76, 83], ["samples", "ANATOMY", 108, 115], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["cloned viral DNA", "DNA", 144, 160], ["Autoradiograms", "TEST", 3, 17], ["the hybridization signal", "TEST", 43, 67], ["test samples", "TEST", 71, 83], ["cloned viral DNA", "PROBLEM", 144, 160], ["amounts", "OBSERVATION_MODIFIER", 133, 140], ["viral DNA", "OBSERVATION", 151, 160]]], ["For samples containing viable virus, DHBV titer was calculated with the method of Reed and Muench.", [["samples", "ANATOMY", 4, 11], ["DHBV", "ORGANISM", 37, 41], ["DHBV", "SPECIES", 37, 41], ["samples containing viable virus", "PROBLEM", 4, 35], ["DHBV titer", "TEST", 37, 47]]], ["29 Titer was expressed as the infectious dose per mL.HBV and HCVApproximately 10 3.5 to 10 5.5 chimpanzee infectious doses (CID 50 ) of HBV (MS-2 strain, NIH repository, Bethesda, MD) or 10 4.5 CID 50 of HCV (Hutchinson strain, NIH repository) in PLT concentrate were evaluated.", [["HBV", "ORGANISM", 53, 56], ["chimpanzee", "ORGANISM", 95, 105], ["HBV", "ORGANISM", 136, 139], ["HCV", "ORGANISM", 204, 207], ["PLT", "CELL", 247, 250], ["HBV", "SPECIES", 53, 56], ["HBV", "SPECIES", 136, 139], ["NIH", "SPECIES", 154, 157], ["HCV", "SPECIES", 204, 207], ["HBV", "PROBLEM", 53, 56], ["HCVApproximately", "TREATMENT", 61, 77], ["HBV (MS", "PROBLEM", 136, 143], ["HCV (Hutchinson strain", "TREATMENT", 204, 226], ["PLT concentrate", "TREATMENT", 247, 262]]], ["[30] [31] [32] Infectivity of these inocula was previously calibrated in chimpanzees na\u00efve to HBV and HCV.", [["[30] [31] [32", "SIMPLE_CHEMICAL", 0, 13], ["chimpanzees", "ORGANISM", 73, 84], ["HBV", "ORGANISM", 94, 97], ["HCV", "ORGANISM", 102, 105], ["HBV", "SPECIES", 94, 97], ["HCV", "SPECIES", 102, 105], ["these inocula", "PROBLEM", 30, 43], ["HBV", "PROBLEM", 94, 97], ["HCV", "PROBLEM", 102, 105]]], ["The residual infectivity of PLT concentrates contaminated with HBV and HCV and subjected to PCT was measured in chimpanzees.", [["PLT concentrates", "ANATOMY", 28, 44], ["PLT", "CELL", 28, 31], ["HBV", "ORGANISM", 63, 66], ["HCV", "ORGANISM", 71, 74], ["chimpanzees", "ORGANISM", 112, 123], ["PLT concentrates", "PROTEIN", 28, 44], ["PCT", "PROTEIN", 92, 95], ["HBV", "SPECIES", 63, 66], ["HCV", "SPECIES", 71, 74], ["The residual infectivity of PLT concentrates", "PROBLEM", 0, 44], ["HBV", "PROBLEM", 63, 66], ["HCV", "PROBLEM", 71, 74], ["PCT", "TEST", 92, 95], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["infectivity", "OBSERVATION_MODIFIER", 13, 24], ["PLT concentrates", "OBSERVATION", 28, 44], ["HCV", "OBSERVATION", 71, 74]]], ["The entire volume of each treated PLT concentrate (300 mL) was transfused into a nonimmune chimpanzee.", [["PLT", "ANATOMY", 34, 37], ["PLT", "CELL", 34, 37], ["chimpanzee", "ORGANISM", 91, 101], ["nonimmune chimpanzee", "SPECIES", 81, 101], ["each treated PLT concentrate", "TREATMENT", 21, 49], ["a nonimmune chimpanzee", "TREATMENT", 79, 101], ["entire", "OBSERVATION_MODIFIER", 4, 10], ["volume", "OBSERVATION_MODIFIER", 11, 17]]], ["The animal experiments were conducted in two phases with three chimpanzees.", [["chimpanzees", "ORGANISM", 63, 74], ["The animal experiments", "TEST", 0, 22]]], ["The dose of virus treated with PCT and order of transfusion were varied (Table 2 ).HBV and HCVIn each phase of the evaluation, sequential serum samples were drawn from each animal over the course of 6 months for alanine aminotransferase (ALT) and apartase aminotransferase (AST) levels, seroconversion (hepatitis B surface antigen, anti-hepatitis B core antigen, anti-hepatitis B surface antigen, or anti-HCV), and the de novo appearance of the appropriate viral nucleic acids (HBV DNA or HCV RNA).", [["serum samples", "ANATOMY", 138, 151], ["alanine", "CHEMICAL", 212, 219], ["hepatitis B surface antigen", "CHEMICAL", 303, 330], ["anti-hepatitis B core antigen", "CHEMICAL", 332, 361], ["nucleic acids", "CHEMICAL", 463, 476], ["alanine", "CHEMICAL", 212, 219], ["HBV", "ORGANISM", 83, 86], ["serum samples", "ORGANISM_SUBSTANCE", 138, 151], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 212, 236], ["ALT", "SIMPLE_CHEMICAL", 238, 241], ["apartase aminotransferase", "GENE_OR_GENE_PRODUCT", 247, 272], ["AST", "SIMPLE_CHEMICAL", 274, 277], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 303, 330], ["anti-hepatitis B core antigen", "GENE_OR_GENE_PRODUCT", 332, 361], ["anti-hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 363, 395], ["HBV", "ORGANISM", 478, 481], ["DNA", "CELLULAR_COMPONENT", 482, 485], ["alanine aminotransferase", "PROTEIN", 212, 236], ["ALT", "PROTEIN", 238, 241], ["apartase aminotransferase", "PROTEIN", 247, 272], ["AST", "PROTEIN", 274, 277], ["hepatitis B surface antigen", "PROTEIN", 303, 330], ["anti-hepatitis B core antigen", "PROTEIN", 332, 361], ["anti-hepatitis B surface antigen", "PROTEIN", 363, 395], ["anti-HCV", "PROTEIN", 400, 408], ["viral nucleic acids", "PROTEIN", 457, 476], ["HBV DNA or HCV RNA", "RNA", 478, 496], ["HBV", "SPECIES", 83, 86], ["HBV", "SPECIES", 478, 481], ["HCV", "SPECIES", 489, 492], ["virus", "PROBLEM", 12, 17], ["PCT", "TREATMENT", 31, 34], ["transfusion", "TREATMENT", 48, 59], ["HBV", "PROBLEM", 83, 86], ["the evaluation", "TEST", 111, 125], ["sequential serum samples", "TEST", 127, 151], ["alanine aminotransferase", "TEST", 212, 236], ["ALT", "TEST", 238, 241], ["apartase aminotransferase", "TEST", 247, 272], ["AST) levels", "TEST", 274, 285], ["seroconversion", "TEST", 287, 301], ["hepatitis B surface antigen", "TEST", 303, 330], ["anti-hepatitis B core antigen", "TEST", 332, 361], ["anti-hepatitis B surface antigen", "TEST", 363, 395], ["anti-HCV", "TEST", 400, 408], ["the appropriate viral nucleic acids", "PROBLEM", 441, 476], ["HBV DNA", "PROBLEM", 478, 485], ["HCV RNA", "PROBLEM", 489, 496]]], ["Viral nucleic acids were detected by a PCR or reverse transcription-PCR assay.", [["nucleic acids", "CHEMICAL", 6, 19], ["Viral nucleic acids", "TEST", 0, 19], ["a PCR", "TEST", 37, 42], ["PCR assay", "TEST", 68, 77], ["nucleic acids", "OBSERVATION", 6, 19]]], ["Liver biopsies were obtained for histologic examination before and after each phase of the evaluation or following any ALT and AST elevation.BVDVBVDV (strain NADL, ATCC, Rockville, MD) was propagated in Madin-Darby bovine kidney (MDBK) cells (ATCC).", [["Liver biopsies", "ANATOMY", 0, 14], ["kidney (MDBK) cells", "ANATOMY", 222, 241], ["ATCC", "ANATOMY", 243, 247], ["BVDVBVDV", "CHEMICAL", 141, 149], ["Liver biopsies", "CANCER", 0, 14], ["ALT", "SIMPLE_CHEMICAL", 119, 122], ["AST", "SIMPLE_CHEMICAL", 127, 130], ["Madin-Darby bovine kidney (MDBK) cells", "CELL", 203, 241], ["ATCC", "CELL", 243, 247], ["AST", "PROTEIN", 127, 130], ["Madin-Darby bovine kidney (MDBK) cells", "CELL_LINE", 203, 241], ["ATCC", "CELL_LINE", 243, 247], ["bovine", "SPECIES", 215, 221], ["BVDVBVDV", "SPECIES", 141, 149], ["MDBK", "SPECIES", 230, 234], ["Liver biopsies", "TEST", 0, 14], ["histologic examination", "TEST", 33, 55], ["the evaluation", "TEST", 87, 101], ["any ALT", "TEST", 115, 122], ["AST elevation", "TEST", 127, 140], ["Darby bovine kidney (MDBK) cells", "TREATMENT", 209, 241], ["biopsies", "OBSERVATION", 6, 14], ["kidney", "ANATOMY", 222, 228]]], ["Virus was harvested from culture supernatant and added to PLT concentrates to achieve a viral titer of approximately 10 5 PFU per mL.", [["supernatant", "ANATOMY", 33, 44], ["Virus", "ORGANISM", 0, 5], ["PLT", "CELL", 58, 61], ["Virus", "PROBLEM", 0, 5], ["culture supernatant", "TEST", 25, 44], ["PLT concentrates", "TREATMENT", 58, 74], ["a viral titer", "TEST", 86, 99]]], ["PLT samples were titrated for BVDV with a plaque assay on bovine turbinate cells (ATCC) ( Table 3) .", [["PLT samples", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 42, 48], ["turbinate cells", "ANATOMY", 65, 80], ["ATCC", "ANATOMY", 82, 86], ["PLT samples", "ORGANISM_SUBSTANCE", 0, 11], ["BVDV", "ORGANISM", 30, 34], ["bovine", "ORGANISM", 58, 64], ["turbinate cells", "CELL", 65, 80], ["ATCC", "CELL", 82, 86], ["bovine turbinate cells", "CELL_TYPE", 58, 80], ["bovine", "SPECIES", 58, 64], ["BVDV", "SPECIES", 30, 34], ["PLT samples", "TEST", 0, 11], ["BVDV", "PROBLEM", 30, 34], ["a plaque assay", "TEST", 40, 54], ["bovine turbinate cells", "TREATMENT", 58, 80], ["plaque", "OBSERVATION", 42, 48]]], ["Titer was expressed as PFU per mL.Human CMVCell-associated CMV inocula were produced by propagating CMV, strain AD169 (ATCC), on human embryonic lung (MRC-5) cells (Cambrex, East Rutherford, NJ).", [["embryonic lung (MRC-5) cells", "ANATOMY", 135, 163], ["Human", "ORGANISM", 34, 39], ["CMVCell", "GENE_OR_GENE_PRODUCT", 40, 47], ["CMV", "ORGANISM", 59, 62], ["CMV", "ORGANISM", 100, 103], ["ATCC", "CELL", 119, 123], ["human", "ORGANISM", 129, 134], ["embryonic lung", "CELL", 135, 149], ["MRC-5) cells", "CELL", 151, 163], ["Cambrex", "CELL", 165, 172], ["human embryonic lung (MRC-5) cells", "CELL_LINE", 129, 163], ["Human", "SPECIES", 34, 39], ["human", "SPECIES", 129, 134], ["Human", "SPECIES", 34, 39], ["CMV", "SPECIES", 59, 62], ["CMV", "SPECIES", 100, 103], ["human", "SPECIES", 129, 134], ["Human CMVCell", "TEST", 34, 47], ["CMV inocula", "PROBLEM", 59, 70], ["propagating CMV", "PROBLEM", 88, 103], ["strain AD169 (ATCC)", "PROBLEM", 105, 124], ["human embryonic lung (MRC", "TREATMENT", 129, 154], ["CMV inocula", "OBSERVATION", 59, 70], ["lung", "ANATOMY", 145, 149]]], ["Approximately 3.5 \u00a5 10 8 infected MRC-5 cells were added to CMV-seronegative PLT concentrates to yield an infectious viral titer of approximately 10 5 PFU per mL PLT concentrate.", [["MRC-5 cells", "ANATOMY", 34, 45], ["MRC-5 cells", "CELL", 34, 45], ["CMV", "ORGANISM", 60, 63], ["PLT", "CELL", 77, 80], ["MRC-5 cells", "CELL_LINE", 34, 45], ["infected MRC", "TEST", 25, 37], ["CMV", "TEST", 60, 63], ["seronegative PLT", "TEST", 64, 80], ["an infectious viral titer", "TEST", 103, 128], ["PLT concentrate", "TEST", 162, 177], ["infectious", "OBSERVATION_MODIFIER", 106, 116]]], ["PLT samples were assayed to determine viable virus titer with a plaque assay on MRC-5 cells.", [["PLT samples", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 64, 70], ["MRC-5 cells", "ANATOMY", 80, 91], ["PLT samples", "ORGANISM_SUBSTANCE", 0, 11], ["MRC-5 cells", "CELL", 80, 91], ["MRC-5 cells", "CELL_LINE", 80, 91], ["PLT samples", "TEST", 0, 11], ["viable virus titer", "PROBLEM", 38, 56], ["a plaque assay", "TEST", 62, 76], ["MRC", "TEST", 80, 83], ["plaque", "OBSERVATION", 64, 70]]], ["For the treated samples, aliquots of 30 mL were assayed undiluted.", [["samples", "ANATOMY", 16, 23]]], ["Inoculated MRC-5 cells were incubated at 37 \u221e C for 7 days and then stained with neutral red.", [["MRC-5 cells", "ANATOMY", 11, 22], ["MRC-5 cells", "CELL", 11, 22], ["MRC-5 cells", "CELL_LINE", 11, 22], ["Inoculated MRC", "TEST", 0, 14], ["neutral red", "OBSERVATION", 81, 92]]], ["Titer was expressed as PFU per mL.SARS-HCoVThe Urbani strain of SARS-HCoV (CDC, Atlanda, GA) was evaluated for sensitivity to PCT in PLT concentrates in two replicate experiments.", [["SARS", "DISEASE", 34, 38], ["SARS-HCoV", "DISEASE", 64, 73], ["PLT", "CELL", 133, 136], ["PCT", "PROTEIN", 126, 129], ["SARS", "TEST", 34, 38], ["SARS", "PROBLEM", 64, 68], ["HCoV", "PROBLEM", 69, 73], ["CDC", "TEST", 75, 78], ["sensitivity", "PROBLEM", 111, 122], ["PCT", "TEST", 126, 129], ["PLT concentrates", "TEST", 133, 149]]], ["The viral stock was prepared from culture supernatant of infected Vero-E6 cells (ATCC) after centrifugation to remove cell debris.", [["supernatant", "ANATOMY", 42, 53], ["Vero-E6 cells", "ANATOMY", 66, 79], ["ATCC", "ANATOMY", 81, 85], ["cell", "ANATOMY", 118, 122], ["Vero-E6 cells", "CELL", 66, 79], ["ATCC", "CELL", 81, 85], ["cell", "CELL", 118, 122], ["infected Vero-E6 cells", "CELL_LINE", 57, 79], ["ATCC", "CELL_LINE", 81, 85], ["Vero-E6", "SPECIES", 66, 73], ["The viral stock", "TREATMENT", 0, 15], ["culture", "TEST", 34, 41], ["infected Vero-E6 cells", "PROBLEM", 57, 79], ["centrifugation", "TREATMENT", 93, 107], ["cell debris", "PROBLEM", 118, 129], ["viral stock", "OBSERVATION", 4, 15], ["cell debris", "OBSERVATION", 118, 129]]], ["The test unit contained 30 mL of PLT concentrate suspended in 35 percent plasma and 65 percent InterSol instead of a full-sized (300 mL) PLT unit.", [["plasma", "ANATOMY", 73, 79], ["InterSol", "CHEMICAL", 95, 103], ["PLT", "CELL", 33, 36], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["InterSol", "SIMPLE_CHEMICAL", 95, 103], ["PLT concentrate", "TREATMENT", 33, 48], ["a full-sized (300 mL) PLT unit", "TREATMENT", 115, 145]]], ["Initial and residual infectivity titers (PFU/mL) were determined by plaque assay on Vero-E6 cells (Table 3) .WNVVirus was harvested from tissue culture supernatants of baby hamster kidney (BHK-21) cells (ATCC) transfected with a full genomic clone (Lineage I, pFL-WNV) of the parental WNV, strain 3356, isolated from the kidney of an American crow.", [["plaque", "ANATOMY", 68, 74], ["Vero-E6 cells", "ANATOMY", 84, 97], ["tissue culture supernatants", "ANATOMY", 137, 164], ["hamster kidney (BHK-21) cells", "ANATOMY", 173, 202], ["ATCC", "ANATOMY", 204, 208], ["clone", "ANATOMY", 242, 247], ["3356", "ANATOMY", 297, 301], ["kidney", "ANATOMY", 321, 327], ["Vero-E6 cells", "CELL", 84, 97], ["WNVVirus", "SIMPLE_CHEMICAL", 109, 117], ["tissue", "ORGANISM_SUBSTANCE", 137, 143], ["baby hamster kidney", "CELL", 168, 187], ["BHK-21) cells", "CELL", 189, 202], ["ATCC", "CELL", 204, 208], ["Lineage I", "GENE_OR_GENE_PRODUCT", 249, 258], ["pFL-WNV", "ORGANISM", 260, 267], ["WNV", "ORGANISM", 285, 288], ["strain 3356", "CELL", 290, 301], ["kidney", "ORGAN", 321, 327], ["Vero-E6 cells", "CELL_LINE", 84, 97], ["baby hamster kidney (BHK-21) cells", "CELL_LINE", 168, 202], ["ATCC", "CELL_LINE", 204, 208], ["hamster", "SPECIES", 173, 180], ["Vero-E6", "SPECIES", 84, 91], ["hamster", "SPECIES", 173, 180], ["WNV", "SPECIES", 264, 267], ["WNV", "SPECIES", 285, 288], ["American crow", "SPECIES", 334, 347], ["residual infectivity titers", "PROBLEM", 12, 39], ["plaque assay", "TEST", 68, 80], ["Vero-E6 cells", "TREATMENT", 84, 97], ["tissue culture supernatants", "TEST", 137, 164], ["BHK", "TEST", 189, 192], ["cells", "TEST", 197, 202], ["ATCC", "TEST", 204, 208], ["a full genomic clone", "PROBLEM", 227, 247], ["pFL", "TEST", 260, 263], ["the parental WNV", "PROBLEM", 272, 288], ["strain", "PROBLEM", 290, 296], ["residual", "OBSERVATION_MODIFIER", 12, 20], ["infectivity", "OBSERVATION_MODIFIER", 21, 32], ["harvested", "OBSERVATION", 122, 131], ["kidney", "ANATOMY", 181, 187], ["parental WNV", "ANATOMY", 276, 288], ["kidney", "ANATOMY", 321, 327], ["American crow", "OBSERVATION", 334, 347]]], ["33 The tissue culture medium was clarified by centrifugation at 10,000 \u00a5 g and stored in aliquots at -80 \u221e C. The titer of the viral stock was approximately 1 \u00a5 10 9 to 5 \u00a5 10 9 PFU per mL.WNVThe procedure for the WNV plaque assay was as previously described.", [["tissue", "ANATOMY", 7, 13], ["plaque", "ANATOMY", 218, 224], ["WNV plaque", "DISEASE", 214, 224], ["tissue", "TISSUE", 7, 13], ["WNV", "ORGANISM", 214, 217], ["WNV", "SPECIES", 214, 217], ["The tissue culture medium", "TEST", 3, 28], ["the viral stock", "TEST", 123, 138], ["procedure", "TREATMENT", 196, 205], ["the WNV plaque assay", "PROBLEM", 210, 230], ["tissue", "ANATOMY", 7, 13], ["WNV", "OBSERVATION_MODIFIER", 214, 217], ["plaque", "OBSERVATION", 218, 224]]], ["33 Samples were inoculated into Vero cells (ATCC).", [["Vero cells", "ANATOMY", 32, 42], ["ATCC", "ANATOMY", 44, 48], ["Vero cells", "CELL", 32, 42], ["ATCC", "CELL", 44, 48], ["Vero cells", "CELL_LINE", 32, 42], ["ATCC", "CELL_LINE", 44, 48], ["Vero cells", "OBSERVATION", 32, 42]]], ["After incubation for 1 hour, the cells were overlayed with culture medium containing 0.6 percent Oxoid agarose (Basingstoke, Hampshire, UK).", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["the cells", "PROBLEM", 29, 38], ["culture medium", "TEST", 59, 73]]], ["The plates were incubated for 2 days at 37 \u221e C and then overlayed with medium containing neutral red stain.", [["neutral red stain", "TEST", 89, 106]]], ["The plates were incubated overnight to allow the plaques to develop and were visually read and counted on Day 3.", [["plaques", "ANATOMY", 49, 56], ["The plates", "TREATMENT", 0, 10], ["the plaques", "PROBLEM", 45, 56], ["plaques", "OBSERVATION", 49, 56]]], ["Titer was expressed as PFU per mL.Vaccinia virusThe IHD-W strain of Vaccinia virus (ATCC) was evaluated for sensitivity to PCT in PLT concentrates in three replicate experiments.", [["Vaccinia virus", "ORGANISM", 34, 48], ["IHD-W strain", "ORGANISM", 52, 64], ["Vaccinia virus", "ORGANISM", 68, 82], ["ATCC", "CELL", 84, 88], ["PLT", "CELL", 130, 133], ["PCT", "PROTEIN", 123, 126], ["Vaccinia virus", "SPECIES", 34, 48], ["Vaccinia virus", "SPECIES", 68, 82], ["Vaccinia virus", "SPECIES", 34, 48], ["Vaccinia virus", "SPECIES", 68, 82], ["ATCC", "SPECIES", 84, 88], ["Vaccinia virus", "PROBLEM", 34, 48], ["The IHD", "PROBLEM", 48, 55], ["Vaccinia virus", "PROBLEM", 68, 82], ["sensitivity", "PROBLEM", 108, 119], ["PCT", "TEST", 123, 126], ["PLT concentrates", "TEST", 130, 146]]], ["The viral stock was prepared from culture supernatant of infected Vero-76 cells (ATCC) after centrifugation to remove cell debris.", [["supernatant", "ANATOMY", 42, 53], ["Vero-76 cells", "ANATOMY", 66, 79], ["ATCC", "ANATOMY", 81, 85], ["cell", "ANATOMY", 118, 122], ["Vero-76 cells", "CELL", 66, 79], ["ATCC", "CELL", 81, 85], ["cell", "CELL", 118, 122], ["infected Vero-76 cells", "CELL_LINE", 57, 79], ["ATCC", "CELL_LINE", 81, 85], ["Vero-76", "SPECIES", 66, 73], ["The viral stock", "TREATMENT", 0, 15], ["culture", "TEST", 34, 41], ["centrifugation", "TREATMENT", 93, 107], ["cell debris", "PROBLEM", 118, 129], ["viral stock", "OBSERVATION", 4, 15], ["cell debris", "OBSERVATION", 118, 129]]], ["Test units contained 30 mL of PLT concentrate suspended in 35 percent plasma and 65 percent InterSol.", [["plasma", "ANATOMY", 70, 76], ["InterSol", "CHEMICAL", 92, 100], ["PLT", "CELL", 30, 33], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["PLT concentrate", "TREATMENT", 30, 45]]], ["Titers were determined by plaque assay on Vero-76 cells (Table 3) .", [["plaque", "ANATOMY", 26, 32], ["Vero-76 cells", "ANATOMY", 42, 55], ["Vero-76 cells", "CELL", 42, 55], ["Vero-76 cells", "CELL_LINE", 42, 55], ["Vero-76", "SPECIES", 42, 49], ["Titers", "TEST", 0, 6], ["plaque assay", "TEST", 26, 38], ["Vero", "TEST", 42, 46]]], ["Titer was expressed as PFU per mL. * Samples containing viruses were serially diluted in cell culture medium as necessary, inoculated onto the appropriate cell layer, and incubated for approximately 1 hour at 37\u221eC. The samples were aspirated and cell layers were overlayed with medium containing 0.75 percent agarose (Seaplaque, FMC Bioproducts, Rockland, ME).", [["cell", "ANATOMY", 89, 93], ["cell layer", "ANATOMY", 155, 165], ["samples", "ANATOMY", 219, 226], ["cell layers", "ANATOMY", 246, 257], ["cell", "CELL", 89, 93], ["cell layer", "CELL", 155, 165], ["cell layers", "CELL", 246, 257], ["agarose", "SIMPLE_CHEMICAL", 309, 316], ["Samples containing viruses", "PROBLEM", 37, 63], ["cell culture medium", "TREATMENT", 89, 108], ["The samples", "TEST", 215, 226], ["cell layers", "TEST", 246, 257], ["medium containing 0.75 percent agarose (Seaplaque, FMC Bioproducts", "TREATMENT", 278, 344], ["appropriate cell", "OBSERVATION_MODIFIER", 143, 159], ["layer", "OBSERVATION_MODIFIER", 160, 165], ["aspirated", "OBSERVATION", 232, 241], ["cell layers", "OBSERVATION", 246, 257]]], ["After the appropriate incubation at 37\u221eC, plaque numbers were scored visually with or without the addition of an overlay containing neutral red (Sigma). \u2020 EMEM = Eagle's minimal essential medium with Earle's salts; FBS = fetal bovine serum.Human adenovirus-5The human adenovirus 5 (gift from Onyx Pharmaceuticals Inc., Richmond, CA) was evaluated for sensitivity to PCT in a single experiment.", [["plaque", "ANATOMY", 42, 48], ["fetal", "ANATOMY", 221, 226], ["serum", "ANATOMY", 234, 239], ["FBS", "ORGANISM_SUBSTANCE", 215, 218], ["bovine", "ORGANISM", 227, 233], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["Human", "ORGANISM", 240, 245], ["adenovirus-5", "ORGANISM", 246, 258], ["human", "ORGANISM", 262, 267], ["adenovirus 5", "ORGANISM", 268, 280], ["gift", "ORGANISM", 282, 286], ["PCT", "PROTEIN", 366, 369], ["bovine", "SPECIES", 227, 233], ["Human", "SPECIES", 240, 245], ["human", "SPECIES", 262, 267], ["bovine", "SPECIES", 227, 233], ["Human adenovirus-5", "SPECIES", 240, 258], ["human", "SPECIES", 262, 267], ["the appropriate incubation", "TREATMENT", 6, 32], ["plaque numbers", "TEST", 42, 56], ["Earle's salts", "TEST", 200, 213], ["FBS", "TEST", 215, 218], ["fetal bovine serum", "TEST", 221, 239], ["Human adenovirus", "TREATMENT", 240, 256], ["The human adenovirus", "TREATMENT", 258, 278], ["Onyx Pharmaceuticals", "TREATMENT", 292, 312], ["PCT", "TEST", 366, 369], ["neutral red", "OBSERVATION", 132, 143], ["minimal", "OBSERVATION_MODIFIER", 170, 177], ["essential", "OBSERVATION_MODIFIER", 178, 187], ["medium", "OBSERVATION_MODIFIER", 188, 194]]], ["The viral stock was prepared from culture supernatant of infected human embryonic kidney cells (HEK293) transformed with sheared human adenovirus 5 DNA (ATCC) after centrifugation to remove cell debris.", [["supernatant", "ANATOMY", 42, 53], ["embryonic kidney cells", "ANATOMY", 72, 94], ["HEK293", "ANATOMY", 96, 102], ["cell", "ANATOMY", 190, 194], ["human", "ORGANISM", 66, 71], ["embryonic kidney cells", "CELL", 72, 94], ["HEK293", "CELL", 96, 102], ["human", "ORGANISM", 129, 134], ["adenovirus", "ORGANISM", 135, 145], ["5", "ORGANISM", 146, 147], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["ATCC", "CELL", 153, 157], ["cell", "CELL", 190, 194], ["infected human embryonic kidney cells", "CELL_LINE", 57, 94], ["HEK293", "CELL_LINE", 96, 102], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 66, 71], ["human adenovirus", "SPECIES", 129, 145], ["ATCC", "SPECIES", 153, 157], ["The viral stock", "TREATMENT", 0, 15], ["culture", "TEST", 34, 41], ["infected human embryonic kidney cells", "PROBLEM", 57, 94], ["sheared human adenovirus 5 DNA (ATCC", "TREATMENT", 121, 157], ["centrifugation", "TREATMENT", 165, 179], ["cell debris", "PROBLEM", 190, 201], ["viral stock", "OBSERVATION", 4, 15], ["infected human embryonic kidney cells", "OBSERVATION", 57, 94], ["cell debris", "OBSERVATION", 190, 201]]], ["The test unit contained a volume of 30 mL of 35 percent plasma and 65 percent InterSol, no PLTs.", [["plasma", "ANATOMY", 56, 62], ["PLTs", "ANATOMY", 91, 95], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["InterSol", "SIMPLE_CHEMICAL", 78, 86], ["PLTs", "CELL", 91, 95], ["PLTs", "CELL_TYPE", 91, 95], ["PLTs", "PROBLEM", 91, 95]]], ["Titers (PFU/mL) were determined by plaque assay on lung carcinoma cells (A549, ATCC, Rockville, MD) ( Table 3) .Bluetongue virusThe bluetongue virus stock (serotype 11, Station strain, ATCC, Rockville, MD) was prepared from the culture supernatant of infected baby hamster kidney-21 (BHK21) cells (ATCC) after centrifugation to remove cell debris.", [["plaque", "ANATOMY", 35, 41], ["lung carcinoma cells", "ANATOMY", 51, 71], ["A549", "ANATOMY", 73, 77], ["ATCC", "ANATOMY", 79, 83], ["Rockville", "ANATOMY", 85, 94], ["supernatant", "ANATOMY", 236, 247], ["hamster kidney-21 (BHK21) cells", "ANATOMY", 265, 296], ["ATCC", "ANATOMY", 298, 302], ["cell", "ANATOMY", 335, 339], ["lung carcinoma", "DISEASE", 51, 65], ["lung carcinoma cells", "CELL", 51, 71], ["A549", "CELL", 73, 77], ["ATCC", "CELL", 79, 83], ["Bluetongue virus", "ORGANISM", 112, 128], ["bluetongue virus", "ORGANISM", 132, 148], ["hamster kidney-21 (BHK21) cells", "CELL", 265, 296], ["ATCC", "CELL", 298, 302], ["cell", "CELL", 335, 339], ["lung carcinoma cells", "CELL_TYPE", 51, 71], ["infected baby hamster kidney-21 (BHK21) cells", "CELL_LINE", 251, 296], ["ATCC", "CELL_LINE", 298, 302], ["Bluetongue virus", "SPECIES", 112, 128], ["bluetongue virus", "SPECIES", 132, 148], ["hamster", "SPECIES", 265, 272], ["Bluetongue virus", "SPECIES", 112, 128], ["bluetongue virus", "SPECIES", 132, 148], ["hamster kidney-21", "SPECIES", 265, 282], ["lung carcinoma cells", "PROBLEM", 51, 71], ["Bluetongue virus", "PROBLEM", 112, 128], ["the culture", "TEST", 224, 235], ["centrifugation", "TREATMENT", 310, 324], ["cell debris", "PROBLEM", 335, 346], ["plaque", "OBSERVATION", 35, 41], ["lung", "ANATOMY", 51, 55], ["carcinoma", "OBSERVATION", 56, 65], ["bluetongue virus stock", "OBSERVATION", 132, 154], ["infected", "OBSERVATION", 251, 259], ["kidney", "ANATOMY", 273, 279], ["cell debris", "OBSERVATION", 335, 346]]], ["The titer of the stock was approximately 10 6 PFU per mL.", [["The titer of the stock", "TREATMENT", 0, 22]]], ["The viral titer in PLT samples was titrated in bovine turbinate cells (ATCC) ( Table 3 ).", [["PLT samples", "ANATOMY", 19, 30], ["turbinate cells", "ANATOMY", 54, 69], ["ATCC", "ANATOMY", 71, 75], ["PLT samples", "ORGANISM_SUBSTANCE", 19, 30], ["bovine", "ORGANISM", 47, 53], ["turbinate cells", "CELL", 54, 69], ["ATCC", "CELL", 71, 75], ["bovine turbinate cells", "CELL_TYPE", 47, 69], ["bovine", "SPECIES", 47, 53], ["The viral titer", "TEST", 0, 15], ["PLT samples", "TEST", 19, 30], ["bovine turbinate cells", "TREATMENT", 47, 69], ["viral titer", "OBSERVATION", 4, 15]]], ["Titer was expressed as PFU per mL.Feline conjunctivitis virusThe feline conjunctivitis virus (FC strain, ATCC) was prepared from the culture supernatant of infected Crandell feline kidney (CrFK) cells (ATCC) after centrifugation to remove cell debris.", [["ATCC", "ANATOMY", 105, 109], ["supernatant", "ANATOMY", 141, 152], ["Crandell feline kidney (CrFK) cells", "ANATOMY", 165, 200], ["ATCC", "ANATOMY", 202, 206], ["cell", "ANATOMY", 239, 243], ["Feline conjunctivitis", "DISEASE", 34, 55], ["feline conjunctivitis", "DISEASE", 65, 86], ["Feline conjunctivitis virus", "ORGANISM", 34, 61], ["feline conjunctivitis virus", "ORGANISM", 65, 92], ["ATCC", "CELL", 105, 109], ["Crandell feline kidney (CrFK) cells", "CELL", 165, 200], ["ATCC", "CELL", 202, 206], ["cell", "CELL", 239, 243], ["Crandell feline kidney (CrFK) cells", "CELL_LINE", 165, 200], ["Feline conjunctivitis virus", "SPECIES", 34, 61], ["feline conjunctivitis virus", "SPECIES", 65, 92], ["feline", "SPECIES", 174, 180], ["Feline conjunctivitis virus", "SPECIES", 34, 61], ["feline conjunctivitis virus", "SPECIES", 65, 92], ["ATCC", "SPECIES", 105, 109], ["Crandell feline kidney", "SPECIES", 165, 187], ["Feline conjunctivitis virus", "PROBLEM", 34, 61], ["The feline conjunctivitis virus (FC strain", "PROBLEM", 61, 103], ["the culture", "TEST", 129, 140], ["infected Crandell feline kidney", "PROBLEM", 156, 187], ["centrifugation", "TREATMENT", 214, 228], ["cell debris", "PROBLEM", 239, 250], ["conjunctivitis", "OBSERVATION", 41, 55], ["feline", "OBSERVATION_MODIFIER", 65, 71], ["conjunctivitis virus", "OBSERVATION", 72, 92], ["infected", "OBSERVATION", 156, 164], ["Crandell feline", "OBSERVATION", 165, 180], ["kidney", "ANATOMY", 181, 187], ["cell debris", "OBSERVATION", 239, 250]]], ["The viral titer in PLT samples was titrated in CrFK cells (Table 3) .", [["PLT samples", "ANATOMY", 19, 30], ["CrFK cells", "ANATOMY", 47, 57], ["PLT samples", "ORGANISM_SUBSTANCE", 19, 30], ["CrFK cells", "CELL", 47, 57], ["CrFK cells", "CELL_LINE", 47, 57], ["The viral titer", "TEST", 0, 15], ["PLT samples", "TEST", 19, 30], ["viral titer", "OBSERVATION", 4, 15]]], ["Titer was expressed in PFU per mL.Simian adenovirus 15The Simian adenovirus 15 (strain AP4398, ATCC) stock (SV-15) was prepared from the culture supernatant of infected fetal rhesus kidney (FRhK) cells (gift from the California Department of Health Services) after centrifugation to remove cell debris.", [["supernatant", "ANATOMY", 145, 156], ["fetal rhesus kidney (FRhK) cells", "ANATOMY", 169, 201], ["cell", "ANATOMY", 290, 294], ["SV-15", "CHEMICAL", 108, 113], ["Simian adenovirus 15", "ORGANISM", 34, 54], ["Simian adenovirus 15", "ORGANISM", 58, 78], ["strain AP4398", "ORGANISM", 80, 93], ["ATCC", "CELL", 95, 99], ["SV-15", "ORGANISM", 108, 113], ["fetal rhesus kidney (FRhK) cells", "CELL", 169, 201], ["cell", "CELL", 290, 294], ["infected fetal rhesus kidney (FRhK) cells", "CELL_TYPE", 160, 201], ["Simian", "SPECIES", 34, 40], ["Simian adenovirus", "SPECIES", 58, 75], ["rhesus", "SPECIES", 175, 181], ["Simian adenovirus 15", "SPECIES", 34, 54], ["Simian adenovirus 15", "SPECIES", 58, 78], ["Simian adenovirus", "PROBLEM", 34, 51], ["The Simian adenovirus", "TEST", 54, 75], ["SV", "TEST", 108, 110], ["the culture", "TEST", 133, 144], ["centrifugation", "TREATMENT", 265, 279], ["cell debris", "PROBLEM", 290, 301], ["infected", "OBSERVATION", 160, 168], ["kidney", "ANATOMY", 182, 188], ["cell debris", "OBSERVATION", 290, 301]]], ["The titer of the stock was approximately 10 7.5 TCID 50 per mL.", [["The titer of the stock", "TREATMENT", 0, 22]]], ["The viral titer in PLT samples was titrated in FRhK cells.", [["PLT samples", "ANATOMY", 19, 30], ["FRhK cells", "ANATOMY", 47, 57], ["PLT samples", "ORGANISM_SUBSTANCE", 19, 30], ["FRhK cells", "CELL", 47, 57], ["FRhK cells", "CELL_LINE", 47, 57], ["The viral titer", "TEST", 0, 15], ["PLT samples", "TEST", 19, 30], ["viral titer", "OBSERVATION", 4, 15]]], ["Samples with additional serial dilutions were made in culture medium as necessary and inoculated onto 96-well plates containing FRhK cells.", [["Samples", "ANATOMY", 0, 7], ["FRhK cells", "ANATOMY", 128, 138], ["FRhK cells", "CELL", 128, 138], ["FRhK cells", "CELL_LINE", 128, 138], ["Samples", "TEST", 0, 7], ["additional serial dilutions", "TREATMENT", 13, 40], ["culture medium", "TEST", 54, 68], ["FRhK cells", "PROBLEM", 128, 138]]], ["After 10 to 14 days of incubation at 37\u221eC in a humidified 5 percent CO 2 incubator to allow for development of cytopathic effect, wells were evaluated for the presence or absence of cytopathic effect with the aid of a microscope, and sample titers were calculated in TCID 50 per mL.PPVThe PPV stock (strain NADL-2, ATCC) was prepared from the culture supernatant of infected porcine kidney-13 (PK13) cells (ATCC) after centrifugation to remove cell debris.", [["sample", "ANATOMY", 234, 240], ["supernatant", "ANATOMY", 351, 362], ["kidney-13 (PK13) cells", "ANATOMY", 383, 405], ["ATCC", "ANATOMY", 407, 411], ["cell", "ANATOMY", 444, 448], ["CO 2", "CHEMICAL", 68, 72], ["C", "SIMPLE_CHEMICAL", 40, 41], ["ATCC", "CELL", 315, 319], ["porcine", "ORGANISM", 375, 382], ["kidney-13 (PK13) cells", "CELL", 383, 405], ["ATCC", "CELL", 407, 411], ["cell", "CELL", 444, 448], ["infected porcine kidney-13 (PK13) cells", "CELL_LINE", 366, 405], ["ATCC", "CELL_LINE", 407, 411], ["porcine", "SPECIES", 375, 382], ["porcine kidney-13", "SPECIES", 375, 392], ["incubation", "TREATMENT", 23, 33], ["a humidified 5 percent CO 2 incubator", "TREATMENT", 45, 82], ["cytopathic effect", "PROBLEM", 111, 128], ["cytopathic effect", "PROBLEM", 182, 199], ["a microscope", "TEST", 216, 228], ["sample titers", "TEST", 234, 247], ["the culture", "TEST", 339, 350], ["infected porcine kidney", "TREATMENT", 366, 389], ["centrifugation", "TREATMENT", 419, 433], ["cell debris", "PROBLEM", 444, 455], ["cytopathic", "OBSERVATION_MODIFIER", 111, 121], ["cytopathic", "OBSERVATION_MODIFIER", 182, 192], ["infected", "OBSERVATION", 366, 374], ["kidney", "ANATOMY", 383, 389], ["cell debris", "OBSERVATION", 444, 455]]], ["The titer of the stock was approximately 10 7.5 PFU per mL.", [["The titer of the stock", "TREATMENT", 0, 22]]], ["The viral titer in PLT samples was titrated in PK13 cells (Table 3) .", [["PLT samples", "ANATOMY", 19, 30], ["PK13 cells", "ANATOMY", 47, 57], ["PLT samples", "ORGANISM_SUBSTANCE", 19, 30], ["PK13 cells", "CELL", 47, 57], ["PK13 cells", "CELL_LINE", 47, 57], ["The viral titer", "TEST", 0, 15], ["PLT samples", "TEST", 19, 30], ["viral titer", "OBSERVATION", 4, 15]]], ["Titer was expressed in PFU per mL.Parvovirus B19Parvovirus B19-infected plasma samples (Alpha Therapeutics, Los Angeles, CA) were evaluated for sensitivity to PCT in 35 percent plasma and 65 percent InterSol.", [["plasma samples", "ANATOMY", 72, 86], ["plasma", "ANATOMY", 177, 183], ["InterSol", "CHEMICAL", 199, 207], ["Parvovirus B19Parvovirus B19", "ORGANISM", 34, 62], ["plasma samples", "ORGANISM_SUBSTANCE", 72, 86], ["plasma", "ORGANISM_SUBSTANCE", 177, 183], ["Parvovirus B19Parvovirus B19", "SPECIES", 34, 62], ["Parvovirus B19Parvovirus B19", "SPECIES", 34, 62], ["Parvovirus B19Parvovirus B19", "TEST", 34, 62], ["plasma samples", "TEST", 72, 86], ["sensitivity", "TEST", 144, 155], ["PCT", "TEST", 159, 162], ["plasma", "TEST", 177, 183]]], ["The test unit had a volume of 30 mL and no PLTs.", [["PLTs", "ANATOMY", 43, 47], ["PLTs", "CELL", 43, 47], ["PLTs", "CELL_TYPE", 43, 47], ["PLTs", "PROBLEM", 43, 47]]], ["Two replicate experiments were performed.", [["Two replicate experiments", "TEST", 0, 25]]], ["Viable virus titer was determined by infection of CD34+ cells (All Cells, Berkeley, CA) and detection of progeny by ELISpot assay.", [["CD34+ cells", "ANATOMY", 50, 61], ["Cells", "ANATOMY", 67, 72], ["CD34", "GENE_OR_GENE_PRODUCT", 50, 54], ["Cells", "CELL", 67, 72], ["CD34", "PROTEIN", 50, 54], ["Viable virus titer", "PROBLEM", 0, 18], ["CD34+ cells", "PROBLEM", 50, 61], ["ELISpot assay", "TEST", 116, 129], ["virus", "OBSERVATION", 7, 12], ["infection", "OBSERVATION", 37, 46]]], ["34 CD34+ cells obtained from granulocyte-macrophage-colony-stimulating factor-mobilized donor PBMNCs were treated with cytokines to induce proliferation and differentiation into CD36+ cells and then infected with serially diluted B19 and transferred to ELISpot plates that had been coated with a polyclonal antibody to B19 proteins (Dako, Carpinteria, CA).", [["CD34+ cells", "ANATOMY", 3, 14], ["PBMNCs", "ANATOMY", 94, 100], ["CD36+ cells", "ANATOMY", 178, 189], ["CD34", "GENE_OR_GENE_PRODUCT", 3, 7], ["granulocyte-macrophage-colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 29, 77], ["PBMNCs", "CELL", 94, 100], ["CD36", "GENE_OR_GENE_PRODUCT", 178, 182], ["B19", "ORGANISM", 230, 233], ["B19", "ORGANISM", 319, 322], ["Dako", "GENE_OR_GENE_PRODUCT", 333, 337], ["CA", "GENE_OR_GENE_PRODUCT", 352, 354], ["CD34", "PROTEIN", 3, 7], ["granulocyte-macrophage-colony-stimulating factor-mobilized donor PBMNCs", "CELL_LINE", 29, 100], ["cytokines", "PROTEIN", 119, 128], ["CD36", "PROTEIN", 178, 182], ["polyclonal antibody", "PROTEIN", 296, 315], ["B19 proteins", "PROTEIN", 319, 331], ["Dako, Carpinteria, CA", "PROTEIN", 333, 354], ["B19", "SPECIES", 230, 233], ["B19", "SPECIES", 319, 322], ["CD34+ cells", "TEST", 3, 14], ["granulocyte", "TEST", 29, 40], ["macrophage", "TEST", 41, 51], ["stimulating factor", "PROBLEM", 59, 77], ["mobilized donor PBMNCs", "TREATMENT", 78, 100], ["cytokines", "TREATMENT", 119, 128], ["proliferation", "PROBLEM", 139, 152], ["CD36+ cells", "PROBLEM", 178, 189], ["serially diluted B19", "TREATMENT", 213, 233], ["ELISpot plates", "TEST", 253, 267], ["a polyclonal antibody", "TEST", 294, 315], ["B19 proteins", "TEST", 319, 331], ["granulocyte", "ANATOMY", 29, 40]]], ["The ELISpot plates were incubated for 72 to 96 hours, and the cells were removed by washing.", [["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["The ELISpot plates", "TEST", 0, 18], ["the cells", "TREATMENT", 58, 67]]], ["B19 antigens bound to the plates were detected by a monoclonal antibody to VP 1 and 2 (Chemicon, Temecula, CA).", [["B19", "ORGANISM", 0, 3], ["Temecula", "GENE_OR_GENE_PRODUCT", 97, 105], ["CA", "GENE_OR_GENE_PRODUCT", 107, 109], ["B19 antigens", "PROTEIN", 0, 12], ["monoclonal antibody", "PROTEIN", 52, 71], ["VP 1 and 2 (Chemicon, Temecula, CA", "PROTEIN", 75, 109], ["B19", "SPECIES", 0, 3], ["B19 antigens", "TEST", 0, 12], ["the plates", "TEST", 22, 32], ["a monoclonal antibody", "TEST", 50, 71], ["VP", "TEST", 75, 77], ["Chemicon", "TEST", 87, 95], ["Temecula", "ANATOMY", 97, 105]]], ["The spots were developed with a silver stain and counted visually with a stereomicroscope or on a plate reader (Immuno-Spot, Celluar Technologics, CTD, Cleveland, OH).", [["silver", "CHEMICAL", 32, 38], ["a silver stain", "TEST", 30, 44], ["a stereomicroscope", "PROBLEM", 71, 89]]], ["The titer was expressed in spot-forming units per mL.Statistical analysisThe level of viral inactivation was calculated as logreduction with the formula Log-reduction = Log(pretreatment viral titer/ posttreatment viral titer).Statistical analysisAfter PCT, if no virus was detected, the viral titer was expressed as <1/V infectious units, where V is the total PLT volume assayed.", [["PLT", "CELL", 360, 363], ["Statistical analysis", "TEST", 53, 73], ["viral inactivation", "PROBLEM", 86, 104], ["the formula Log-reduction", "TREATMENT", 141, 166], ["pretreatment viral titer", "TEST", 173, 197], ["posttreatment viral titer", "TEST", 199, 224], ["Statistical analysisAfter PCT", "TEST", 226, 255], ["virus", "PROBLEM", 263, 268], ["the viral titer", "TEST", 283, 298], ["the total PLT volume", "TEST", 350, 370], ["viral inactivation", "OBSERVATION", 86, 104]]], ["No virus detected indicated inactivation to below the limit of detection; thus the log-reduction was expressed as greater than the input titer.", [["virus", "PROBLEM", 3, 8], ["the log-reduction", "TREATMENT", 79, 96], ["virus", "OBSERVATION", 3, 8]]], ["If no virus was detected in a sample volume significantly smaller than the volume of the PLT unit (300 mL), statistical analysis was performed with the Poisson distribution to calculate the concentration [C] of virus required to be detected with 95 percent probability according to the formula.Statistical analysiswhere P 0 , taken as 0.05 for 95 percent, represents the probability that no virus would be present in a sample of volume V. 20RESULTSEnveloped viruses of varying size and nucleic acid content were uniformly sensitive to PCT with 150 mmol per L amo-tosalen and 3 J per cm 2 UVA in PLT concentrates (Table 4) .", [["sample", "ANATOMY", 30, 36], ["nucleic acid", "CHEMICAL", 486, 498], ["UVA", "CHEMICAL", 588, 591], ["amo-tosalen", "CHEMICAL", 559, 570], ["nucleic acid", "SIMPLE_CHEMICAL", 486, 498], ["V. 20RESULTSEnveloped viruses", "SPECIES", 436, 465], ["virus", "PROBLEM", 6, 11], ["a sample volume", "TEST", 28, 43], ["the PLT unit", "TREATMENT", 85, 97], ["statistical analysis", "TEST", 108, 128], ["virus", "PROBLEM", 211, 216], ["virus", "PROBLEM", 391, 396], ["varying size", "PROBLEM", 469, 481], ["nucleic acid content", "PROBLEM", 486, 506], ["PCT", "TEST", 535, 538], ["PLT concentrates", "TEST", 595, 611], ["no", "UNCERTAINTY", 3, 5], ["virus", "OBSERVATION", 6, 11], ["smaller", "OBSERVATION_MODIFIER", 58, 65], ["varying", "OBSERVATION_MODIFIER", 469, 476], ["size", "OBSERVATION_MODIFIER", 477, 481], ["acid content", "OBSERVATION", 494, 506]]], ["High levels of a broad spectrum of enveloped viruses were inactivated to the limit of detection.", [["enveloped viruses", "PROBLEM", 35, 52], ["enveloped", "OBSERVATION_MODIFIER", 35, 44], ["viruses", "OBSERVATION", 45, 52]]], ["When feasible, inactivation studies were designed to achieve a 6-log dynamic range in infectivity.", [["inactivation studies", "TEST", 15, 35]]], ["For clinical HIV isolates, viral stocks with the highest available titer were used and the level of inactivation was at the limit of the dynamic range achievable for these clinical isolates.", [["HIV", "ORGANISM", 13, 16], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["clinical HIV isolates", "TREATMENT", 4, 25], ["viral stocks", "TREATMENT", 27, 39]]], ["Inactivation of HIV clinical isolates was shown to be as sensitive to PCT as laboratory adapted strains.", [["HIV", "ORGANISM", 16, 19], ["HIV", "SPECIES", 16, 19], ["HIV", "SPECIES", 16, 19], ["HIV clinical isolates", "PROBLEM", 16, 37], ["PCT", "TEST", 70, 73]]], ["The inactivation level, expressed as log-reduction, was first calculated with the experimental findings regardless of the sample volume (Table 4 , Column 5).", [["sample", "ANATOMY", 122, 128], ["the sample volume", "TEST", 118, 135]]], ["When the sample volume used for the measurement of residual viral titer was significantly lower than the treatment volume of 300 mL per unit PLT concentrate, the Poisson distribution was used to estimate the minimum concentration of virus that would have to be present in the PLT unit to be detected with 95 percent probability in a smaller sample volume.", [["sample", "ANATOMY", 9, 15], ["sample", "ANATOMY", 341, 347], ["PLT unit", "DNA", 276, 284], ["the sample volume", "TEST", 5, 22], ["residual viral titer", "PROBLEM", 51, 71], ["the treatment volume", "TREATMENT", 101, 121], ["PLT concentrate", "TREATMENT", 141, 156], ["virus", "PROBLEM", 233, 238], ["the PLT unit", "TEST", 272, 284], ["viral titer", "OBSERVATION", 60, 71]]], ["This led to a conservative and lower limit on the viral log-reduction (Table 4 , Column 6).RESULTSWhen inactivation below the detection limit was obtained, log-reduction was reported as greater than the input titer.", [["a conservative and lower limit", "TREATMENT", 12, 42], ["the viral log-reduction (Table 4 , Column", "TREATMENT", 46, 87], ["the detection limit", "TEST", 122, 141], ["lower limit", "OBSERVATION_MODIFIER", 31, 42]]], ["For HTLV assays, there was a low level of naturally occurring b-galactosidase expression in the BHK21 indicator cells, and it was not possible in this study to differentiate whether the few b-galactosidase-expressing cells present in wells inoculated with treated samples were a result of this natural b-galactosidase expression or whether they were truly infected with HTLV.", [["BHK21 indicator cells", "ANATOMY", 96, 117], ["cells", "ANATOMY", 217, 222], ["samples", "ANATOMY", 264, 271], ["HTLV", "ORGANISM", 4, 8], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 62, 77], ["BHK21 indicator cells", "CELL", 96, 117], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 190, 205], ["cells", "CELL", 217, 222], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 302, 317], ["HTLV", "ORGANISM", 370, 374], ["b-galactosidase", "PROTEIN", 62, 77], ["BHK21 indicator cells", "CELL_LINE", 96, 117], ["b-galactosidase-expressing cells", "CELL_LINE", 190, 222], ["b-galactosidase", "PROTEIN", 302, 317], ["HTLV", "SPECIES", 4, 8], ["HTLV assays", "TEST", 4, 15], ["the BHK21 indicator cells", "PROBLEM", 92, 117], ["this study", "TEST", 146, 156], ["expressing cells", "PROBLEM", 206, 222], ["HTLV", "PROBLEM", 370, 374], ["low level", "OBSERVATION_MODIFIER", 29, 38], ["infected", "OBSERVATION", 356, 364]]], ["The conservative approach was used in the calculation of inactivation by assuming that all b-galactosidase production was the result of infection.RESULTSFor HBV and HCV, inactivation was demonstrated with the well-documented and characterized MS2 and Hutchinson strain, respectively.", [["b-galactosidase", "CHEMICAL", 91, 106], ["infection", "DISEASE", 136, 145], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 91, 106], ["HBV", "ORGANISM", 157, 160], ["HCV", "ORGANISM", 165, 168], ["HBV", "SPECIES", 157, 160], ["HCV", "SPECIES", 165, 168], ["The conservative approach", "TREATMENT", 0, 25], ["all b-galactosidase production", "PROBLEM", 87, 117], ["infection", "PROBLEM", 136, 145], ["HBV", "PROBLEM", 157, 160], ["HCV", "PROBLEM", 165, 168], ["Hutchinson strain", "PROBLEM", 251, 268], ["infection", "OBSERVATION", 136, 145], ["HCV", "OBSERVATION", 165, 168], ["MS2", "OBSERVATION", 243, 246], ["Hutchinson strain", "OBSERVATION", 251, 268]]], ["The highest available titers of calibrated viral stocks were used for these studies.", [["calibrated viral stocks", "TREATMENT", 32, 55], ["these studies", "TEST", 70, 83], ["viral stocks", "OBSERVATION", 43, 55]]], ["Infectivity was measured in nonimmune chimpanzees.", [["chimpanzees", "ORGANISM", 38, 49], ["Infectivity", "PROBLEM", 0, 11], ["nonimmune chimpanzees", "OBSERVATION", 28, 49]]], ["In both phases of the study, none of the animals showed serologic, viral nucleic acid, biochemical, or histologic evidence of viral hepatitis during a 6-month follow-up.", [["viral hepatitis", "DISEASE", 126, 141], ["animals", "ORGANISM", 41, 48], ["the study", "TEST", 18, 27], ["serologic", "TEST", 56, 65], ["viral nucleic acid", "TEST", 67, 85], ["viral hepatitis", "PROBLEM", 126, 141], ["viral hepatitis", "OBSERVATION", 126, 141]]], ["The results demonstrated inactivation of up to greater than 5.5 logs of HBV and up to greater than 4.5 logs of HCV.", [["HBV", "ORGANISM", 72, 75], ["HCV", "ORGANISM", 111, 114], ["HBV", "SPECIES", 72, 75], ["HCV", "SPECIES", 111, 114], ["HBV", "PROBLEM", 72, 75], ["HCV", "PROBLEM", 111, 114]]], ["To further evaluate the efficacy of PCT for hepatitis viruses and to expand the dynamic range for HBV and HCV, model viruses were used.", [["hepatitis viruses", "DISEASE", 44, 61], ["HBV", "ORGANISM", 98, 101], ["HCV", "ORGANISM", 106, 109], ["PCT", "PROTEIN", 36, 39], ["hepatitis viruses", "SPECIES", 44, 61], ["HBV", "SPECIES", 98, 101], ["HCV", "SPECIES", 106, 109], ["PCT", "TEST", 36, 39], ["hepatitis viruses", "PROBLEM", 44, 61], ["HBV", "PROBLEM", 98, 101], ["HCV, model viruses", "TREATMENT", 106, 124]]], ["DHBV has been chosen as a model for HBV because of its extensive genetic and ultrastructural homology with HBV.", [["DHBV", "ORGANISM", 0, 4], ["HBV", "ORGANISM", 36, 39], ["HBV", "ORGANISM", 107, 110], ["DHBV", "SPECIES", 0, 4], ["HBV", "SPECIES", 36, 39], ["HBV", "SPECIES", 107, 110], ["DHBV", "TREATMENT", 0, 4], ["HBV", "PROBLEM", 36, 39], ["HBV", "PROBLEM", 107, 110]]], ["35 BVDV was selected as a model for HCV because of ultrastructural similarity between HCV and BVDV.", [["BVDV", "ORGANISM", 3, 7], ["HCV", "ORGANISM", 36, 39], ["HCV", "ORGANISM", 86, 89], ["BVDV", "ORGANISM", 94, 98], ["BVDV", "SPECIES", 94, 98], ["BVDV", "SPECIES", 3, 7], ["HCV", "SPECIES", 36, 39], ["HCV", "SPECIES", 86, 89], ["BVDV", "SPECIES", 94, 98], ["BVDV", "PROBLEM", 3, 7], ["HCV", "PROBLEM", 36, 39], ["HCV", "PROBLEM", 86, 89], ["BVDV", "PROBLEM", 94, 98], ["HCV", "OBSERVATION", 86, 89], ["BVDV", "OBSERVATION", 94, 98]]], ["36 By use of these model viruses, greater than 6 logs of inactivation were demonstrated.RESULTSCMV was shown to be sensitive to PCT.", [["RESULTSCMV", "PROTEIN", 88, 98], ["PCT", "PROTEIN", 128, 131], ["RESULTSCMV", "SPECIES", 88, 98], ["inactivation", "PROBLEM", 57, 69], ["PCT", "TEST", 128, 131], ["viruses", "OBSERVATION", 25, 32]]], ["Previous studies have demonstrated that high levels of CMV inactivation could be achieved with an efficacy margin of more than 100-fold.", [["CMV", "ORGANISM", 55, 58], ["Previous studies", "TEST", 0, 16], ["CMV inactivation", "PROBLEM", 55, 71], ["high", "OBSERVATION_MODIFIER", 40, 44], ["CMV inactivation", "OBSERVATION", 55, 71], ["efficacy", "OBSERVATION_MODIFIER", 98, 106], ["margin", "OBSERVATION_MODIFIER", 107, 113]]], ["No virus was detected in the volume assayed. \u2020 Highest possible titer. \u2021 No \" >\" was assigned because there was a low level of naturally occurring b-galactosidase expression in the BHK21 indicator cells, and it was not possible to differentiate whether the few b-galactosidase-expressing cells present in wells inoculate with treated samples were a result of this natural b-galactosidase expression or whether they were truly infected with HTLV-I or -II.", [["BHK21 indicator cells", "ANATOMY", 181, 202], ["cells", "ANATOMY", 288, 293], ["samples", "ANATOMY", 334, 341], ["b-galactosidase", "SIMPLE_CHEMICAL", 147, 162], ["cells", "CELL", 197, 202], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 261, 276], ["cells", "CELL", 288, 293], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 372, 387], ["HTLV-I", "ORGANISM", 440, 446], ["-II", "ORGANISM", 450, 453], ["b-galactosidase", "PROTEIN", 147, 162], ["BHK21 indicator cells", "CELL_LINE", 181, 202], ["b-galactosidase-expressing cells", "CELL_LINE", 261, 293], ["b-galactosidase", "PROTEIN", 372, 387], ["HTLV-I", "SPECIES", 440, 446], ["virus", "PROBLEM", 3, 8], ["titer", "PROBLEM", 64, 69], ["the BHK21 indicator cells", "PROBLEM", 177, 202], ["expressing cells", "PROBLEM", 277, 293], ["virus", "OBSERVATION", 3, 8], ["titer", "OBSERVATION", 64, 69]]], ["The conservative approach assumed that all b-galactosidase production was the result of HTLV infection. \u00a7 Inactivation experiments were performed with 30-mL aliquots of PLT concentrates instead of the full-sized (300 mL) units.", [["HTLV infection", "DISEASE", 88, 102], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 43, 58], ["HTLV", "ORGANISM", 88, 92], ["PLT", "SIMPLE_CHEMICAL", 169, 172], ["The conservative approach", "TREATMENT", 0, 25], ["all b-galactosidase production", "PROBLEM", 39, 69], ["HTLV infection", "PROBLEM", 88, 102], ["Inactivation experiments", "TEST", 106, 130], ["PLT concentrates", "TREATMENT", 169, 185], ["the full-sized", "TREATMENT", 197, 211], ["HTLV infection", "OBSERVATION", 88, 102]]], ["In addition, although four replicate experiments were performed for other viruses, only two and three replicates were performed for SARS-HCoV and vaccinia virus, respectively.RESULTSNonenveloped viruses demonstrated variable inactivation with PCT with 150 mmol per L amotosalen and 3 J per cm 2 UVA in PLT concentrates (Table 5) .", [["UVA", "CHEMICAL", 295, 298], ["amotosalen", "CHEMICAL", 267, 277], ["SARS-HCoV", "ORGANISM", 132, 141], ["vaccinia virus", "ORGANISM", 146, 160], ["SARS-HCoV", "SPECIES", 132, 141], ["vaccinia virus", "SPECIES", 146, 160], ["other viruses", "PROBLEM", 68, 81], ["SARS", "PROBLEM", 132, 136], ["HCoV", "TREATMENT", 137, 141], ["vaccinia virus", "TREATMENT", 146, 160], ["variable inactivation", "PROBLEM", 216, 237], ["PCT", "TEST", 243, 246], ["L amotosalen", "TREATMENT", 265, 277], ["PLT concentrates", "TREATMENT", 302, 318], ["vaccinia virus", "OBSERVATION", 146, 160]]], ["Although the most relevant, blood-borne, human nonenveloped viruses, such as parvovirus B19 and human adenovirus 5, were sensitive to PCT, inactivation of other nonenveloped viruses did not reach the limit of detection.", [["blood", "ANATOMY", 28, 33], ["parvovirus B19", "DISEASE", 77, 91], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["human", "ORGANISM", 41, 46], ["parvovirus B19", "ORGANISM", 77, 91], ["human adenovirus 5", "ORGANISM", 96, 114], ["human", "SPECIES", 41, 46], ["parvovirus B19", "SPECIES", 77, 91], ["human", "SPECIES", 96, 101], ["adenovirus", "SPECIES", 102, 112], ["human nonenveloped viruses", "SPECIES", 41, 67], ["parvovirus B19", "SPECIES", 77, 91], ["human adenovirus 5", "SPECIES", 96, 114], ["human nonenveloped viruses", "PROBLEM", 41, 67], ["parvovirus B19", "TEST", 77, 91], ["human adenovirus", "TREATMENT", 96, 112], ["PCT", "TEST", 134, 137], ["other nonenveloped viruses", "PROBLEM", 155, 181], ["viruses", "OBSERVATION", 60, 67], ["viruses", "OBSERVATION", 174, 181]]], ["Of all nonenveloped viruses evaluated to date, only hepatitis A virus and PPV have shown resistance to PCT.DISCUSSIONAn effective pathogen inactivation system for blood components must have a broad-spectrum inactivation capability while maintaining the biologic properties of the blood components.", [["blood", "ANATOMY", 163, 168], ["blood", "ANATOMY", 280, 285], ["hepatitis A", "DISEASE", 52, 63], ["hepatitis A virus", "ORGANISM", 52, 69], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["hepatitis A virus", "SPECIES", 52, 69], ["hepatitis A virus", "SPECIES", 52, 69], ["all nonenveloped viruses", "PROBLEM", 3, 27], ["hepatitis A virus", "PROBLEM", 52, 69], ["PPV", "TREATMENT", 74, 77], ["PCT.DISCUSSIONAn effective pathogen inactivation system", "TREATMENT", 103, 158], ["blood components", "PROBLEM", 163, 179], ["a broad-spectrum inactivation capability", "PROBLEM", 190, 230], ["nonenveloped", "OBSERVATION_MODIFIER", 7, 19], ["viruses", "OBSERVATION", 20, 27], ["blood", "ANATOMY", 280, 285]]], ["In the development of the PCT system for PLTs described in this report, studies were performed to demonstrate inactivation of bacteria, viruses, protozoa, and white blood cells (WBCs) in PLT concentrates.", [["PLTs", "ANATOMY", 41, 45], ["white blood cells", "ANATOMY", 159, 176], ["WBCs", "ANATOMY", 178, 182], ["PLT", "ANATOMY", 187, 190], ["PLTs", "CELL", 41, 45], ["white blood cells", "CELL", 159, 176], ["WBCs", "CELL", 178, 182], ["PLT", "CELL", 187, 190], ["PLTs", "CELL_TYPE", 41, 45], ["white blood cells", "CELL_TYPE", 159, 176], ["WBCs", "CELL_TYPE", 178, 182], ["the PCT system", "TEST", 22, 36], ["PLTs", "PROBLEM", 41, 45], ["studies", "TEST", 72, 79], ["bacteria", "PROBLEM", 126, 134], ["viruses", "PROBLEM", 136, 143], ["protozoa", "PROBLEM", 145, 153], ["white blood cells", "TEST", 159, 176], ["WBCs", "TEST", 178, 182], ["PLT concentrates", "TEST", 187, 203], ["bacteria", "OBSERVATION", 126, 134]]], ["15, 16, 19, 37, 38 To demonstrate the efficacy of virus inactivation, a three-pronged approach was used.", [["virus inactivation", "TREATMENT", 50, 68], ["a three-pronged approach", "TREATMENT", 70, 94]]], ["The first was to demonstrate inactivation of viruses that are most relevant to blood transfusion and are routinely tested for in blood donations, including HIV-1, HIV-2, HBV, HCV, HTLV-I, and HTLV-II.", [["blood", "ANATOMY", 79, 84], ["blood", "ANATOMY", 129, 134], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["HIV-1", "ORGANISM", 156, 161], ["HIV-2", "ORGANISM", 163, 168], ["HBV", "ORGANISM", 170, 173], ["HCV", "ORGANISM", 175, 178], ["HTLV-I", "ORGANISM", 180, 186], ["HTLV-II.", "ORGANISM", 192, 200], ["HIV-1", "SPECIES", 156, 161], ["HIV-2", "SPECIES", 163, 168], ["HIV-1", "SPECIES", 156, 161], ["HIV-2", "SPECIES", 163, 168], ["HBV", "SPECIES", 170, 173], ["HCV", "SPECIES", 175, 178], ["HTLV-I", "SPECIES", 180, 186], ["HTLV-II.", "SPECIES", 192, 200], ["inactivation of viruses", "PROBLEM", 29, 52], ["blood transfusion", "TREATMENT", 79, 96], ["blood donations", "TEST", 129, 144], ["HIV", "TEST", 156, 159], ["HIV", "TEST", 163, 166], ["HBV", "PROBLEM", 170, 173], ["HCV", "PROBLEM", 175, 178], ["HTLV", "TEST", 180, 184], ["viruses", "OBSERVATION", 45, 52]]], ["Although testing for CMV is not routinely required, it is included because of its significance for immunocompromised patients.", [["CMV", "ORGANISM", 21, 24], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["CMV", "SPECIES", 21, 24], ["testing", "TEST", 9, 16], ["CMV", "PROBLEM", 21, 24], ["immunocompromised patients", "PROBLEM", 99, 125]]], ["The second was to evaluate the inactivation of viruses that are of emerging interest, including parvovirus B19, WNV, SARS-HCoV, and vaccinia virus.", [["parvovirus B19", "DISEASE", 96, 110], ["SARS-HCoV, and vaccinia virus", "DISEASE", 117, 146], ["parvovirus B19", "ORGANISM", 96, 110], ["WNV", "ORGANISM", 112, 115], ["SARS-HCoV", "ORGANISM", 117, 126], ["vaccinia virus", "ORGANISM", 132, 146], ["parvovirus B19", "SPECIES", 96, 110], ["vaccinia virus", "SPECIES", 132, 146], ["parvovirus B19", "SPECIES", 96, 110], ["WNV", "SPECIES", 112, 115], ["SARS-HCoV", "SPECIES", 117, 126], ["vaccinia virus", "SPECIES", 132, 146], ["viruses", "PROBLEM", 47, 54], ["parvovirus B19", "PROBLEM", 96, 110], ["WNV", "PROBLEM", 112, 115], ["SARS", "PROBLEM", 117, 121], ["HCoV", "TREATMENT", 122, 126], ["vaccinia virus", "PROBLEM", 132, 146], ["viruses", "OBSERVATION", 47, 54], ["vaccinia virus", "OBSERVATION", 132, 146]]], ["The third was to use model viruses that represent a broad spectrum with respect to envelopes, genome and capsid types, virion sizes, and resistance to treatment, including DHBV, BVDV, bluetongue virus, feline conjunctivitis virus, simian adenovirus 15, and PPV.", [["bluetongue virus", "DISEASE", 184, 200], ["feline conjunctivitis", "DISEASE", 202, 223], ["DHBV", "ORGANISM", 172, 176], ["BVDV", "ORGANISM", 178, 182], ["bluetongue virus", "ORGANISM", 184, 200], ["feline conjunctivitis virus", "ORGANISM", 202, 229], ["simian adenovirus 15", "ORGANISM", 231, 251], ["BVDV", "SPECIES", 178, 182], ["bluetongue virus", "SPECIES", 184, 200], ["feline conjunctivitis virus", "SPECIES", 202, 229], ["simian adenovirus", "SPECIES", 231, 248], ["DHBV", "SPECIES", 172, 176], ["BVDV", "SPECIES", 178, 182], ["bluetongue virus", "SPECIES", 184, 200], ["feline conjunctivitis virus", "SPECIES", 202, 229], ["simian adenovirus 15", "SPECIES", 231, 251], ["model viruses", "PROBLEM", 21, 34], ["genome and capsid types, virion sizes", "PROBLEM", 94, 131], ["treatment", "TREATMENT", 151, 160], ["DHBV", "PROBLEM", 172, 176], ["BVDV", "PROBLEM", 178, 182], ["bluetongue virus", "PROBLEM", 184, 200], ["feline conjunctivitis virus", "PROBLEM", 202, 229], ["simian adenovirus", "TREATMENT", 231, 248], ["PPV", "TREATMENT", 257, 260], ["viruses", "OBSERVATION", 27, 34], ["capsid types", "OBSERVATION", 105, 117], ["virion sizes", "OBSERVATION", 119, 131], ["bluetongue virus", "OBSERVATION", 184, 200]]], ["Use of model viruses increased the dynamic range of an infectivity assay where use of authentic human viruses may not be practical or when infectivity assays were lacking.DISCUSSIONThe FDA has suggested that ideally a pathogen reduction (inactivation) treatment system would have the ability to reduce the pathogen load in a blood product by 6 to 10 logs, because some viral titers in the window period of infected donors can reach levels of 10 8 to 10 10 genome equivalents (geq) per mL.", [["blood", "ANATOMY", 325, 330], ["human", "ORGANISM", 96, 101], ["blood", "ORGANISM_SUBSTANCE", 325, 330], ["donors", "ORGANISM", 415, 421], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["model viruses", "PROBLEM", 7, 20], ["an infectivity assay", "TREATMENT", 52, 72], ["authentic human viruses", "TREATMENT", 86, 109], ["infectivity assays", "TEST", 139, 157], ["a pathogen reduction (inactivation) treatment system", "TREATMENT", 216, 268], ["the pathogen load", "PROBLEM", 302, 319], ["a blood product", "TREATMENT", 323, 338], ["some viral titers", "PROBLEM", 364, 381], ["infected donors", "PROBLEM", 406, 421], ["viruses", "OBSERVATION", 13, 20], ["infected", "OBSERVATION", 406, 414]]], ["21 It should be noted that a viral titer in geq per mL is measured by quantitative PCR of a small fragment (100-200 bases) of the viral genome.", [["viral genome", "DNA", 130, 142], ["a viral titer", "TEST", 27, 40], ["quantitative PCR", "TEST", 70, 86], ["a small fragment", "PROBLEM", 90, 106], ["the viral genome", "PROBLEM", 126, 142], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["titer", "OBSERVATION", 35, 40], ["small", "OBSERVATION_MODIFIER", 92, 97], ["fragment", "OBSERVATION", 98, 106], ["viral genome", "OBSERVATION", 130, 142]]], ["Whether 1 geq corresponds to 1 infectious unit of a virus has not been unequivocally demonstrated.", [["a virus", "PROBLEM", 50, 57], ["virus", "OBSERVATION", 52, 57]]], ["Published ratios of geq to infectivity were between 10 4 :1 and 10 5 :1 for parvovirus B19 and 360:1 for SARS-HCoV.", [["parvovirus B19", "DISEASE", 76, 90], ["SARS", "DISEASE", 105, 109], ["geq", "GENE_OR_GENE_PRODUCT", 20, 23], ["parvovirus B19", "ORGANISM", 76, 90], ["SARS-HCoV", "ORGANISM", 105, 114], ["parvovirus B19", "SPECIES", 76, 90], ["parvovirus B19", "SPECIES", 76, 90], ["SARS-HCoV", "SPECIES", 105, 114], ["Published ratios", "TEST", 0, 16], ["infectivity", "TEST", 27, 38], ["parvovirus B19", "TEST", 76, 90], ["SARS", "PROBLEM", 105, 109]]], ["[39] [40] [41] Therefore, experiments conducted in this report were targeted to have a 6-log dynamic range in infectivity of a virus whenever possible.", [["a virus", "PROBLEM", 125, 132]]], ["In contrast to geq titers, infectivity titers are measures of intact, functional viral genomes, which are required for replication and disease transmission.", [["geq", "GENE_OR_GENE_PRODUCT", 15, 18], ["viral genomes", "DNA", 81, 94], ["infectivity titers", "TEST", 27, 45], ["functional viral genomes", "PROBLEM", 70, 94], ["disease transmission", "PROBLEM", 135, 155], ["intact", "OBSERVATION_MODIFIER", 62, 68], ["viral genomes", "OBSERVATION", 81, 94]]], ["Reduction in viral infectivity titers is directly related to the risk reduction of viral transmission.DISCUSSIONThe aggregate results summarized in this report demonstrate that all enveloped viruses routinely screened in blood banks were sensitive to PCT, and high levels of inactivation were obtained.", [["blood", "ANATOMY", 221, 226], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["PCT", "PROTEIN", 251, 254], ["Reduction in viral infectivity titers", "PROBLEM", 0, 37], ["viral transmission", "PROBLEM", 83, 101], ["all enveloped viruses", "PROBLEM", 177, 198], ["blood banks", "TEST", 221, 232], ["PCT", "TEST", 251, 254], ["high levels of inactivation", "PROBLEM", 260, 287], ["viral infectivity titers", "OBSERVATION", 13, 37], ["reduction", "OBSERVATION_MODIFIER", 70, 79], ["viral transmission", "OBSERVATION", 83, 101]]], ["PCT, however, did not inactivate all nonenveloped viruses evaluated.", [["PCT", "TEST", 0, 3], ["all nonenveloped viruses", "PROBLEM", 33, 57], ["viruses", "OBSERVATION", 50, 57]]], ["Bluetongue virus was more sensitive to inactivation than feline conjunctivitis virus or simian adenovirus 15.", [["feline conjunctivitis", "DISEASE", 57, 78], ["Bluetongue virus", "ORGANISM", 0, 16], ["feline conjunctivitis virus", "ORGANISM", 57, 84], ["simian adenovirus 15", "ORGANISM", 88, 108], ["feline conjunctivitis virus", "SPECIES", 57, 84], ["simian adenovirus", "SPECIES", 88, 105], ["Bluetongue virus", "SPECIES", 0, 16], ["feline conjunctivitis virus", "SPECIES", 57, 84], ["simian adenovirus 15", "SPECIES", 88, 108], ["Bluetongue virus", "PROBLEM", 0, 16], ["feline conjunctivitis virus", "PROBLEM", 57, 84], ["simian adenovirus", "PROBLEM", 88, 105]]], ["Nonenveloped viruses with tight capsids, for example, PPV, are resistant to inactivation.", [["PPV", "PROTEIN", 54, 57], ["tight capsids", "TREATMENT", 26, 39], ["PPV", "TREATMENT", 54, 57], ["viruses", "OBSERVATION", 13, 20], ["tight capsids", "OBSERVATION_MODIFIER", 26, 39]]], ["Because PCT is a nucleic acid targeting method, PCT will not impact the transfusion risk due to prions, which contain no nucleic acid and cause variant Creutzfeldt-Jakob disease and possibly chronic wasting disease.", [["nucleic acid", "CHEMICAL", 17, 29], ["nucleic acid", "CHEMICAL", 121, 133], ["Creutzfeldt-Jakob disease", "DISEASE", 152, 177], ["chronic wasting disease", "DISEASE", 191, 214], ["PCT", "PROTEIN", 8, 11], ["PCT", "TEST", 8, 11], ["a nucleic acid targeting method", "TREATMENT", 15, 46], ["PCT", "TEST", 48, 51], ["the transfusion risk", "TREATMENT", 68, 88], ["prions", "PROBLEM", 96, 102], ["nucleic acid", "PROBLEM", 121, 133], ["Jakob disease", "PROBLEM", 164, 177], ["chronic wasting disease", "PROBLEM", 191, 214], ["no", "UNCERTAINTY", 118, 120], ["nucleic acid", "OBSERVATION", 121, 133], ["Jakob disease", "OBSERVATION", 164, 177], ["possibly", "UNCERTAINTY", 182, 190], ["chronic", "OBSERVATION_MODIFIER", 191, 198], ["wasting", "OBSERVATION_MODIFIER", 199, 206], ["disease", "OBSERVATION", 207, 214]]], ["42, 43 Although PCT did not reduce the titers of PPV, the human erythrovirus B19 was inactivated.", [["human", "ORGANISM", 58, 63], ["erythrovirus B19", "ORGANISM", 64, 80], ["PCT", "PROTEIN", 16, 19], ["PPV", "PROTEIN", 49, 52], ["human", "SPECIES", 58, 63], ["human erythrovirus B19", "SPECIES", 58, 80], ["PCT", "TEST", 16, 19], ["PPV", "TREATMENT", 49, 52], ["the human erythrovirus B19", "TREATMENT", 54, 80]]], ["Other investigators also reported disparate results for these two viruses, suggesting that PPV is not an appropriate model virus for B19.", [["B19", "DISEASE", 133, 136], ["B19", "ORGANISM", 133, 136], ["B19", "SPECIES", 133, 136], ["these two viruses", "PROBLEM", 56, 73], ["PPV", "TREATMENT", 91, 94], ["B19", "PROBLEM", 133, 136]]], ["39, 44 By use of an ELISpot assay 34 that detects and quantifies infectious parvovirus B19 particles, PCT inactivation of up to greater than 5 logs of infectious B19 has been demonstrated.", [["B19", "DISEASE", 162, 165], ["parvovirus", "ORGANISM", 76, 86], ["B19", "ORGANISM", 87, 90], ["B19", "ORGANISM", 162, 165], ["parvovirus B19", "SPECIES", 76, 90], ["infectious parvovirus B19", "SPECIES", 65, 90], ["B19", "SPECIES", 162, 165], ["an ELISpot assay", "TEST", 17, 33], ["quantifies infectious parvovirus B19 particles", "PROBLEM", 54, 100], ["PCT inactivation", "TEST", 102, 118], ["infectious B19", "PROBLEM", 151, 165], ["infectious", "OBSERVATION", 151, 161]]], ["The effect of PCT on parvovirus B19 can be improved when amotosalen is incubated with infected PLTs for 1 hour or more, in which case up to 5.8 logs can be inactivated in PLT concentrates.", [["PLTs", "ANATOMY", 95, 99], ["parvovirus B19", "DISEASE", 21, 35], ["amotosalen", "CHEMICAL", 57, 67], ["parvovirus B19", "ORGANISM", 21, 35], ["amotosalen", "SIMPLE_CHEMICAL", 57, 67], ["PLTs", "CELL", 95, 99], ["PLT", "CELL", 171, 174], ["PCT", "PROTEIN", 14, 17], ["infected PLTs", "CELL_TYPE", 86, 99], ["parvovirus B19", "SPECIES", 21, 35], ["parvovirus B19", "SPECIES", 21, 35], ["PCT", "TEST", 14, 17], ["parvovirus B19", "PROBLEM", 21, 35], ["infected PLTs", "TREATMENT", 86, 99], ["PLT concentrates", "TEST", 171, 187]]], ["45 The incubation period allowed penetration of amotosalen through the viral capsid and subsequent reaction with the viral genome upon UVA illumination.DISCUSSIONEmerging viruses are a persistent threat to blood transfusion safety.", [["blood", "ANATOMY", 206, 211], ["UVA", "CHEMICAL", 135, 138], ["UVA", "SIMPLE_CHEMICAL", 135, 138], ["blood", "ORGANISM_SUBSTANCE", 206, 211], ["viral genome", "DNA", 117, 129], ["amotosalen", "TREATMENT", 48, 58], ["the viral capsid", "PROBLEM", 67, 83], ["subsequent reaction", "PROBLEM", 88, 107], ["the viral genome", "PROBLEM", 113, 129], ["UVA illumination", "TREATMENT", 135, 151], ["blood transfusion safety", "TREATMENT", 206, 230], ["viral capsid", "OBSERVATION", 71, 83], ["viral genome", "OBSERVATION", 117, 129], ["UVA illumination", "OBSERVATION", 135, 151], ["persistent", "OBSERVATION_MODIFIER", 185, 195]]], ["In recent years, the most important examples of emerging viruses have been WNV, introduced into North America, and SARS virus, reported in Asia.", [["SARS virus", "DISEASE", 115, 125], ["WNV", "ORGANISM", 75, 78], ["SARS virus", "ORGANISM", 115, 125], ["WNV", "SPECIES", 75, 78], ["SARS virus", "SPECIES", 115, 125], ["emerging viruses", "PROBLEM", 48, 64], ["WNV", "PROBLEM", 75, 78], ["SARS virus", "PROBLEM", 115, 125], ["viruses", "OBSERVATION", 57, 64]]], ["46 Vaccinia virus, a model for smallpox virus, is of interest because the blood supply could represent a soft target for bioterrorists.", [["blood", "ANATOMY", 74, 79], ["smallpox virus", "DISEASE", 31, 45], ["46", "ORGANISM", 0, 2], ["Vaccinia virus", "ORGANISM", 3, 17], ["smallpox virus", "ORGANISM", 31, 45], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["Vaccinia virus", "SPECIES", 3, 17], ["Vaccinia virus", "SPECIES", 3, 17], ["smallpox virus", "SPECIES", 31, 45], ["Vaccinia virus", "PROBLEM", 3, 17], ["smallpox virus", "PROBLEM", 31, 45], ["Vaccinia virus", "OBSERVATION", 3, 17], ["soft target", "OBSERVATION", 105, 116]]], ["New viruses continue to emerge at a rate of one every 2 to 3 years with a potentially damaging virus transmitted through blood every 5 years.", [["blood", "ANATOMY", 121, 126], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["New viruses", "PROBLEM", 0, 11], ["a potentially damaging virus", "PROBLEM", 72, 100], ["viruses", "OBSERVATION", 4, 11]]], ["47 Testing remains a reactive approach to blood safety.", [["blood", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["blood safety", "TEST", 42, 54], ["reactive", "OBSERVATION", 21, 29]]], ["The new viruses must be identified before sensitive tests can be developed.", [["The new viruses", "PROBLEM", 0, 15], ["sensitive tests", "TEST", 42, 57], ["new", "OBSERVATION_MODIFIER", 4, 7], ["viruses", "OBSERVATION", 8, 15]]], ["Although the time to develop an assay has shortened as the technology improves, the time it takes for a new virus in the blood supply to be recognized as a threat may be significant as demonstrated by the current WNV outbreak in the United States.", [["blood", "ANATOMY", 121, 126], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["WNV", "SPECIES", 213, 216], ["an assay", "TEST", 29, 37], ["a new virus", "PROBLEM", 102, 113]]], ["48 Furthermore, all tests have a sensitivity threshold that can allow contaminated units to escape detection.", [["all tests", "TEST", 16, 25], ["escape detection", "TEST", 92, 108]]], ["For WNV, in spite of the institution of NAT in 2003 under an FDA-approved investigational new drug application, six transfusion-transmitted WNV infections were confirmed.", [["WNV", "DISEASE", 4, 7], ["WNV infections", "DISEASE", 140, 154], ["WNV", "ORGANISM", 140, 143], ["WNV", "SPECIES", 4, 7], ["WNV", "SPECIES", 140, 143], ["WNV", "PROBLEM", 4, 7], ["an FDA", "TREATMENT", 58, 64], ["investigational new drug application", "TREATMENT", 74, 110], ["six transfusion", "TREATMENT", 112, 127], ["transmitted WNV infections", "PROBLEM", 128, 154], ["WNV", "OBSERVATION", 4, 7]]], ["49 In addition, testing only applies to a small percentage of the organisms that may infect blood; a number of bacteria and protozoan parasites, including the agents of Lyme disease, babesiosis, malaria, Chagas disease, and leishmaniasis, are known to be transmitted by blood transfusion, but no routine testing has been implemented in Europe or the United States.DISCUSSIONIn contrast, pathogen inactivation with PCT is a proactive approach to blood safety.", [["blood", "ANATOMY", 92, 97], ["blood", "ANATOMY", 270, 275], ["blood", "ANATOMY", 445, 450], ["protozoan parasites", "DISEASE", 124, 143], ["Lyme disease", "DISEASE", 169, 181], ["babesiosis", "DISEASE", 183, 193], ["malaria", "DISEASE", 195, 202], ["Chagas disease", "DISEASE", 204, 218], ["leishmaniasis", "DISEASE", 224, 237], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 270, 275], ["blood", "ORGANISM_SUBSTANCE", 445, 450], ["testing", "TEST", 16, 23], ["the organisms", "PROBLEM", 62, 75], ["infect blood", "PROBLEM", 85, 97], ["bacteria", "PROBLEM", 111, 119], ["protozoan parasites", "PROBLEM", 124, 143], ["Lyme disease", "PROBLEM", 169, 181], ["babesiosis", "PROBLEM", 183, 193], ["malaria", "PROBLEM", 195, 202], ["Chagas disease", "PROBLEM", 204, 218], ["leishmaniasis", "PROBLEM", 224, 237], ["blood transfusion", "TEST", 270, 287], ["routine testing", "TEST", 296, 311], ["blood safety", "TEST", 445, 457], ["bacteria", "OBSERVATION", 111, 119], ["protozoan parasites", "OBSERVATION", 124, 143], ["Lyme disease", "OBSERVATION", 169, 181], ["babesiosis", "OBSERVATION", 183, 193], ["Chagas disease", "OBSERVATION", 204, 218], ["leishmaniasis", "OBSERVATION", 224, 237]]], ["Inactivation of up to greater than 6 logs of viral infectivity has been demonstrated for a broad spectrum of viruses.", [["viral infectivity", "PROBLEM", 45, 62], ["viruses", "PROBLEM", 109, 116], ["viral infectivity", "OBSERVATION", 45, 62], ["viruses", "OBSERVATION", 109, 116]]], ["A previous publication has reported inactivation of up to greater than 6 logs of a wide variety of bacteria.", [["a wide variety of bacteria", "PROBLEM", 81, 107], ["bacteria", "OBSERVATION", 99, 107]]], ["19 In addition, WBCs contain nuclear DNA and are targets for inactivation.", [["WBCs", "ANATOMY", 16, 20], ["nuclear", "ANATOMY", 29, 36], ["WBCs", "CELL", 16, 20], ["nuclear", "CELLULAR_COMPONENT", 29, 36], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["WBCs", "CELL_TYPE", 16, 20], ["nuclear DNA", "DNA", 29, 40], ["WBCs", "TEST", 16, 20], ["nuclear DNA", "TEST", 29, 40], ["inactivation", "PROBLEM", 61, 73], ["nuclear DNA", "OBSERVATION", 29, 40]]], ["Previous studies showed that PCT induced one amotosalen-DNA adduct in approximately every 83 bp.", [["PCT", "GENE_OR_GENE_PRODUCT", 29, 32], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["PCT", "PROTEIN", 29, 32], ["Previous studies", "TEST", 0, 16], ["PCT", "TEST", 29, 32], ["DNA adduct", "PROBLEM", 56, 66], ["bp", "TEST", 93, 95], ["DNA adduct", "OBSERVATION", 56, 66]]], ["37 Therefore, PCT can potentially offer a one-step process that inactivates contaminating pathogens as well as WBCs.", [["WBCs", "ANATOMY", 111, 115], ["WBCs", "CELL", 111, 115], ["PCT", "PROTEIN", 14, 17], ["WBCs", "CELL_TYPE", 111, 115], ["a one-step process", "TREATMENT", 40, 58], ["contaminating pathogens", "PROBLEM", 76, 99], ["WBCs", "TEST", 111, 115]]], ["These advances in pathogen inactivation may ultimately influence the strategy of testing versus inactivation.", [["pathogen inactivation", "TREATMENT", 18, 39], ["inactivation", "PROBLEM", 96, 108]]], ["In a recent article, 15 international experts expressed their opinions on whether any of the current tests on donor blood can be omitted when PCT is used.", [["blood", "ANATOMY", 116, 121], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["PCT", "PROTEIN", 142, 145], ["donor blood", "TEST", 110, 121], ["PCT", "TEST", 142, 145]]], ["50 Most do not think pathogen inactivation and testing are mutually exclusive.", [["pathogen inactivation", "PROBLEM", 21, 42], ["testing", "TEST", 47, 54]]], ["No current tests can be omitted until pathogen inactivation methods for all blood components are available.", [["blood", "ANATOMY", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["current tests", "PROBLEM", 3, 16], ["all blood components", "TEST", 72, 92]]], ["Suggested possible exceptions may include omission of tests for syphilis, CMV, bacterial testing for apheresis PLT concentrates, and gamma irradiation.", [["syphilis", "DISEASE", 64, 72], ["CMV", "ORGANISM", 74, 77], ["CMV", "SPECIES", 74, 77], ["tests", "TEST", 54, 59], ["syphilis", "PROBLEM", 64, 72], ["CMV", "PROBLEM", 74, 77], ["bacterial testing", "TEST", 79, 96], ["apheresis PLT concentrates", "TREATMENT", 101, 127], ["gamma irradiation", "TREATMENT", 133, 150]]], ["The development of new tests for emerging pathogens may be eliminated or delayed.", [["new tests", "TEST", 19, 28], ["emerging pathogens", "PROBLEM", 33, 51], ["new", "OBSERVATION_MODIFIER", 19, 22]]], ["However, owing to the concerns of the geq titer of greater than 10 10 for viruses such as B19 in the window period, the conservative approach would be to retain the most sensitive current tests to assure that levels of viremia are well below the documented pathogen inactivation effectiveness threshold.", [["B19", "DISEASE", 90, 93], ["viremia", "DISEASE", 219, 226], ["geq", "GENE_OR_GENE_PRODUCT", 38, 41], ["B19", "ORGANISM", 90, 93], ["B19", "SPECIES", 90, 93], ["the geq titer", "TEST", 34, 47], ["viruses", "PROBLEM", 74, 81], ["B19", "TREATMENT", 90, 93], ["the conservative approach", "TREATMENT", 116, 141], ["viremia", "PROBLEM", 219, 226], ["viremia", "OBSERVATION", 219, 226]]], ["Some new tests may be required, even in the setting of universal pathogen inactivation, to safeguard against various high-titer pathogens that could potentially \"breakthrough\" pathogen inactivation.DISCUSSIONAmong the currently licensed pathogen inactivation and/or reduction methods for plasma and plasma derivatives, such as solvent/detergent (S/D), 51 methylene blue, 52 heat inactivation, 53 and ultrafiltration, 54 the antiviral effect varies among each approach.", [["plasma", "ANATOMY", 288, 294], ["plasma", "ANATOMY", 299, 305], ["methylene blue", "CHEMICAL", 355, 369], ["methylene blue", "CHEMICAL", 355, 369], ["plasma", "ORGANISM_SUBSTANCE", 288, 294], ["plasma", "ORGANISM_SUBSTANCE", 299, 305], ["D", "SIMPLE_CHEMICAL", 348, 349], ["methylene blue", "SIMPLE_CHEMICAL", 355, 369], ["Some new tests", "TEST", 0, 14], ["universal pathogen inactivation", "PROBLEM", 55, 86], ["various high-titer pathogens", "PROBLEM", 109, 137], ["pathogen inactivation", "PROBLEM", 176, 197], ["pathogen inactivation", "TREATMENT", 237, 258], ["reduction methods", "TREATMENT", 266, 283], ["plasma and plasma derivatives", "TREATMENT", 288, 317], ["methylene blue", "TREATMENT", 355, 369], ["heat inactivation", "TREATMENT", 374, 391], ["ultrafiltration", "TREATMENT", 400, 415], ["the antiviral effect", "TREATMENT", 420, 440]]], ["S/D is not effective against nonenveloped viruses, and methylene blue is not effective in inactivating nucleated cells and, correspondingly, intracellular and cell-associated virus.", [["cells", "ANATOMY", 113, 118], ["intracellular", "ANATOMY", 141, 154], ["cell", "ANATOMY", 159, 163], ["methylene blue", "CHEMICAL", 55, 69], ["methylene blue", "CHEMICAL", 55, 69], ["S/D", "SIMPLE_CHEMICAL", 0, 3], ["methylene blue", "SIMPLE_CHEMICAL", 55, 69], ["cells", "CELL", 113, 118], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["cell", "CELL", 159, 163], ["nucleated cells", "CELL_TYPE", 103, 118], ["nonenveloped viruses", "PROBLEM", 29, 49], ["methylene blue", "TREATMENT", 55, 69], ["inactivating nucleated cells", "PROBLEM", 90, 118], ["intracellular and cell-associated virus", "PROBLEM", 141, 180], ["viruses", "OBSERVATION", 42, 49], ["methylene blue", "OBSERVATION", 55, 69], ["nucleated cells", "OBSERVATION", 103, 118], ["cell", "OBSERVATION", 159, 163], ["virus", "OBSERVATION", 175, 180]]], ["55 Heat inactivation is effective against some enveloped viruses, but parvovirus B19 transmission has been reported for heattreated clotting factor concentrates.", [["parvovirus B19", "DISEASE", 70, 84], ["Heat", "GENE_OR_GENE_PRODUCT", 3, 7], ["parvovirus B19", "ORGANISM", 70, 84], ["heattreated clotting factor", "GENE_OR_GENE_PRODUCT", 120, 147], ["heattreated clotting factor concentrates", "PROTEIN", 120, 160], ["parvovirus B19", "SPECIES", 70, 84], ["parvovirus B19", "SPECIES", 70, 84], ["Heat inactivation", "PROBLEM", 3, 20], ["some enveloped viruses", "PROBLEM", 42, 64], ["parvovirus B19 transmission", "PROBLEM", 70, 97], ["heattreated clotting factor concentrates", "TREATMENT", 120, 160], ["enveloped", "OBSERVATION_MODIFIER", 47, 56], ["viruses", "OBSERVATION", 57, 64]]], ["56 Ultrafiltration may offer the possibilities of reducing the viral load of small nonenveloped viruses that are difficult to inactivate by chemical methods.", [["Ultrafiltration", "TREATMENT", 3, 18], ["the viral load", "PROBLEM", 59, 73], ["small nonenveloped viruses", "PROBLEM", 77, 103], ["viral load", "OBSERVATION", 63, 73], ["small", "OBSERVATION_MODIFIER", 77, 82], ["nonenveloped viruses", "OBSERVATION", 83, 103]]], ["These licensed pathogen reduction methods, however, are only for cell-free blood products; none is applicable to blood cellular component PLT concentrates.", [["cell", "ANATOMY", 65, 69], ["blood", "ANATOMY", 75, 80], ["blood cellular", "ANATOMY", 113, 127], ["cell", "CELL", 65, 69], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["cellular", "CELL", 119, 127], ["PLT", "CELL", 138, 141], ["These licensed pathogen reduction methods", "PROBLEM", 0, 41], ["cell-free blood products", "TREATMENT", 65, 89], ["blood cellular component", "TEST", 113, 137], ["PLT concentrates", "TEST", 138, 154], ["pathogen", "OBSERVATION_MODIFIER", 15, 23], ["reduction", "OBSERVATION_MODIFIER", 24, 33]]], ["The PCT system described in this report represents the first pathogen inactivation method for PLT concentrates with a comprehensive broad-spectrum activity.", [["PLT", "CELL", 94, 97], ["PLT", "PROTEIN", 94, 97], ["The PCT system", "TEST", 0, 14], ["PLT concentrates", "TREATMENT", 94, 110]]], ["The PCT system has been CE Mark approved and is in clinical use in several countries in Europe.", [["The PCT system", "TEST", 0, 14]]], ["Another system involving riboflavin photochemistry in development for PLT concentrates has not demonstrated this degree of activity.", [["riboflavin", "CHEMICAL", 25, 35], ["riboflavin", "CHEMICAL", 25, 35], ["riboflavin", "SIMPLE_CHEMICAL", 25, 35], ["PLT", "CELL", 70, 73], ["PLT", "PROTEIN", 70, 73], ["riboflavin photochemistry", "TREATMENT", 25, 50], ["PLT concentrates", "TEST", 70, 86], ["riboflavin photochemistry", "OBSERVATION", 25, 50]]], ["57 In conclusion, results in this report show that PCT is effective in inactivating viruses from 10 different families, including enveloped, nonenveloped, DNA-or RNAcontaining, proviral, cell-free, and cell-associated viruses and, therefore, offers the potential to prospectively pre-vent the majority of PLT transfusion-associated viral diseases.", [["cell", "ANATOMY", 187, 191], ["cell", "ANATOMY", 202, 206], ["viral diseases", "DISEASE", 332, 346], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["cell", "CELL", 187, 191], ["cell", "CELL", 202, 206], ["PLT", "CELL", 305, 308], ["PCT", "TEST", 51, 54], ["inactivating viruses", "PROBLEM", 71, 91], ["DNA", "TEST", 155, 158], ["RNAcontaining", "TREATMENT", 162, 175], ["proviral", "PROBLEM", 177, 185], ["cell-associated viruses", "PROBLEM", 202, 225], ["PLT transfusion", "TREATMENT", 305, 320], ["viral diseases", "PROBLEM", 332, 346], ["viruses", "OBSERVATION", 218, 225], ["viral diseases", "OBSERVATION", 332, 346]]]], "54c6b92139b5dd9cbda55615760c19aaa2190a31": [["There is limited data on critically ill pregnant women hospitalized with coronavirus 55 disease 2019 .", [["critically ill", "DISEASE", 25, 39], ["coronavirus 55 disease", "DISEASE", 73, 95], ["women", "ORGANISM", 49, 54], ["women", "SPECIES", 49, 54], ["coronavirus 55 disease", "PROBLEM", 73, 95]]], ["Although maternal mortality has been reported, 1-3 the 56 frequency with which this devastating outcome occurs is unknown.", [["maternal mortality", "PROBLEM", 9, 27]]], ["The objective of this 57 study was to determine the rate of maternal death among pregnant and postpartum 58 women with COVID-19 admitted to intensive care units (ICU) in a large integrated 59 health system in the New York metropolitan area.", [["death", "DISEASE", 69, 74], ["women", "ORGANISM", 108, 113], ["women", "SPECIES", 108, 113], ["this 57 study", "TEST", 17, 30], ["maternal death", "PROBLEM", 60, 74], ["COVID", "TEST", 119, 124]]], ["We describe patient demographics, 60 baseline comorbidities, clinical presentation, hospital course, and maternal outcomes.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["61STUDY DESIGN 63This case series evaluated all consecutively hospitalized pregnant and immediately 64 postpartum women with laboratory-confirmed COVID-19 who were admitted to the ICU 65 at ten hospitals within Northwell Health, the largest academic health system in New 66 York, and Maimonides Medical Center, an affiliate of Northwell Health in Brooklyn, New 67STUDY DESIGN 63York, from March 1 -May 6, 2020.", [["women", "ORGANISM", 114, 119], ["women", "SPECIES", 114, 119], ["largest", "OBSERVATION_MODIFIER", 233, 240]]], ["Respiratory specimens were collected by 70 nasopharyngeal swab.", [["Respiratory specimens", "ANATOMY", 0, 21], ["nasopharyngeal swab", "ANATOMY", 43, 62], ["Respiratory specimens", "CANCER", 0, 21], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 43, 62], ["Respiratory specimens", "TEST", 0, 21], ["nasopharyngeal swab", "TEST", 43, 62]]], ["Symptomatic patients with a positive result on severe acute 71 respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) 72 assay were included.", [["acute 71 respiratory syndrome coronavirus", "DISEASE", 54, 95], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["severe acute 71 respiratory syndrome coronavirus", "SPECIES", 47, 95], ["SARS-CoV", "SPECIES", 99, 107], ["severe acute 71 respiratory syndrome coronavirus", "PROBLEM", 47, 95], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["polymerase chain reaction", "PROBLEM", 111, 136], ["PCR", "TEST", 138, 141], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["Patients who had a critical care consultation but 74 were not directly managed by an intensivist were not included.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Women who tested 75 positive for the virus but were admitted to the ICU for indications other than acute or 76 impending hypoxemic respiratory failure were excluded (e.g. postpartum hemorrhage).", [["respiratory", "ANATOMY", 131, 142], ["hypoxemic respiratory failure", "DISEASE", 121, 150], ["hemorrhage", "DISEASE", 182, 192], ["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["the virus", "PROBLEM", 33, 42], ["impending hypoxemic respiratory failure", "PROBLEM", 111, 150], ["postpartum hemorrhage", "PROBLEM", 171, 192], ["hypoxemic", "OBSERVATION_MODIFIER", 121, 130], ["respiratory failure", "OBSERVATION", 131, 150], ["hemorrhage", "OBSERVATION", 182, 192]]], ["Some women in this study were included in previous 80 publications characterizing COVID-19 hospitalizations within the Northwell Health 81 system, 4,5 and one maternal death was previously presented as a case report.", [["death", "DISEASE", 168, 173], ["women", "ORGANISM", 5, 10], ["women", "SPECIES", 5, 10], ["this study", "TEST", 14, 24]]], ["Between March 1 and May 6, 2020, at the eleven included hospitals, there were 462 98 pregnant women who tested positive for SARS-CoV-2, and 70 (15%) were classified as 99 severe or critical COVID-19 per National Institutes of Health (NIH) criteria.", [["SARS", "DISEASE", 124, 128], ["women", "ORGANISM", 94, 99], ["women", "SPECIES", 94, 99], ["SARS-CoV", "SPECIES", 124, 132], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132], ["critical COVID", "TEST", 181, 195]]], ["Out of these 100 70 patients, a total of 13 (19%) were admitted to the ICU for acute or impending 101 hypoxemic respiratory failure ( Figure 1 ).", [["respiratory", "ANATOMY", 112, 123], ["hypoxemic respiratory failure", "DISEASE", 102, 131], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["impending 101 hypoxemic respiratory failure", "PROBLEM", 88, 131], ["hypoxemic", "OBSERVATION_MODIFIER", 102, 111], ["respiratory failure", "OBSERVATION", 112, 131]]], ["103 104 Women admitted to the ICU had a mean maternal age of 33.8\u00b15.2 years and 69% were 105 multiparous.", [["Women", "SPECIES", 8, 13]]], ["Hispanic women constituted the largest racial/ethnic group (38%).", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["largest", "OBSERVATION_MODIFIER", 31, 38], ["racial", "OBSERVATION_MODIFIER", 39, 45]]], ["The 106 most common comorbidities were obesity (38%) and pulmonary conditions (23%) such 107 as asthma and obstructive sleep apnea (OSA).", [["pulmonary", "ANATOMY", 57, 66], ["obesity", "DISEASE", 39, 46], ["asthma", "DISEASE", 96, 102], ["obstructive sleep apnea", "DISEASE", 107, 130], ["OSA", "DISEASE", 132, 135], ["pulmonary", "ORGAN", 57, 66], ["obesity", "PROBLEM", 39, 46], ["pulmonary conditions", "PROBLEM", 57, 77], ["asthma", "PROBLEM", 96, 102], ["obstructive sleep apnea", "PROBLEM", 107, 130], ["OSA", "PROBLEM", 132, 135], ["obesity", "OBSERVATION", 39, 46], ["pulmonary", "ANATOMY", 57, 66], ["obstructive", "OBSERVATION_MODIFIER", 107, 118], ["sleep apnea", "OBSERVATION", 119, 130]]], ["However, nearly half of the patients 108 (46%) had no baseline comorbidities.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["baseline comorbidities", "PROBLEM", 54, 76]]], ["All pregnancies were singleton gestations.", [["singleton gestations", "PROBLEM", 21, 41]]], ["The 109 majority of patients were tachycardic, tachypneic and hypoxemic on initial evaluation but 110 few were febrile.", [["tachypneic", "DISEASE", 47, 57], ["hypoxemic", "DISEASE", 62, 71], ["febrile", "DISEASE", 111, 118], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["tachycardic", "PROBLEM", 34, 45], ["tachypneic", "PROBLEM", 47, 57], ["hypoxemic", "PROBLEM", 62, 71], ["initial evaluation", "TEST", 75, 93], ["febrile", "PROBLEM", 111, 118], ["hypoxemic", "OBSERVATION", 62, 71]]], ["Nearly all patients (92%) met NIH criteria for severe COVID-19 at 111 admission.", [["COVID", "DISEASE", 54, 59], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["severe COVID", "PROBLEM", 47, 59]]], ["Lymphopenia, elevated transaminases, and elevated inflammatory markers 112STUDY DESIGN 63were common laboratory findings.", [["Lymphopenia", "DISEASE", 0, 11], ["Lymphopenia", "PROBLEM", 0, 11], ["elevated transaminases", "PROBLEM", 13, 35], ["elevated inflammatory markers", "PROBLEM", 41, 70], ["elevated", "OBSERVATION_MODIFIER", 13, 21], ["transaminases", "OBSERVATION_MODIFIER", 22, 35], ["elevated", "OBSERVATION_MODIFIER", 41, 49], ["inflammatory markers", "OBSERVATION", 50, 70]]], ["The mean gestational age at hospitalization for 113 COVID-19 was 33.3\u00b15.3 weeks, and symptoms started 8\u00b13 days before admission.", [["COVID", "TEST", 52, 57], ["symptoms", "PROBLEM", 85, 93]]], ["114115The median length of hospitalization and ICU stay were 13 and 8 days, respectively.", [["median", "OBSERVATION_MODIFIER", 10, 16], ["length", "OBSERVATION_MODIFIER", 17, 23]]], ["Invasive mechanical ventilation was required in 8 (62%) 118 cases (at initiation, 6 were postpartum and 2 were pregnant), and the median duration 119 of therapy was 8 days.", [["Invasive mechanical ventilation", "TREATMENT", 0, 31], ["therapy", "TREATMENT", 153, 160], ["mechanical ventilation", "OBSERVATION", 9, 31]]], ["Among this group, 7 (88%) required vasopressors.", [["vasopressors", "TREATMENT", 35, 47]]], ["One patient 120 was extubated but remained ventilator-dependent with a tracheostomy.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a tracheostomy", "TREATMENT", 69, 83], ["tracheostomy", "OBSERVATION", 71, 83]]], ["All patients 121 admitted to the ICU received either prophylactic or therapeutic dose anticoagulation 7 (100%); there were no known cases of venous thromboembolism.", [["venous", "ANATOMY", 141, 147], ["venous thromboembolism", "DISEASE", 141, 163], ["patients", "ORGANISM", 4, 12], ["venous", "MULTI-TISSUE_STRUCTURE", 141, 147], ["patients", "SPECIES", 4, 12], ["therapeutic dose anticoagulation", "TREATMENT", 69, 101], ["venous thromboembolism", "PROBLEM", 141, 163], ["venous", "ANATOMY", 141, 147], ["thromboembolism", "OBSERVATION", 148, 163]]], ["Most patients 123 received hydroxychloroquine (85%) and antibiotics for community-acquired pneumonia 124 (92%); some were enrolled in clinical trials for the antiviral drug remdesivir (23%), 125 interleukin-6-receptor inhibitors (38%), or convalescent plasma therapy (15%).", [["plasma", "ANATOMY", 252, 258], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["pneumonia", "DISEASE", 91, 100], ["remdesivir", "CHEMICAL", 173, 183], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["remdesivir", "CHEMICAL", 173, 183], ["patients", "ORGANISM", 5, 13], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["remdesivir", "SIMPLE_CHEMICAL", 173, 183], ["interleukin-6-receptor inhibitors", "SIMPLE_CHEMICAL", 195, 228], ["plasma", "ORGANISM_SUBSTANCE", 252, 258], ["interleukin", "PROTEIN", 195, 206], ["patients", "SPECIES", 5, 13], ["hydroxychloroquine", "TREATMENT", 27, 45], ["antibiotics", "TREATMENT", 56, 67], ["community-acquired pneumonia", "PROBLEM", 72, 100], ["the antiviral drug remdesivir", "TREATMENT", 154, 183], ["interleukin", "TREATMENT", 195, 206], ["receptor inhibitors", "TREATMENT", 209, 228], ["convalescent plasma therapy", "TREATMENT", 239, 266], ["pneumonia", "OBSERVATION", 91, 100]]], ["126127Of the two patients who died, one had a long, protracted course in the ICU complicated 128 by fetal demise at a periviable gestational age; she developed multiple organ failure, 129 required renal replacement therapy, and after extensive counseling in the setting of a 130 poor maternal prognosis, the family opted for no obstetrical intervention.", [["fetal", "ANATOMY", 100, 105], ["organ", "ANATOMY", 169, 174], ["renal", "ANATOMY", 197, 202], ["organ failure", "DISEASE", 169, 182], ["patients", "ORGANISM", 17, 25], ["fetal", "ORGAN", 100, 105], ["organ", "ORGAN", 169, 174], ["renal", "ORGAN", 197, 202], ["patients", "SPECIES", 17, 25], ["fetal demise", "PROBLEM", 100, 112], ["multiple organ failure", "PROBLEM", 160, 182], ["renal replacement therapy", "TREATMENT", 197, 222], ["obstetrical intervention", "TREATMENT", 328, 352], ["multiple", "OBSERVATION_MODIFIER", 160, 168], ["organ", "ANATOMY", 169, 174], ["failure", "OBSERVATION", 175, 182], ["renal", "ANATOMY", 197, 202], ["replacement therapy", "OBSERVATION", 203, 222]]], ["She had a pre-131 pregnancy body mass index (BMI) greater than 40 kg/m 2 and OSA.", [["body", "ANATOMY", 28, 32], ["OSA", "DISEASE", 77, 80], ["body", "ORGANISM_SUBDIVISION", 28, 32], ["a pre-131 pregnancy body mass index", "PROBLEM", 8, 43], ["OSA", "PROBLEM", 77, 80]]], ["The second patient 132 who died had a rapid clinical deterioration postpartum, which was complicated by 133 severe respiratory distress, multiple organ failure, and cardiopulmonary arrest.", [["respiratory", "ANATOMY", 115, 126], ["organ", "ANATOMY", 146, 151], ["cardiopulmonary", "ANATOMY", 165, 180], ["respiratory distress", "DISEASE", 115, 135], ["multiple organ failure", "DISEASE", 137, 159], ["cardiopulmonary arrest", "DISEASE", 165, 187], ["patient", "ORGANISM", 11, 18], ["organ", "ORGAN", 146, 151], ["patient", "SPECIES", 11, 18], ["a rapid clinical deterioration", "PROBLEM", 36, 66], ["severe respiratory distress", "PROBLEM", 108, 135], ["multiple organ failure", "PROBLEM", 137, 159], ["cardiopulmonary arrest", "PROBLEM", 165, 187], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["respiratory distress", "OBSERVATION", 115, 135], ["multiple", "OBSERVATION_MODIFIER", 137, 145], ["organ", "ANATOMY", 146, 151], ["failure", "OBSERVATION", 152, 159], ["cardiopulmonary arrest", "OBSERVATION", 165, 187]]], ["1 She had 134 a pre-pregnancy BMI less than 30 kg/m 2 and no baseline comorbidities.", [["a pre-pregnancy BMI", "TEST", 14, 33], ["baseline comorbidities", "PROBLEM", 61, 83]]], ["Prone 135 positioning to improve oxygenation during mechanical ventilation was used in the first 136 case but not the second because of her rapid clinical decline.", [["mechanical ventilation", "TREATMENT", 52, 74], ["her rapid clinical decline", "PROBLEM", 136, 162]]], ["These cases were 137 critically reviewed by a multidisciplinary team; it was determined that the standard of 138 care was met in both cases, and that the outcomes were a consequence of the disease 139 process.", [["the disease 139 process", "PROBLEM", 185, 208]]], ["At present, that study represents the largest report of such patients but it is limited by 160 the fact that half of the critically ill patients (11/20) were still hospitalized at the 161 completion of data collection.", [["critically ill", "DISEASE", 121, 135], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 136, 144], ["that study", "TEST", 12, 22], ["data collection", "TEST", 202, 217]]], ["In our study, approximately half of the women admitted to 162 the ICU had no baseline comorbidities making it difficult to identify those who are at 163 highest risk of respiratory failure and death.", [["respiratory", "ANATOMY", 169, 180], ["respiratory failure", "DISEASE", 169, 188], ["death", "DISEASE", 193, 198], ["women", "ORGANISM", 40, 45], ["women", "SPECIES", 40, 45], ["our study", "TEST", 3, 12], ["baseline comorbidities", "PROBLEM", 77, 99], ["respiratory failure", "PROBLEM", 169, 188], ["death", "PROBLEM", 193, 198], ["respiratory failure", "OBSERVATION", 169, 188]]], ["The patients were generally older, 164 multiparous and racial/ethnic minorities, which may reflect underlying disease 165 prevalence (a product of various factors, including household size and ability to social 166 distance) rather than intrinsic susceptibility to adverse outcomes.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["multiparous and racial/ethnic minorities", "PROBLEM", 39, 79], ["underlying disease", "PROBLEM", 99, 117], ["intrinsic susceptibility to adverse outcomes", "PROBLEM", 237, 281], ["ethnic minorities", "OBSERVATION", 62, 79], ["may reflect", "UNCERTAINTY", 87, 98]]], ["Larger studies are 167 needed to determine which laboratory and imaging findings are most predictive of 168 rapidly progressive respiratory failure in pregnancy.", [["respiratory", "ANATOMY", 128, 139], ["respiratory failure", "DISEASE", 128, 147], ["Larger studies", "TEST", 0, 14], ["imaging findings", "TEST", 64, 80], ["rapidly progressive respiratory failure in pregnancy", "PROBLEM", 108, 160], ["rapidly", "OBSERVATION_MODIFIER", 108, 115], ["progressive", "OBSERVATION_MODIFIER", 116, 127], ["respiratory failure", "OBSERVATION", 128, 147]]], ["In our study, most patients were 169 delivered in the setting of worsening disease; it is not known how autotransfusion and 170 other physiologic and immunologic changes immediately after delivery affect maternal 171 outcomes.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["our study", "TEST", 3, 12], ["worsening disease", "PROBLEM", 65, 82], ["autotransfusion", "TEST", 104, 119], ["immunologic changes", "PROBLEM", 150, 169], ["worsening", "OBSERVATION_MODIFIER", 65, 74], ["disease", "OBSERVATION", 75, 82], ["not known", "UNCERTAINTY", 90, 99]]], ["172 173 Strengths of this study include consecutive patient enrollment over a well-defined time 174127interval, explicit inclusion and exclusion criteria, utilization of data from a single medical 175 record system, and evaluation of clinically relevant outcomes.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["this study", "TEST", 21, 31], ["evaluation", "TEST", 220, 230]]], ["In addition, no patients 176 remained hospitalized at study completion, allowing all in-hospital outcomes to be fully 177 evaluated, without omission, further reducing the risk of bias.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["no", "UNCERTAINTY", 13, 15]]], ["This study also has 178 limitations.", [["This study", "TEST", 0, 10]]], ["First, our sample size remains small due to the rarity of ICU admissions 179 among pregnant women with COVID-19.", [["women", "ORGANISM", 92, 97], ["women", "SPECIES", 92, 97], ["our sample size", "TEST", 7, 22], ["COVID", "TEST", 103, 108], ["size", "OBSERVATION_MODIFIER", 18, 22], ["small", "OBSERVATION_MODIFIER", 31, 36]]], ["5 During the study, ICU bed availability was 180 limited and patients requiring significant non-invasive respiratory support (e.g. oxygen 181 delivery via nasal cannula or face mask) were often managed on lower acuity units.", [["respiratory", "ANATOMY", 105, 116], ["nasal", "ANATOMY", 155, 160], ["oxygen", "CHEMICAL", 131, 137], ["oxygen", "CHEMICAL", 131, 137], ["patients", "ORGANISM", 61, 69], ["oxygen", "SIMPLE_CHEMICAL", 131, 137], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 155, 168], ["patients", "SPECIES", 61, 69], ["the study", "TEST", 9, 18], ["significant non-invasive respiratory support", "TREATMENT", 80, 124], ["oxygen", "TREATMENT", 131, 137], ["nasal cannula", "TREATMENT", 155, 168], ["face mask", "TREATMENT", 172, 181], ["lower acuity units", "TREATMENT", 205, 223], ["respiratory support", "OBSERVATION", 105, 124]]], ["182127Second, laboratory testing and radiologic imaging were not uniform.", [["laboratory testing", "TEST", 14, 32], ["radiologic imaging", "TEST", 37, 55]]], ["Third, treatment 183 algorithms changed throughout the study period and were not identical for all patients.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["treatment 183 algorithms", "TREATMENT", 7, 31]]], ["184127Finally, the true prevalence of COVID-19 among pregnant women in these communities 185 is unknown; a SARS-CoV-2 testing strategy that only includes patients admitted the 186 hospital, predominantly for delivery, doesn't reflect this number.", [["184127", "CHEMICAL", 0, 6], ["COVID-19", "CHEMICAL", 38, 46], ["women", "ORGANISM", 62, 67], ["patients", "ORGANISM", 154, 162], ["women", "SPECIES", 62, 67], ["patients", "SPECIES", 154, 162], ["184127", "SPECIES", 0, 6], ["COVID", "TEST", 38, 43], ["a SARS", "TEST", 105, 111], ["CoV", "TEST", 112, 115], ["delivery", "TREATMENT", 208, 216]]], ["Universal testing for 187 SARS-CoV-2 was implemented in the middle of the study period on our obstetrical Data are n (%) and mean \u00b1 standard deviation unless otherwise specified.", [["SARS", "DISEASE", 26, 30], ["Universal testing", "TEST", 0, 17], ["CoV", "TEST", 31, 34], ["the study", "TEST", 70, 79], ["our obstetrical Data", "TEST", 90, 110], ["mean \u00b1 standard deviation", "PROBLEM", 125, 150]]]], "892360bd50a26bb5b914d23ca905794894a339dd": [["We share our early multicenter experience with children admitted from March 27 th , 2020 to April 27 th , 2020 with a history of congenital heart disease who were hospitalized with COVID-19 as diagnosed by SARS-CoV-2 polymerase chain reaction (PCR).", [["heart", "ANATOMY", 140, 145], ["congenital heart disease", "DISEASE", 129, 153], ["children", "ORGANISM", 47, 55], ["heart", "ORGAN", 140, 145], ["children", "SPECIES", 47, 55], ["congenital heart disease", "PROBLEM", 129, 153], ["COVID", "TEST", 181, 186], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["2 polymerase chain reaction", "PROBLEM", 215, 242], ["PCR", "TEST", 244, 247], ["heart", "ANATOMY", 140, 145], ["disease", "OBSERVATION", 146, 153]]]], "ec85fddb316d71605d2e8e705555005a3b31d3ea": [["Middle East Respiratory Syndrome (MERS) coronavirus is the most recent among the Coronaviridae family to jump species and infect humans [1] .", [["Middle East Respiratory Syndrome (MERS) coronavirus", "DISEASE", 0, 51], ["Middle East Respiratory", "ORGANISM", 0, 23], ["humans", "ORGANISM", 129, 135], ["humans", "SPECIES", 129, 135], ["Middle East Respiratory Syndrome (MERS) coronavirus", "SPECIES", 0, 51], ["humans", "SPECIES", 129, 135], ["Middle East Respiratory Syndrome", "PROBLEM", 0, 32], ["coronavirus", "PROBLEM", 40, 51], ["Respiratory Syndrome", "OBSERVATION", 12, 32]]], ["Despite the potential role of camels in disease transmission, the current burden of the virus lies in its association with healthcare-based outbreaks [2, 3, 4] .", [["camels", "ORGANISM", 30, 36], ["disease transmission", "PROBLEM", 40, 60], ["the virus", "PROBLEM", 84, 93], ["virus", "OBSERVATION", 88, 93]]], ["Hospital outbreaks emphasize the importance of compliance with infection control standards, where not only the obvious practices of hand hygiene and proper use of personal protective equipment (PPE) are important but other interventions addressing patient triage, placement and flow within and between healthcare facilities are also critical to preventing disease spread.", [["hand", "ANATOMY", 132, 136], ["infection", "DISEASE", 63, 72], ["hand", "ORGANISM_SUBDIVISION", 132, 136], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 248, 255], ["infection control standards", "TREATMENT", 63, 90], ["hand hygiene", "TREATMENT", 132, 144], ["personal protective equipment", "TREATMENT", 163, 192], ["patient triage", "TEST", 248, 262], ["placement", "TREATMENT", 264, 273], ["disease spread", "PROBLEM", 356, 370]]], ["The largest reported outbreak was in Jeddah, Saudi Arabia, in the spring of 2014, where 255 individuals were diagnosed with MERS and an estimated 97.3% were healthcare-associated infections [2] .", [["MERS", "DISEASE", 124, 128], ["infections", "DISEASE", 179, 189], ["individuals", "ORGANISM", 92, 103], ["MERS", "PROBLEM", 124, 128], ["associated infections", "PROBLEM", 168, 189], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["outbreak", "OBSERVATION_MODIFIER", 21, 29]]], ["A more recent outbreak in the Republic of Korea was traced back to one traveler from the Arabian Peninsula, and again, a substantial portion of infections was associated with healthcare [3] .", [["infections", "DISEASE", 144, 154], ["a substantial portion of infections", "PROBLEM", 119, 154], ["outbreak", "OBSERVATION_MODIFIER", 14, 22], ["Arabian Peninsula", "ANATOMY", 89, 106], ["substantial", "OBSERVATION_MODIFIER", 121, 132], ["portion", "OBSERVATION_MODIFIER", 133, 140], ["infections", "OBSERVATION", 144, 154]]]], "PMC3968140": [["IntroductionThe development and implementation of targeted monoclonal antibody (MAb) therapy have provided new opportunities for controlling a wide range of diseases.", [["targeted monoclonal antibody", "PROTEIN", 50, 78], ["MAb", "PROTEIN", 80, 83], ["targeted monoclonal antibody (MAb) therapy", "TREATMENT", 50, 92], ["diseases", "PROBLEM", 157, 165]]], ["Although MAbs produced in mammalian cell culture systems have achieved remarkable clinical success, their high cost, long manufacturing time, and restricted production capacity have limited the availability, utility and potential of these drugs.", [["cell culture", "ANATOMY", 36, 48], ["MAbs", "GENE_OR_GENE_PRODUCT", 9, 13], ["cell", "CELL", 36, 40], ["MAbs", "PROTEIN", 9, 13], ["mammalian cell culture systems", "TEST", 26, 56], ["restricted production capacity", "PROBLEM", 146, 176], ["these drugs", "TREATMENT", 233, 244], ["mammalian cell", "OBSERVATION", 26, 40]]], ["Several of these challenges might be overcome by using plant expression systems, because they offer scalable production of MAbs at low cost with a low risk of introducing adventitious human or animal pathogens [1]\u2013[3].", [["human", "ORGANISM", 184, 189], ["MAbs", "PROTEIN", 123, 127], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["plant expression systems", "TREATMENT", 55, 79], ["scalable production of MAbs", "TREATMENT", 100, 127]]], ["Functional antibody production requires a eukaryotic host cell that can assemble four antibody polypeptides into a heterotetramer and perform complex N-linked glycosylation.", [["cell", "ANATOMY", 58, 62], ["N", "CHEMICAL", 150, 151], ["host cell", "CELL", 53, 62], ["antibody polypeptides", "PROTEIN", 86, 107], ["heterotetramer", "PROTEIN", 115, 129], ["Functional antibody production", "PROBLEM", 0, 30], ["a eukaryotic host cell", "TREATMENT", 40, 62], ["four antibody polypeptides", "TREATMENT", 81, 107], ["a heterotetramer", "TREATMENT", 113, 129], ["complex N-linked glycosylation", "TREATMENT", 142, 172], ["antibody production", "OBSERVATION", 11, 30], ["host cell", "OBSERVATION", 53, 62]]], ["Despite this complexity, a MAb was successfully expressed in tobacco plants only three years after the first plant-made biologic [4].", [["MAb", "GENE_OR_GENE_PRODUCT", 27, 30], ["tobacco", "ORGANISM", 61, 68], ["MAb", "PROTEIN", 27, 30], ["tobacco", "SPECIES", 61, 68], ["tobacco", "SPECIES", 61, 68], ["a MAb", "TREATMENT", 25, 30]]], ["Since then, a variety of MAbs and their derivatives, such as IgG, IgA, single-chain variable fragments (scFv), and diabodies have been produced in plants [3].", [["MAbs", "GENE_OR_GENE_PRODUCT", 25, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgA", "GENE_OR_GENE_PRODUCT", 66, 69], ["scFv", "GENE_OR_GENE_PRODUCT", 104, 108], ["diabodies", "GENE_OR_GENE_PRODUCT", 115, 124], ["MAbs", "PROTEIN", 25, 29], ["IgG", "PROTEIN", 61, 64], ["IgA", "PROTEIN", 66, 69], ["single-chain variable fragments", "PROTEIN", 71, 102], ["scFv", "PROTEIN", 104, 108], ["diabodies", "PROTEIN", 115, 124], ["MAbs", "TREATMENT", 25, 29], ["their derivatives", "TREATMENT", 34, 51], ["IgG", "TEST", 61, 64], ["single-chain variable fragments (scFv", "TREATMENT", 71, 108], ["diabodies", "TREATMENT", 115, 124]]], ["The largest reported MAb-based molecule produced in plants is a recombinant immune complex (RIC) [5].", [["MAb", "GENE_OR_GENE_PRODUCT", 21, 24], ["MAb-based molecule", "PROTEIN", 21, 39], ["recombinant immune complex", "PROTEIN", 64, 90], ["a recombinant immune complex (RIC)", "TREATMENT", 62, 96], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["MAb", "OBSERVATION", 21, 24], ["based molecule", "OBSERVATION", 25, 39]]], ["The ability of plants to express and assemble larger or more complex MAb-derived molecules such as tetravalent MAbs or bifunctional MAbs has not been described.IntroductionN-linked glycosylation of proteins occurs as a series of post-translational modification steps in host cells and depends on the proper folding of the target protein and its transport to the appropriate endomembrane compartments [6].", [["cells", "ANATOMY", 275, 280], ["endomembrane compartments", "ANATOMY", 374, 399], ["MAb", "GENE_OR_GENE_PRODUCT", 69, 72], ["host cells", "CELL", 270, 280], ["endomembrane", "CELLULAR_COMPONENT", 374, 386], ["complex MAb", "PROTEIN", 61, 72], ["tetravalent MAbs", "PROTEIN", 99, 115], ["bifunctional MAbs", "PROTEIN", 119, 136], ["host cells", "CELL_TYPE", 270, 280], ["target protein", "PROTEIN", 322, 336], ["assemble larger or more complex MAb-derived molecules", "PROBLEM", 37, 90], ["tetravalent MAbs", "TREATMENT", 99, 115], ["bifunctional MAbs", "TREATMENT", 119, 136], ["IntroductionN", "TREATMENT", 160, 173], ["glycosylation of proteins", "TREATMENT", 181, 206], ["post-translational modification steps in host cells", "TREATMENT", 229, 280], ["larger", "OBSERVATION_MODIFIER", 46, 52], ["host cells", "OBSERVATION", 270, 280]]], ["As such, MAb variants with significant polypeptide structural differences from the native molecule also may have appreciable differences in glycan structures.", [["MAb", "GENE_OR_GENE_PRODUCT", 9, 12], ["MAb variants", "PROTEIN", 9, 21], ["significant polypeptide structural differences", "PROBLEM", 27, 73], ["appreciable differences in glycan structures", "PROBLEM", 113, 157], ["native molecule", "OBSERVATION", 83, 98]]], ["Structural differences also may impact the pharmacokinetics, antigen binding, stability, effector functions, immunogenicity, and efficacy of a MAb and its derivatives.IntroductionWest Nile virus (WNV) is a neurotropic virus that infects the central nervous system (CNS) of human and animals.", [["central nervous system", "ANATOMY", 241, 263], ["CNS", "ANATOMY", 265, 268], ["infects the central nervous system", "DISEASE", 229, 263], ["MAb", "GENE_OR_GENE_PRODUCT", 143, 146], ["IntroductionWest Nile virus", "ORGANISM", 167, 194], ["WNV", "ORGANISM", 196, 199], ["neurotropic virus", "ORGANISM", 206, 223], ["central nervous system", "ANATOMICAL_SYSTEM", 241, 263], ["CNS", "ANATOMICAL_SYSTEM", 265, 268], ["human", "ORGANISM", 273, 278], ["Nile virus", "SPECIES", 184, 194], ["human", "SPECIES", 273, 278], ["IntroductionWest Nile virus", "SPECIES", 167, 194], ["WNV", "SPECIES", 196, 199], ["neurotropic virus", "SPECIES", 206, 223], ["human", "SPECIES", 273, 278], ["a MAb", "TREATMENT", 141, 146], ["its derivatives", "TREATMENT", 151, 166], ["IntroductionWest Nile virus (WNV", "PROBLEM", 167, 199], ["a neurotropic virus", "PROBLEM", 204, 223], ["stability", "OBSERVATION_MODIFIER", 78, 87], ["neurotropic virus", "OBSERVATION", 206, 223], ["central", "ANATOMY_MODIFIER", 241, 248], ["nervous system", "ANATOMY", 249, 263]]], ["Historically, WNV was an Old World disease found mostly in the Eastern Europe, Africa, and the Middle East.", [["WNV", "DISEASE", 14, 17], ["WNV", "ORGANISM", 14, 17], ["WNV", "SPECIES", 14, 17], ["an Old World disease", "PROBLEM", 22, 42], ["Middle", "ANATOMY_MODIFIER", 95, 101]]], ["However, in 1999, WNV entered the Western hemisphere and subsequently spread across the United States (US), Canada, the Caribbean region and Latin America [7] with outbreaks occurring on an annual basis.", [["WNV", "SPECIES", 18, 21], ["spread", "OBSERVATION_MODIFIER", 70, 76]]], ["The elderly and immunocompromised are the most vulnerable for developing severe neurological disease, long-term morbidity, and death [8], although genetic factors also are associated with an increase risk of disease [9], [10].", [["neurological", "ANATOMY", 80, 92], ["neurological disease", "DISEASE", 80, 100], ["death", "DISEASE", 127, 132], ["immunocompromised", "PROBLEM", 16, 33], ["developing severe neurological disease", "PROBLEM", 62, 100], ["long-term morbidity", "PROBLEM", 102, 121], ["death", "PROBLEM", 127, 132], ["genetic factors", "PROBLEM", 147, 162], ["disease", "PROBLEM", 208, 215], ["immunocompromised", "OBSERVATION", 16, 33], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["neurological disease", "OBSERVATION", 80, 100]]], ["Currently, there is no vaccine or therapeutic approved for human use.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["vaccine", "TREATMENT", 23, 30], ["no", "UNCERTAINTY", 20, 22]]], ["The global threat of WNV epidemics and the lack of treatment warrant the development of antiviral therapeutics and production platforms that can bring products to market at low cost.", [["WNV", "DISEASE", 21, 24], ["WNV", "ORGANISM", 21, 24], ["WNV", "SPECIES", 21, 24], ["WNV epidemics", "PROBLEM", 21, 34], ["treatment", "TREATMENT", 51, 60], ["antiviral therapeutics", "TREATMENT", 88, 110], ["production platforms", "TREATMENT", 115, 135], ["global", "OBSERVATION_MODIFIER", 4, 10], ["threat", "OBSERVATION_MODIFIER", 11, 17], ["WNV", "OBSERVATION", 21, 24]]], ["We previously reported a plant-derived, humanized murine MAb (pHu-E16) that binds to an epitope on domain III (DIII) of WNV envelope (E) protein, as a post-exposure therapeutic candidate for WNV [11].", [["murine", "ORGANISM", 50, 56], ["MAb", "GENE_OR_GENE_PRODUCT", 57, 60], ["pHu-E16", "ORGANISM", 62, 69], ["DIII", "GENE_OR_GENE_PRODUCT", 111, 115], ["WNV envelope (E)", "GENE_OR_GENE_PRODUCT", 120, 136], ["WNV", "ORGANISM", 191, 194], ["humanized murine MAb", "PROTEIN", 40, 60], ["pHu", "PROTEIN", 62, 65], ["E16", "PROTEIN", 66, 69], ["epitope", "PROTEIN", 88, 95], ["domain III", "PROTEIN", 99, 109], ["DIII", "PROTEIN", 111, 115], ["WNV envelope (E) protein", "PROTEIN", 120, 144], ["murine", "SPECIES", 50, 56], ["WNV", "SPECIES", 191, 194], ["humanized murine MAb", "TREATMENT", 40, 60], ["WNV", "PROBLEM", 191, 194]]], ["We demonstrated that pHu-E16 was produced at high levels and assembled efficiently in both Nicotiana benthamiana and lettuce plants [11], [12]. pHu-E16 retained antigen binding specificity, neutralized WNV infection, and protected mice from lethal infection equivalently compared to the mammalian cell-produced Hu-E16 (mHu-E16) [11].", [["cell", "ANATOMY", 297, 301], ["pHu", "CHEMICAL", 21, 24], ["pHu", "CHEMICAL", 144, 147], ["WNV infection", "DISEASE", 202, 215], ["infection", "DISEASE", 248, 257], ["pHu-E16", "GENE_OR_GENE_PRODUCT", 21, 28], ["Nicotiana benthamiana", "ORGANISM", 91, 112], ["pHu-E16", "GENE_OR_GENE_PRODUCT", 144, 151], ["antigen", "GENE_OR_GENE_PRODUCT", 161, 168], ["WNV", "ORGANISM", 202, 205], ["mice", "ORGANISM", 231, 235], ["mammalian cell", "CELL", 287, 301], ["Hu-E16", "ORGANISM", 311, 317], ["pHu", "PROTEIN", 21, 24], ["E16", "PROTEIN", 25, 28], ["pHu", "PROTEIN", 144, 147], ["E16", "PROTEIN", 148, 151], ["Hu", "PROTEIN", 311, 313], ["Nicotiana benthamiana", "SPECIES", 91, 112], ["mice", "SPECIES", 231, 235], ["Nicotiana benthamiana", "SPECIES", 91, 112], ["lettuce", "SPECIES", 117, 124], ["WNV", "SPECIES", 202, 205], ["mice", "SPECIES", 231, 235], ["pHu", "TEST", 21, 24], ["pHu", "TEST", 144, 147], ["neutralized WNV infection", "PROBLEM", 190, 215], ["lethal infection", "PROBLEM", 241, 257], ["the mammalian cell", "TEST", 283, 301], ["Nicotiana benthamiana", "OBSERVATION", 91, 112], ["WNV", "OBSERVATION_MODIFIER", 202, 205], ["infection", "OBSERVATION", 206, 215], ["infection", "OBSERVATION", 248, 257]]], ["Because WNV is a neurotropic virus, peripheral delivery of pHu-E16, however, likely will have a limited window of efficacy due to its inability to cross the blood brain barrier (BBB) efficiently and accumulate in the brain at concentrations sufficient for neutralization.", [["blood brain barrier", "ANATOMY", 157, 176], ["BBB", "ANATOMY", 178, 181], ["brain", "ANATOMY", 217, 222], ["WNV", "DISEASE", 8, 11], ["WNV", "ORGANISM", 8, 11], ["neurotropic virus", "ORGANISM", 17, 34], ["pHu-E16", "ORGANISM", 59, 66], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 157, 176], ["BBB", "MULTI-TISSUE_STRUCTURE", 178, 181], ["brain", "ORGAN", 217, 222], ["WNV", "SPECIES", 8, 11], ["WNV", "PROBLEM", 8, 11], ["a neurotropic virus", "PROBLEM", 15, 34], ["its inability", "PROBLEM", 130, 143], ["neutralization", "PROBLEM", 256, 270], ["brain", "ANATOMY", 217, 222], ["neutralization", "OBSERVATION", 256, 270]]], ["Thus, it would be desirable to develop pHu-E16 variants, such as bifunctional MAbs, that can cross the BBB while retaining targeted therapeutic activity.IntroductionTo test the ability of plants in producing such complex MAb variants, here we expressed several pHu-E16 derivatives including a pHu-E16scFv fused to the heavy chain (HC) constant domains (CH1-3) of human IgG (pHu-E16scFv-CH1-3) and a large tetravalent molecule (Tetra pHu-E16) assembled from pHu-E16scFv-CH1-3 with another pHu-E16scFv fused to the light chain (LC) constant region (CL) (pHu-E16scFv-CL).", [["BBB", "ANATOMY", 103, 106], ["pHu-E16", "GENE_OR_GENE_PRODUCT", 39, 46], ["BBB", "MULTI-TISSUE_STRUCTURE", 103, 106], ["MAb", "GENE_OR_GENE_PRODUCT", 221, 224], ["human", "ORGANISM", 363, 368], ["IgG", "GENE_OR_GENE_PRODUCT", 369, 372], ["pHu-E16scFv", "SIMPLE_CHEMICAL", 488, 499], ["CL", "MULTI-TISSUE_STRUCTURE", 547, 549], ["pHu", "PROTEIN", 39, 42], ["bifunctional MAbs", "PROTEIN", 65, 82], ["complex MAb variants", "PROTEIN", 213, 233], ["pHu", "PROTEIN", 261, 264], ["pHu", "PROTEIN", 293, 296], ["E16scFv", "PROTEIN", 297, 304], ["heavy chain (HC) constant domains", "PROTEIN", 318, 351], ["CH1", "PROTEIN", 353, 356], ["human IgG", "PROTEIN", 363, 372], ["pHu", "PROTEIN", 374, 377], ["E16scFv", "PROTEIN", 378, 385], ["CH1", "PROTEIN", 386, 389], ["tetravalent molecule", "PROTEIN", 405, 425], ["pHu", "PROTEIN", 433, 436], ["E16", "PROTEIN", 437, 440], ["pHu", "PROTEIN", 457, 460], ["E16scFv", "PROTEIN", 461, 468], ["CH1", "PROTEIN", 469, 472], ["pHu", "PROTEIN", 488, 491], ["E16scFv", "PROTEIN", 492, 499], ["light chain (LC) constant region", "PROTEIN", 513, 545], ["pHu", "PROTEIN", 552, 555], ["E16scFv", "PROTEIN", 556, 563], ["CL", "PROTEIN", 564, 566], ["human", "SPECIES", 363, 368], ["human", "SPECIES", 363, 368], ["pHu-E16 variants", "PROBLEM", 39, 55], ["bifunctional MAbs", "TREATMENT", 65, 82], ["several pHu-E16 derivatives", "TREATMENT", 253, 280], ["a pHu", "TEST", 291, 296], ["human IgG", "TEST", 363, 372], ["pHu", "TEST", 374, 377], ["a large tetravalent molecule", "PROBLEM", 397, 425], ["pHu", "TEST", 457, 460], ["another pHu", "TEST", 480, 491], ["pHu", "TEST", 552, 555], ["human IgG", "ANATOMY", 363, 372], ["large", "OBSERVATION_MODIFIER", 399, 404], ["tetravalent molecule", "OBSERVATION", 405, 425], ["LC", "ANATOMY", 526, 528]]], ["We demonstrated that plants can express and assemble these pHu-E16 variants efficiently.", [["pHu", "GENE_OR_GENE_PRODUCT", 59, 62], ["pHu", "PROTEIN", 59, 62]]], ["These pHu-E16 variants also showed at least equivalent protection as the parent pHu-E16 or mHu-E16 against a lethal WNV challenge in a mouse model.", [["WNV", "DISEASE", 116, 119], ["pHu-E16", "GENE_OR_GENE_PRODUCT", 6, 13], ["pHu-E16", "ORGANISM", 80, 87], ["mHu-E16", "ORGANISM", 91, 98], ["WNV", "ORGANISM", 116, 119], ["mouse", "ORGANISM", 135, 140], ["pHu", "PROTEIN", 6, 9], ["mouse", "SPECIES", 135, 140], ["WNV", "SPECIES", 116, 119], ["mouse", "SPECIES", 135, 140], ["a lethal WNV challenge", "TREATMENT", 107, 129]]], ["Our results also revealed differences in N-linked glycosylation pattern between different MAb variants, and demonstrated that the proper pairing of HC and LC was essential for the complete N-glycan processing of antibodies in both plant and animal cells.", [["cells", "ANATOMY", 248, 253], ["N", "CHEMICAL", 41, 42], ["MAb", "GENE_OR_GENE_PRODUCT", 90, 93], ["HC", "CELLULAR_COMPONENT", 148, 150], ["cells", "CELL", 248, 253], ["MAb variants", "PROTEIN", 90, 102], ["antibodies", "PROTEIN", 212, 222], ["plant and animal cells", "CELL_TYPE", 231, 253], ["differences in N-linked glycosylation pattern", "PROBLEM", 26, 71], ["different MAb variants", "PROBLEM", 80, 102], ["antibodies", "PROBLEM", 212, 222], ["MAb variants", "OBSERVATION", 90, 102], ["LC", "ANATOMY", 155, 157], ["animal cells", "OBSERVATION", 241, 253]]], ["We also found that pHu-E16, pHu-E16scFv-CH1-3 and Tetra pHu-E16 exhibited differential binding to specific Fc\u03b3 receptors (Fc\u03b3Rs) and C1q, the complement opsonin that activates the classical complement pathway.", [["pHu-E16", "GENE_OR_GENE_PRODUCT", 19, 26], ["pHu-E16scFv-CH1-3", "GENE_OR_GENE_PRODUCT", 28, 45], ["Fc\u03b3 receptors", "GENE_OR_GENE_PRODUCT", 107, 120], ["Fc\u03b3Rs", "GENE_OR_GENE_PRODUCT", 122, 127], ["C1q", "GENE_OR_GENE_PRODUCT", 133, 136], ["complement opsonin", "GENE_OR_GENE_PRODUCT", 142, 160], ["E16scFv", "PROTEIN", 32, 39], ["CH1", "PROTEIN", 40, 43], ["pHu", "PROTEIN", 56, 59], ["E16", "PROTEIN", 60, 63], ["Fc\u03b3 receptors", "PROTEIN", 107, 120], ["Fc\u03b3Rs", "PROTEIN", 122, 127], ["C1q", "PROTEIN", 133, 136], ["complement opsonin", "PROTEIN", 142, 160], ["pHu", "TEST", 19, 22], ["pHu", "TEST", 28, 31], ["E16scFv", "TEST", 32, 39], ["CH1", "TEST", 40, 43], ["Tetra pHu", "TEST", 50, 59], ["differential binding", "PROBLEM", 74, 94]]], ["In human K562 cells, none of the plant-derived Hu-E16 variants showed significant antibody-dependent enhancement (ADE) activity, a phenomenon that is an impediment for developing MAb-based therapeutics against flaviviruses, such as the related Dengue virus.", [["K562 cells", "ANATOMY", 9, 19], ["flaviviruses", "DISEASE", 210, 222], ["Dengue virus", "DISEASE", 244, 256], ["human", "ORGANISM", 3, 8], ["K562 cells", "CELL", 9, 19], ["Hu-E16", "ORGANISM", 47, 53], ["MAb", "GENE_OR_GENE_PRODUCT", 179, 182], ["flaviviruses", "ORGANISM", 210, 222], ["Dengue virus", "ORGANISM", 244, 256], ["human K562 cells", "CELL_LINE", 3, 19], ["Hu", "PROTEIN", 47, 49], ["human", "SPECIES", 3, 8], ["Dengue virus", "SPECIES", 244, 256], ["human", "SPECIES", 3, 8], ["Dengue virus", "SPECIES", 244, 256], ["Hu-E16 variants", "TEST", 47, 62], ["significant antibody-dependent enhancement", "PROBLEM", 70, 112], ["a phenomenon", "PROBLEM", 129, 141], ["developing MAb", "TREATMENT", 168, 182], ["flaviviruses", "PROBLEM", 210, 222], ["the related Dengue virus", "PROBLEM", 232, 256], ["K562 cells", "OBSERVATION", 9, 19], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["antibody", "OBSERVATION", 82, 90], ["dependent", "OBSERVATION_MODIFIER", 91, 100], ["enhancement", "OBSERVATION_MODIFIER", 101, 112], ["Dengue virus", "OBSERVATION", 244, 256]]], ["Overall, this study demonstrates the capacity of a plant to assemble a large and complex IgG-like tetravalent MAb, which offers a step forward toward the development of bifunctional MAbs in plants.Expression and assembly of pHu-E16 scFv-CH1-3 in N. benthamiana::: ResultsAn important prerequisite for the generation of bifunctional Hu-E16 MAb is the correct assembly of its functional component: pHu-E16scFv-CH1-3.", [["IgG", "GENE_OR_GENE_PRODUCT", 89, 92], ["MAbs", "GENE_OR_GENE_PRODUCT", 182, 186], ["pHu", "GENE_OR_GENE_PRODUCT", 224, 227], ["CH1-3", "GENE_OR_GENE_PRODUCT", 237, 242], ["N. benthamiana", "ORGANISM", 246, 260], ["Hu-E16 MAb", "GENE_OR_GENE_PRODUCT", 332, 342], ["pHu-E16scFv-CH1-3", "GENE_OR_GENE_PRODUCT", 396, 413], ["IgG", "PROTEIN", 89, 92], ["tetravalent MAb", "PROTEIN", 98, 113], ["bifunctional MAbs", "PROTEIN", 169, 186], ["pHu", "PROTEIN", 224, 227], ["E16 scFv", "PROTEIN", 228, 236], ["CH1", "PROTEIN", 237, 240], ["Hu", "PROTEIN", 332, 334], ["E16 MAb", "PROTEIN", 335, 342], ["pHu", "PROTEIN", 396, 399], ["E16scFv", "PROTEIN", 400, 407], ["CH1", "PROTEIN", 408, 411], ["N. benthamiana", "SPECIES", 246, 260], ["N. benthamiana", "SPECIES", 246, 260], ["this study", "TEST", 9, 19], ["a large and complex IgG", "PROBLEM", 69, 92], ["tetravalent MAb", "TREATMENT", 98, 113], ["bifunctional MAbs", "TREATMENT", 169, 186], ["pHu", "TEST", 224, 227], ["bifunctional Hu-E16 MAb", "TREATMENT", 319, 342], ["pHu", "TEST", 396, 399], ["large", "OBSERVATION_MODIFIER", 71, 76], ["complex", "OBSERVATION_MODIFIER", 81, 88], ["IgG", "OBSERVATION", 89, 92], ["tetravalent MAb", "OBSERVATION", 98, 113], ["bifunctional MAbs", "OBSERVATION", 169, 186], ["benthamiana", "ANATOMY", 249, 260]]], ["The DNA sequence of the variable region of HC (VH) and LC (VL) of pHu-E16 [11] was fused together first to generate pHu-E16scFv, and then fused to the coding sequence of the CH1-3 of human IgG1 (Fig 1A).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["HC (VH)", "GENE_OR_GENE_PRODUCT", 43, 50], ["pHu-E16", "GENE_OR_GENE_PRODUCT", 66, 73], ["pHu-E16scFv", "GENE_OR_GENE_PRODUCT", 116, 127], ["CH1-3", "GENE_OR_GENE_PRODUCT", 174, 179], ["human", "ORGANISM", 183, 188], ["IgG1", "GENE_OR_GENE_PRODUCT", 189, 193], ["HC", "PROTEIN", 43, 45], ["VH", "PROTEIN", 47, 49], ["pHu", "PROTEIN", 66, 69], ["pHu", "PROTEIN", 116, 119], ["E16scFv", "PROTEIN", 120, 127], ["CH1", "PROTEIN", 174, 177], ["human IgG1", "PROTEIN", 183, 193], ["Fig 1A", "PROTEIN", 195, 201], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["The DNA sequence", "TEST", 0, 16], ["LC", "TEST", 55, 57], ["LC", "ANATOMY", 55, 57]]], ["The resulting coding sequence of pHu-E16scFv-CH1-3 was cloned into a MagnICON-based plant expression vector [13], and transformed into Agrobacterium tumefaciens.", [["pHu-E16scFv-CH1-3", "GENE_OR_GENE_PRODUCT", 33, 50], ["Agrobacterium tumefaciens", "ORGANISM", 135, 160], ["pHu", "DNA", 33, 36], ["E16scFv", "DNA", 37, 44], ["CH1-3", "DNA", 45, 50], ["MagnICON-based plant expression vector", "DNA", 69, 107], ["Agrobacterium tumefaciens", "SPECIES", 135, 160], ["Agrobacterium tumefaciens", "SPECIES", 135, 160], ["The resulting coding sequence", "TEST", 0, 29], ["pHu", "TEST", 33, 36], ["a MagnICON-based plant expression vector", "TREATMENT", 67, 107]]], ["A. tumefaciens strains containing the pHu-E16scFv-CH1-3 construct were co-delivered into N. benthamiana leaves along with the promoter module and an integrase construct through agroinfiltration [14], [15].", [["leaves", "ANATOMY", 104, 110], ["A. tumefaciens strains", "ORGANISM", 0, 22], ["pHu", "GENE_OR_GENE_PRODUCT", 38, 41], ["E16scFv-CH1-3", "GENE_OR_GENE_PRODUCT", 42, 55], ["N. benthamiana", "ORGANISM", 89, 103], ["pHu-E16scFv-CH1-3 construct", "DNA", 38, 65], ["promoter module", "DNA", 126, 141], ["integrase construct", "DNA", 149, 168], ["A. tumefaciens", "SPECIES", 0, 14], ["N. benthamiana", "SPECIES", 89, 103], ["A. tumefaciens", "SPECIES", 0, 14], ["N. benthamiana", "SPECIES", 89, 103], ["A. tumefaciens strains", "PROBLEM", 0, 22], ["the pHu", "TEST", 34, 41], ["the promoter module", "TREATMENT", 122, 141], ["an integrase construct through agroinfiltration", "TREATMENT", 146, 193]]], ["Western blot analysis after reducing or non-reducing gel electrophoresis confirmed that pHu-E16scFv-CH1-3 was produced in leaves with the expected molecular weight (Fig 1B", [["leaves", "ANATOMY", 122, 128], ["pHu-E16scFv-CH1-3", "CHEMICAL", 88, 105], ["pHu-E16scFv-CH1-3", "GENE_OR_GENE_PRODUCT", 88, 105], ["pHu", "PROTEIN", 88, 91], ["E16scFv", "PROTEIN", 92, 99], ["CH1", "PROTEIN", 100, 103], ["Western blot analysis", "TEST", 0, 21], ["non-reducing gel electrophoresis", "TEST", 40, 72], ["pHu", "TEST", 88, 91]]]], "4f37bf17ad3f6441ec3b86ff8adcc27123538a07": [["IntroductionPneumococcal/lobar pneumonia is a serious worldwide pediatric health issue because the disease often occurs with complications and drug resistance, especially in cases infected by Streptococcus pneumoniae.", [["Pneumococcal/lobar pneumonia", "DISEASE", 12, 40], ["Streptococcus pneumoniae", "DISEASE", 192, 216], ["Streptococcus pneumoniae", "ORGANISM", 192, 216], ["Streptococcus pneumoniae", "SPECIES", 192, 216], ["Streptococcus pneumoniae", "SPECIES", 192, 216], ["Pneumococcal/lobar pneumonia", "PROBLEM", 12, 40], ["the disease", "PROBLEM", 95, 106], ["complications", "PROBLEM", 125, 138], ["drug resistance", "PROBLEM", 143, 158], ["Streptococcus pneumoniae", "PROBLEM", 192, 216], ["lobar", "OBSERVATION_MODIFIER", 25, 30], ["pneumonia", "OBSERVATION", 31, 40], ["serious", "OBSERVATION_MODIFIER", 46, 53], ["disease", "OBSERVATION", 99, 106], ["Streptococcus pneumoniae", "OBSERVATION", 192, 216]]], ["According to the World Health Organization, S. pneumoniae is the leading cause of severe pneumonia worldwide in children younger than 5 years old, causing more than one million deaths in children each year [19] .", [["S. pneumoniae", "DISEASE", 44, 57], ["pneumonia", "DISEASE", 89, 98], ["deaths", "DISEASE", 177, 183], ["S. pneumoniae", "ORGANISM", 44, 57], ["children", "ORGANISM", 112, 120], ["children", "ORGANISM", 187, 195], ["S. pneumoniae", "SPECIES", 44, 57], ["children", "SPECIES", 112, 120], ["children", "SPECIES", 187, 195], ["S. pneumoniae", "SPECIES", 44, 57], ["S. pneumoniae", "PROBLEM", 44, 57], ["severe pneumonia", "PROBLEM", 82, 98], ["pneumoniae", "OBSERVATION", 47, 57], ["leading cause of", "UNCERTAINTY", 65, 81], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["pneumonia", "OBSERVATION", 89, 98]]], ["Empyema, one of the most severe complications of bacterial pneumonia, has been reported in 20% to 30% of all cases in Utah of USA [2] .", [["Empyema", "DISEASE", 0, 7], ["bacterial pneumonia", "DISEASE", 49, 68], ["Empyema", "PROBLEM", 0, 7], ["bacterial pneumonia", "PROBLEM", 49, 68], ["most severe", "OBSERVATION_MODIFIER", 20, 31], ["complications", "OBSERVATION", 32, 45], ["bacterial", "OBSERVATION_MODIFIER", 49, 58], ["pneumonia", "OBSERVATION", 59, 68]]], ["Although the incidence of invasive pneumococcal disease has decreased since the use of pneumococcal conjugated vaccine (PCV) [4] , developed countries such as USA have seen an emergence of empyema and necrotizing pneumonia episodes caused by nonvaccine serotypes [1, 3] .", [["pneumococcal disease", "DISEASE", 35, 55], ["empyema", "DISEASE", 189, 196], ["pneumonia", "DISEASE", 213, 222], ["pneumococcal", "SPECIES", 35, 47], ["pneumococcal", "SPECIES", 87, 99], ["PCV", "SPECIES", 120, 123], ["invasive pneumococcal disease", "PROBLEM", 26, 55], ["pneumococcal conjugated vaccine", "TREATMENT", 87, 118], ["empyema", "PROBLEM", 189, 196], ["necrotizing pneumonia episodes", "PROBLEM", 201, 231], ["nonvaccine serotypes", "PROBLEM", 242, 262], ["invasive", "OBSERVATION_MODIFIER", 26, 34], ["pneumococcal", "OBSERVATION_MODIFIER", 35, 47], ["disease", "OBSERVATION", 48, 55], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["empyema", "OBSERVATION", 189, 196], ["necrotizing", "OBSERVATION_MODIFIER", 201, 212], ["pneumonia", "OBSERVATION", 213, 222]]], ["In Taiwan, the represented pneumococcal serotypes in hospitalized children with invasive pneumococcal diseases (IPD) were serotypes 14, 19F, 3, 6B, and 23F, and the seven-valent pneumococcal conjugate vaccines covered 73% of IPD cases in children aged between 2 and 4 years and 65% of cases in children aged <2 years [11, 12] .", [["invasive pneumococcal diseases", "DISEASE", 80, 110], ["IPD", "DISEASE", 112, 115], ["IPD", "DISEASE", 225, 228], ["pneumococcal serotypes", "ORGANISM", 27, 49], ["children", "ORGANISM", 66, 74], ["6B", "GENE_OR_GENE_PRODUCT", 144, 146], ["children", "ORGANISM", 238, 246], ["children", "ORGANISM", 294, 302], ["children", "SPECIES", 66, 74], ["children", "SPECIES", 238, 246], ["children", "SPECIES", 294, 302], ["pneumococcal", "SPECIES", 27, 39], ["pneumococcal", "SPECIES", 89, 101], ["pneumococcal", "SPECIES", 178, 190], ["pneumococcal serotypes", "TREATMENT", 27, 49], ["invasive pneumococcal diseases", "PROBLEM", 80, 110], ["serotypes", "TEST", 122, 131], ["the seven-valent pneumococcal conjugate vaccines", "TREATMENT", 161, 209], ["pneumococcal serotypes", "OBSERVATION", 27, 49], ["invasive", "OBSERVATION_MODIFIER", 80, 88], ["pneumococcal diseases", "OBSERVATION", 89, 110]]], ["To date, little research has been done into the epidemiology and population-based incidence of pneumococcal/lobar pneumonia and empyema in the Asian and subtropical areas.IntroductionIn Taiwan, the medical care of 98% of the population is covered by a universal national health care system of National Health Insurance (NHI) established in 1995 [8] .IntroductionUsing the NHI database, we calculated the age-specific incidences and mortality rates of children hospitalized for pneumococcal/lobar pneumonia and empyema in Taiwan over an 8-year period, from 1997 to 2004.", [["pneumococcal/lobar pneumonia", "DISEASE", 95, 123], ["empyema", "DISEASE", 128, 135], ["pneumococcal/lobar pneumonia", "DISEASE", 477, 505], ["empyema", "DISEASE", 510, 517], ["children", "ORGANISM", 451, 459], ["children", "SPECIES", 451, 459], ["pneumococcal", "SPECIES", 95, 107], ["pneumococcal", "SPECIES", 477, 489], ["pneumococcal/lobar pneumonia", "PROBLEM", 95, 123], ["empyema", "PROBLEM", 128, 135], ["pneumococcal/lobar pneumonia", "PROBLEM", 477, 505], ["empyema", "PROBLEM", 510, 517], ["pneumococcal", "OBSERVATION_MODIFIER", 95, 107], ["lobar", "OBSERVATION_MODIFIER", 108, 113], ["pneumonia", "OBSERVATION", 114, 123], ["empyema", "OBSERVATION", 128, 135], ["subtropical", "ANATOMY_MODIFIER", 153, 164], ["lobar", "ANATOMY", 490, 495], ["pneumonia", "OBSERVATION", 496, 505], ["empyema", "OBSERVATION", 510, 517]]], ["The findings of such a study might provide important information relevant to future universal PCV vaccination policies thereMaterials and methodsTaiwan has a population of 22.9 million people, and the NHI covered most of the health care costs for 98% of its population in 2006 [8] ; the remaining 2% of its population is living in the foreign countries or in families with monthly household incomes less than US $1,000 [18] .", [["people", "ORGANISM", 185, 191], ["people", "SPECIES", 185, 191], ["a study", "TEST", 21, 28], ["universal PCV vaccination policies", "TREATMENT", 84, 118]]], ["Taiwan's NHI database includes health care data collected from over 95% of Taiwan's hospitals caring for 98% of its population.Materials and methodsUsing the NHI claims database, we collected the data of children under 18 years old hospitalized for lobar pneumonia or pneumococcal pneumonia and empyema, as defined by the International Classifications of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) codes.", [["lobar", "ANATOMY", 249, 254], ["pneumonia", "DISEASE", 255, 264], ["pneumococcal pneumonia", "DISEASE", 268, 290], ["empyema", "DISEASE", 295, 302], ["CM", "DISEASE", 410, 412], ["children", "ORGANISM", 204, 212], ["children", "SPECIES", 204, 212], ["pneumococcal", "SPECIES", 268, 280], ["lobar pneumonia", "PROBLEM", 249, 264], ["pneumococcal pneumonia", "PROBLEM", 268, 290], ["empyema", "PROBLEM", 295, 302], ["Diseases", "PROBLEM", 355, 363], ["Ninth Revision", "TREATMENT", 365, 379], ["Clinical Modification (ICD", "TREATMENT", 381, 407], ["lobar", "OBSERVATION_MODIFIER", 249, 254], ["pneumonia", "OBSERVATION", 255, 264], ["pneumococcal", "OBSERVATION_MODIFIER", 268, 280], ["pneumonia", "OBSERVATION", 281, 290], ["empyema", "OBSERVATION", 295, 302], ["Diseases", "OBSERVATION", 355, 363]]], ["We included those classified as ICD-9 CM code 481 for pneumococcal/lobar pneumonia, 510 for empyema, 510.0 for empyema with fistula, 510.9 for empyema without fistula, and 511.1 for pleurisy with bacterial causes.", [["empyema", "ANATOMY", 92, 99], ["fistula", "ANATOMY", 124, 131], ["empyema", "ANATOMY", 143, 150], ["fistula", "ANATOMY", 159, 166], ["CM", "DISEASE", 38, 40], ["pneumococcal/lobar pneumonia", "DISEASE", 54, 82], ["empyema", "DISEASE", 92, 99], ["empyema", "DISEASE", 111, 118], ["fistula", "DISEASE", 124, 131], ["empyema", "DISEASE", 143, 150], ["fistula", "DISEASE", 159, 166], ["pleurisy", "DISEASE", 182, 190], ["fistula", "PATHOLOGICAL_FORMATION", 124, 131], ["fistula", "PATHOLOGICAL_FORMATION", 159, 166], ["pneumococcal", "SPECIES", 54, 66], ["ICD", "TREATMENT", 32, 35], ["pneumococcal/lobar pneumonia", "PROBLEM", 54, 82], ["empyema", "PROBLEM", 92, 99], ["empyema", "PROBLEM", 111, 118], ["fistula", "PROBLEM", 124, 131], ["empyema", "PROBLEM", 143, 150], ["fistula", "PROBLEM", 159, 166], ["pleurisy", "PROBLEM", 182, 190], ["bacterial causes", "PROBLEM", 196, 212], ["lobar", "ANATOMY", 67, 72], ["pneumonia", "OBSERVATION", 73, 82], ["empyema", "OBSERVATION", 92, 99], ["empyema", "OBSERVATION", 111, 118], ["fistula", "OBSERVATION", 124, 131], ["empyema", "OBSERVATION", 143, 150], ["fistula", "OBSERVATION", 159, 166], ["pleurisy", "OBSERVATION", 182, 190], ["bacterial causes", "OBSERVATION", 196, 212]]], ["ICD-9 code 481 was for both pneumococcal pneumonia and lobar pneumonia, and not all of them were pneumococcal pneumonia.Materials and methodsAmong these hospitalized children with the above ICD-9 CM diagnoses, we also collected the data of whether they received the procedures used to manage complicated pneumonia, including ICD-9 CM code 32 for excision of lung and bronchus; 34 for operations on chest wall, pleura, mediastinum, and diaphragm; 96.05 code for other intubations of respiratory tract; and 96.7 for continuous mechanical ventilation.", [["lung", "ANATOMY", 358, 362], ["bronchus", "ANATOMY", 367, 375], ["chest wall", "ANATOMY", 398, 408], ["pleura", "ANATOMY", 410, 416], ["mediastinum", "ANATOMY", 418, 429], ["diaphragm", "ANATOMY", 435, 444], ["respiratory tract", "ANATOMY", 482, 499], ["ICD-9 code 481", "CHEMICAL", 0, 14], ["pneumococcal pneumonia", "DISEASE", 28, 50], ["lobar pneumonia", "DISEASE", 55, 70], ["pneumonia", "DISEASE", 110, 119], ["CM", "DISEASE", 196, 198], ["pneumonia", "DISEASE", 304, 313], ["CM", "DISEASE", 331, 333], ["children", "ORGANISM", 166, 174], ["lung", "ORGAN", 358, 362], ["bronchus", "ORGAN", 367, 375], ["chest wall", "MULTI-TISSUE_STRUCTURE", 398, 408], ["pleura", "MULTI-TISSUE_STRUCTURE", 410, 416], ["mediastinum", "ORGAN", 418, 429], ["diaphragm", "ORGAN", 435, 444], ["tract", "ORGANISM_SUBDIVISION", 494, 499], ["children", "SPECIES", 166, 174], ["pneumococcal", "SPECIES", 28, 40], ["pneumococcal", "SPECIES", 97, 109], ["ICD", "TREATMENT", 0, 3], ["pneumococcal pneumonia", "PROBLEM", 28, 50], ["lobar pneumonia", "PROBLEM", 55, 70], ["pneumococcal pneumonia", "PROBLEM", 97, 119], ["the above ICD", "TREATMENT", 180, 193], ["the procedures", "TREATMENT", 262, 276], ["complicated pneumonia", "PROBLEM", 292, 313], ["ICD", "TREATMENT", 325, 328], ["excision of lung and bronchus", "TREATMENT", 346, 375], ["operations on chest wall, pleura, mediastinum, and diaphragm", "TEST", 384, 444], ["respiratory tract", "PROBLEM", 482, 499], ["continuous mechanical ventilation", "TREATMENT", 514, 547], ["pneumococcal", "OBSERVATION_MODIFIER", 28, 40], ["pneumonia", "OBSERVATION", 41, 50], ["lobar", "OBSERVATION_MODIFIER", 55, 60], ["pneumonia", "OBSERVATION", 61, 70], ["pneumococcal", "OBSERVATION_MODIFIER", 97, 109], ["pneumonia", "OBSERVATION", 110, 119], ["9 CM", "OBSERVATION_MODIFIER", 194, 198], ["pneumonia", "OBSERVATION", 304, 313], ["lung", "ANATOMY", 358, 362], ["bronchus", "ANATOMY", 367, 375], ["chest", "ANATOMY", 398, 403], ["wall", "ANATOMY_MODIFIER", 404, 408], ["pleura", "ANATOMY", 410, 416], ["mediastinum", "ANATOMY", 418, 429], ["diaphragm", "ANATOMY", 435, 444], ["respiratory tract", "ANATOMY", 482, 499], ["mechanical ventilation", "OBSERVATION", 525, 547]]], ["Because intensive care unit and general wards are different categories in NHI claims database, the rate of requiring intensive care among patients was obtained by analyzing the categories of the wards.Materials and methodsWe analyzed the pneumococcal/lobar pneumonia and empyema-associated hospitalizations and the need of intensive care by age group, gender, and month of hospitalization.", [["pneumonia", "DISEASE", 257, 266], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["pneumococcal", "SPECIES", 238, 250], ["the pneumococcal/lobar pneumonia", "PROBLEM", 234, 266], ["pneumococcal", "OBSERVATION_MODIFIER", 238, 250], ["lobar", "OBSERVATION_MODIFIER", 251, 256], ["pneumonia", "OBSERVATION", 257, 266]]], ["The annual age-specific pneumococcal/lobar pneumonia episodes were divided by the midyear agespecific gender-specific population [9] to calculate the annual age-specific pneumococcal/lobar pneumonia incidence, and the annual age-specific empyema episodes were divided by the midyear age-specific gender-specific population to calculate the annual age-specific empyema incidence.", [["pneumonia", "DISEASE", 43, 52], ["pneumonia", "DISEASE", 189, 198], ["empyema", "DISEASE", 238, 245], ["empyema", "DISEASE", 360, 367], ["pneumococcal", "ORGANISM", 24, 36], ["pneumococcal", "ORGANISM", 170, 182], ["pneumococcal", "SPECIES", 24, 36], ["pneumococcal", "SPECIES", 170, 182], ["specific pneumococcal/lobar pneumonia episodes", "PROBLEM", 15, 61], ["specific pneumococcal/lobar pneumonia incidence", "PROBLEM", 161, 208], ["specific empyema episodes", "PROBLEM", 229, 254], ["specific empyema incidence", "PROBLEM", 351, 377], ["pneumococcal", "OBSERVATION_MODIFIER", 24, 36], ["lobar", "OBSERVATION_MODIFIER", 37, 42], ["pneumonia", "OBSERVATION", 43, 52], ["pneumococcal", "OBSERVATION_MODIFIER", 170, 182], ["lobar", "OBSERVATION_MODIFIER", 183, 188], ["pneumonia", "OBSERVATION", 189, 198], ["empyema", "OBSERVATION", 238, 245], ["empyema", "OBSERVATION", 360, 367]]], ["The mortality due to pneumococcal/lobar pneumonia or empyema was also analyzed.", [["lobar", "ANATOMY", 34, 39], ["pneumonia", "DISEASE", 40, 49], ["empyema", "DISEASE", 53, 60], ["pneumococcal", "SPECIES", 21, 33], ["The mortality", "PROBLEM", 0, 13], ["pneumococcal/lobar pneumonia", "PROBLEM", 21, 49], ["empyema", "PROBLEM", 53, 60], ["pneumococcal", "OBSERVATION_MODIFIER", 21, 33], ["lobar", "OBSERVATION_MODIFIER", 34, 39], ["pneumonia", "OBSERVATION", 40, 49], ["empyema", "OBSERVATION", 53, 60]]], ["The difference of annual incidence among various age groups, the difference of annual incidences in different years, and the difference in seasonal distribution were measured with goodness-of-fit \u03c7 2 test.", [["goodness", "TEST", 180, 188], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["A P value of <0.05 was considered significant.ResultsThe incidence of pneumococcal/lobar pneumonia Pneumococcal/lobar pneumonia (ICD-9 CM code 481) accounted for 1.3% (range 0.7-2.1%) of all children hospitalized for pneumonia during the 8-year study period.", [["pneumonia", "DISEASE", 89, 98], ["pneumonia", "DISEASE", 118, 127], ["CM", "DISEASE", 135, 137], ["pneumonia", "DISEASE", 217, 226], ["children", "ORGANISM", 191, 199], ["children", "SPECIES", 191, 199], ["pneumococcal", "SPECIES", 70, 82], ["A P value", "TEST", 0, 9], ["pneumococcal/lobar pneumonia", "PROBLEM", 70, 98], ["Pneumococcal/lobar pneumonia", "PROBLEM", 99, 127], ["ICD", "TREATMENT", 129, 132], ["pneumonia", "PROBLEM", 217, 226], ["pneumococcal", "OBSERVATION_MODIFIER", 70, 82], ["lobar", "OBSERVATION_MODIFIER", 83, 88], ["pneumonia", "OBSERVATION", 89, 98], ["Pneumococcal", "OBSERVATION_MODIFIER", 99, 111], ["lobar", "OBSERVATION_MODIFIER", 112, 117], ["pneumonia", "OBSERVATION", 118, 127], ["9 CM", "OBSERVATION_MODIFIER", 133, 137], ["pneumonia", "OBSERVATION", 217, 226]]], ["An average of 1,009 (range 420 to 1,775) episodes of pneumococcal/lobar pneumonia was reported yearly.", [["lobar", "ANATOMY", 66, 71], ["pneumococcal/lobar pneumonia", "DISEASE", 53, 81], ["pneumococcal", "SPECIES", 53, 65], ["pneumococcal/lobar pneumonia", "PROBLEM", 53, 81], ["average", "OBSERVATION_MODIFIER", 3, 10], ["pneumococcal", "OBSERVATION_MODIFIER", 53, 65], ["lobar", "OBSERVATION_MODIFIER", 66, 71], ["pneumonia", "OBSERVATION", 72, 81]]], ["The male-to-female ratio was 1.09:1.", [["female", "ORGANISM", 12, 18]]], ["In children below the age of 18 year old, the annual population-based incidence of children hospitalized for pneumococcal/lobar pneumonia averaged 16.6 episodes per 100,000 children-year (range 6.4-31.4 episodes per 100,000 children-year).", [["pneumococcal/lobar pneumonia", "DISEASE", 109, 137], ["children", "ORGANISM", 3, 11], ["children", "ORGANISM", 83, 91], ["children", "SPECIES", 3, 11], ["children", "SPECIES", 83, 91], ["children", "SPECIES", 173, 181], ["children", "SPECIES", 224, 232], ["pneumococcal", "SPECIES", 109, 121], ["pneumococcal/lobar pneumonia", "PROBLEM", 109, 137], ["lobar", "ANATOMY", 122, 127], ["pneumonia", "OBSERVATION", 128, 137]]], ["The annual population-based incidence of pneumococcal/lobar pneumonia increased significantly year by year (p<0.01; Fig. 1 ).", [["lobar", "ANATOMY", 54, 59], ["pneumonia", "DISEASE", 60, 69], ["pneumococcal", "SPECIES", 41, 53], ["The annual population", "TEST", 0, 21], ["pneumococcal/lobar pneumonia", "PROBLEM", 41, 69], ["pneumococcal", "OBSERVATION_MODIFIER", 41, 53], ["lobar", "OBSERVATION_MODIFIER", 54, 59], ["pneumonia", "OBSERVATION", 60, 69], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["significantly", "OBSERVATION_MODIFIER", 80, 93]]], ["Figure 1 shows the annual population-based incidence of hospitalized pneumococcal/lobar pneumonia in children under 2, 2-5, and 5-18 years old from 1997 to 2004.ResultsChildren aged between 2 and 5 had the highest incidence, and there is a significant difference of population-based incidence between these three age groups (P<0.01).ResultsChildren under 5 years old were the most susceptible to pneumococcal/lobar pneumonia (64.7% of all cases).", [["pneumococcal/lobar pneumonia", "DISEASE", 69, 97], ["pneumococcal/lobar pneumonia", "DISEASE", 396, 424], ["children", "ORGANISM", 101, 109], ["Children", "ORGANISM", 168, 176], ["Children", "ORGANISM", 340, 348], ["children", "SPECIES", 101, 109], ["Children", "SPECIES", 168, 176], ["Children", "SPECIES", 340, 348], ["pneumococcal", "SPECIES", 69, 81], ["pneumococcal", "SPECIES", 396, 408], ["the annual population", "PROBLEM", 15, 36], ["hospitalized pneumococcal/lobar pneumonia", "PROBLEM", 56, 97], ["pneumococcal/lobar pneumonia", "PROBLEM", 396, 424], ["pneumococcal", "OBSERVATION_MODIFIER", 69, 81], ["lobar", "OBSERVATION_MODIFIER", 82, 87], ["pneumonia", "OBSERVATION", 88, 97], ["significant", "OBSERVATION_MODIFIER", 240, 251], ["difference", "OBSERVATION_MODIFIER", 252, 262], ["lobar", "ANATOMY", 409, 414], ["pneumonia", "OBSERVATION", 415, 424]]], ["The overall annual population-based incidence of pneumococcal/ lobar pneumonia in children in that age group was 44.9 episodes per 100,000 children-year.", [["pneumococcal/ lobar pneumonia", "DISEASE", 49, 78], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["children", "SPECIES", 139, 147], ["pneumococcal", "SPECIES", 49, 61], ["pneumococcal/ lobar pneumonia", "PROBLEM", 49, 78], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["annual", "OBSERVATION_MODIFIER", 12, 18], ["population", "OBSERVATION_MODIFIER", 19, 29], ["pneumococcal", "OBSERVATION_MODIFIER", 49, 61], ["lobar", "OBSERVATION_MODIFIER", 63, 68], ["pneumonia", "OBSERVATION", 69, 78]]], ["The age-specific incidence increased gradually, peaking at 4 to 5 years old.", [["increased", "OBSERVATION_MODIFIER", 27, 36], ["gradually", "OBSERVATION_MODIFIER", 37, 46]]], ["After the age of 5, incidence decreased yearly (Fig. 2) .ResultsThe seasonal distribution of pneumococcal/lobar pneumonia We analyzed the seasonal distribution of hospitalizations for pneumococcal/lobar pneumonia (Fig. 3) .", [["pneumonia", "DISEASE", 112, 121], ["pneumococcal/lobar pneumonia", "DISEASE", 184, 212], ["pneumococcal", "SPECIES", 93, 105], ["pneumococcal", "SPECIES", 184, 196], ["pneumococcal/lobar pneumonia", "PROBLEM", 93, 121], ["pneumococcal/lobar pneumonia", "PROBLEM", 184, 212], ["pneumococcal", "OBSERVATION_MODIFIER", 93, 105], ["lobar", "OBSERVATION_MODIFIER", 106, 111], ["pneumonia", "OBSERVATION", 112, 121], ["pneumococcal", "OBSERVATION_MODIFIER", 184, 196], ["lobar", "ANATOMY_MODIFIER", 197, 202], ["pneumonia", "OBSERVATION", 203, 212]]], ["Incidence was significantly higher in the spring and winter seasons (P< 0.01).", [["significantly", "OBSERVATION_MODIFIER", 14, 27], ["higher", "OBSERVATION_MODIFIER", 28, 34]]], ["Peak incidence occurred in the spring every year and the nadir usually in the autumn except the year 2003.", [["Peak incidence", "PROBLEM", 0, 14], ["the nadir", "TEST", 53, 62]]], ["During the 8-year study period, the lowest incidence of hospitalizations for pneumococcal/lobar pneumonia was in the summer of 2003, the year Taiwan had a large outbreak of severe acute respiratory syndrome (SARS).The incidence of empyemaThe average annual number of empyema (ICD-9 CM code 510.0, 510.9, or 511.1) was 237 episodes per year (range 138-341 episodes).", [["pneumococcal/lobar pneumonia", "DISEASE", 77, 105], ["acute respiratory syndrome", "DISEASE", 180, 206], ["SARS", "DISEASE", 208, 212], ["empyema", "DISEASE", 231, 238], ["empyema", "DISEASE", 267, 274], ["CM", "DISEASE", 282, 284], ["pneumococcal", "SPECIES", 77, 89], ["pneumococcal/lobar pneumonia", "PROBLEM", 77, 105], ["severe acute respiratory syndrome", "PROBLEM", 173, 206], ["empyema", "PROBLEM", 231, 238], ["empyema", "PROBLEM", 267, 274], ["ICD", "TEST", 276, 279], ["pneumococcal", "OBSERVATION_MODIFIER", 77, 89], ["lobar", "OBSERVATION_MODIFIER", 90, 95], ["pneumonia", "OBSERVATION", 96, 105], ["large", "OBSERVATION_MODIFIER", 155, 160], ["outbreak", "OBSERVATION_MODIFIER", 161, 169], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["respiratory syndrome", "OBSERVATION", 186, 206], ["empyema", "OBSERVATION", 231, 238], ["average", "OBSERVATION_MODIFIER", 242, 249], ["annual", "OBSERVATION_MODIFIER", 250, 256], ["number", "OBSERVATION_MODIFIER", 257, 263], ["empyema", "OBSERVATION", 267, 274]]], ["Male-to-female ratio was 1.14:1.", [["female", "ORGANISM", 8, 14]]], ["The overall population-based incidence of empyema in children below the age of 18 years old was 3.9 episodes per 100,000 children-year (range 2.1 to 5.8 episodes per 100,000 children-year).", [["empyema", "DISEASE", 42, 49], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["children", "SPECIES", 121, 129], ["children", "SPECIES", 174, 182], ["empyema", "PROBLEM", 42, 49], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["population", "OBSERVATION_MODIFIER", 12, 22], ["incidence", "OBSERVATION_MODIFIER", 29, 38], ["empyema", "OBSERVATION", 42, 49]]], ["Incidence increased significantly from year to year, peaking in 2002 and slightly declining in 2003 and 2004 (Fig. 4) .", [["slightly", "OBSERVATION_MODIFIER", 73, 81], ["declining", "OBSERVATION_MODIFIER", 82, 91]]], ["Figure 4 shows the annual population-based incidence of empyema in children under 2, 2-5, and 5-18 years old from 1997 to 2004.", [["empyema", "DISEASE", 56, 63], ["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["the annual population", "PROBLEM", 15, 36], ["empyema", "PROBLEM", 56, 63], ["incidence", "OBSERVATION_MODIFIER", 43, 52], ["empyema", "OBSERVATION", 56, 63]]], ["Again, children aged between 2 and 5 had the highest incidence of empyema among these three age groups (P<0.01).The incidence of empyemaAbout 64% (63.8%) of empyema episodes occurred in children 5 years old or below.", [["empyema", "ANATOMY", 157, 164], ["empyema", "DISEASE", 66, 73], ["empyemaAbout", "DISEASE", 129, 141], ["empyema", "DISEASE", 157, 164], ["children", "ORGANISM", 7, 15], ["empyema", "PATHOLOGICAL_FORMATION", 157, 164], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 7, 15], ["children", "SPECIES", 186, 194], ["empyema", "PROBLEM", 66, 73], ["empyemaAbout", "TEST", 129, 141], ["empyema episodes", "PROBLEM", 157, 173], ["empyema", "OBSERVATION", 66, 73], ["empyema", "OBSERVATION", 157, 164]]], ["In this population, the annual incidence of empyema was 10.5 episodes per 100,000 childrenyear (range 4.9 to 15.5 episodes per 100,000 children-year).", [["empyema", "DISEASE", 44, 51], ["children", "SPECIES", 135, 143], ["empyema", "PROBLEM", 44, 51], ["empyema", "OBSERVATION", 44, 51]]], ["The age-specific incidence of empyema increased in these children up to 5 years old.", [["empyema", "DISEASE", 30, 37], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["empyema", "PROBLEM", 30, 37], ["empyema", "OBSERVATION", 30, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["As was found with lobar pneumonia hospitalizations, incidence of empyema decreased with age after 5 years old, too (Fig. 5) .", [["pneumonia", "DISEASE", 24, 33], ["empyema", "DISEASE", 65, 72], ["lobar pneumonia hospitalizations", "PROBLEM", 18, 50], ["empyema", "PROBLEM", 65, 72], ["lobar", "OBSERVATION_MODIFIER", 18, 23], ["pneumonia", "OBSERVATION", 24, 33], ["empyema", "OBSERVATION", 65, 72], ["decreased", "OBSERVATION_MODIFIER", 73, 82]]], ["The morbidity and case fatality rate of children with pneumococcal/lobar pneumonia and empyemaThe incidence of empyemaIn total, 2.3% of the children with pneumococcal/lobar pneumonia required mechanical ventilation and 34% required intensive care.", [["pneumococcal/lobar pneumonia", "DISEASE", 54, 82], ["empyema", "DISEASE", 87, 94], ["pneumonia", "DISEASE", 173, 182], ["children", "ORGANISM", 40, 48], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 40, 48], ["children", "SPECIES", 140, 148], ["pneumococcal", "SPECIES", 54, 66], ["pneumococcal", "SPECIES", 154, 166], ["pneumococcal/lobar pneumonia", "PROBLEM", 54, 82], ["empyema", "PROBLEM", 87, 94], ["pneumococcal/lobar pneumonia", "PROBLEM", 154, 182], ["mechanical ventilation", "TREATMENT", 192, 214], ["intensive care", "TREATMENT", 232, 246], ["morbidity", "OBSERVATION", 4, 13], ["lobar", "ANATOMY", 67, 72], ["pneumonia", "OBSERVATION", 73, 82], ["empyema", "OBSERVATION", 87, 94], ["lobar", "OBSERVATION_MODIFIER", 167, 172], ["pneumonia", "OBSERVATION", 173, 182], ["mechanical ventilation", "OBSERVATION", 192, 214]]], ["Of those with pneumococcal/ lobar pneumonia complicated with empyema, 12.0% require mechanical ventilation and 58.1% required intensive care, which were significantly higher rates than those found for children with pneumococcal/lobar pneumonia alone (p <0.01).", [["pneumococcal/ lobar pneumonia", "DISEASE", 14, 43], ["empyema", "DISEASE", 61, 68], ["pneumococcal/lobar pneumonia", "DISEASE", 215, 243], ["children", "ORGANISM", 201, 209], ["children", "SPECIES", 201, 209], ["pneumococcal", "SPECIES", 14, 26], ["pneumococcal", "SPECIES", 215, 227], ["pneumococcal/ lobar pneumonia", "PROBLEM", 14, 43], ["empyema", "PROBLEM", 61, 68], ["mechanical ventilation", "TREATMENT", 84, 106], ["intensive care", "TREATMENT", 126, 140], ["pneumococcal/lobar pneumonia", "PROBLEM", 215, 243], ["pneumococcal", "OBSERVATION", 14, 26], ["lobar", "OBSERVATION_MODIFIER", 28, 33], ["pneumonia", "OBSERVATION", 34, 43], ["empyema", "OBSERVATION", 61, 68], ["pneumococcal", "OBSERVATION", 215, 227], ["lobar", "ANATOMY_MODIFIER", 228, 233], ["pneumonia", "OBSERVATION", 234, 243]]], ["Furthermore, 63.4% of those complicated with empyema also received invasive procedures of chest tube insertions and/or thoracotomies.", [["chest tube", "ANATOMY", 90, 100], ["empyema", "DISEASE", 45, 52], ["chest tube", "MULTI-TISSUE_STRUCTURE", 90, 100], ["empyema", "PROBLEM", 45, 52], ["invasive procedures", "TREATMENT", 67, 86], ["chest tube insertions", "TREATMENT", 90, 111], ["thoracotomies", "TREATMENT", 119, 132], ["empyema", "OBSERVATION", 45, 52], ["chest", "ANATOMY", 90, 95], ["tube insertions", "OBSERVATION", 96, 111], ["thoracotomies", "OBSERVATION", 119, 132]]], ["Of 1,169 patients with empyema, 66 (5.6%) cases received lung excision and bronchus.", [["lung", "ANATOMY", 57, 61], ["bronchus", "ANATOMY", 75, 83], ["empyema", "DISEASE", 23, 30], ["patients", "ORGANISM", 9, 17], ["lung", "ORGAN", 57, 61], ["bronchus", "ORGAN", 75, 83], ["patients", "SPECIES", 9, 17], ["empyema", "PROBLEM", 23, 30], ["lung excision", "TREATMENT", 57, 70], ["bronchus", "TREATMENT", 75, 83], ["empyema", "OBSERVATION", 23, 30], ["lung", "ANATOMY", 57, 61], ["excision", "OBSERVATION", 62, 70], ["bronchus", "ANATOMY", 75, 83]]], ["Children with pneumococcal/ lobar pneumonia and those children with empyema had a crude case fatality rate of 0.43% (range 0.19-0.61%) and 2.74% (range 1.02-5.07%), respectively.", [["pneumococcal/ lobar pneumonia", "DISEASE", 14, 43], ["empyema", "DISEASE", 68, 75], ["Children", "ORGANISM", 0, 8], ["children", "ORGANISM", 54, 62], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 54, 62], ["pneumococcal", "SPECIES", 14, 26], ["pneumococcal/ lobar pneumonia", "PROBLEM", 14, 43], ["empyema", "PROBLEM", 68, 75], ["fatality rate", "TEST", 93, 106], ["pneumococcal", "OBSERVATION_MODIFIER", 14, 26], ["lobar", "ANATOMY", 28, 33], ["pneumonia", "OBSERVATION", 34, 43], ["empyema", "OBSERVATION", 68, 75]]], ["In general, cases complicated with empyema had a significantly higher case fatality rate than those without this complication (odds ratio (OR) 118; 95% confidence interval (CI) 28-492; P< 0.001).DiscussionIn this first study of the population-based incidence of pneumococcal/lobar pneumonia and empyema in Taiwan, we found the average annual population-based incidence of pneumococcal/lobar pneumonia in children under 5 to be 44.9 episodes per 100,000 children-year and the disease complicated with empyema in the same age group to be 10.5 episodes per 100,000 children-year.", [["empyema", "DISEASE", 35, 42], ["pneumococcal/lobar pneumonia", "DISEASE", 262, 290], ["empyema", "DISEASE", 295, 302], ["pneumococcal/lobar pneumonia", "DISEASE", 372, 400], ["empyema", "DISEASE", 500, 507], ["children", "ORGANISM", 404, 412], ["children", "ORGANISM", 453, 461], ["children", "SPECIES", 404, 412], ["children", "SPECIES", 453, 461], ["children", "SPECIES", 562, 570], ["pneumococcal", "SPECIES", 262, 274], ["pneumococcal", "SPECIES", 372, 384], ["empyema", "PROBLEM", 35, 42], ["this complication", "PROBLEM", 108, 125], ["CI", "TEST", 173, 175], ["pneumococcal/lobar pneumonia", "PROBLEM", 262, 290], ["empyema", "PROBLEM", 295, 302], ["pneumococcal/lobar pneumonia", "PROBLEM", 372, 400], ["the disease", "PROBLEM", 471, 482], ["empyema", "PROBLEM", 500, 507], ["empyema", "OBSERVATION", 35, 42], ["pneumococcal", "OBSERVATION_MODIFIER", 262, 274], ["lobar", "OBSERVATION_MODIFIER", 275, 280], ["pneumonia", "OBSERVATION", 281, 290], ["empyema", "OBSERVATION", 295, 302], ["pneumococcal", "OBSERVATION_MODIFIER", 372, 384], ["lobar", "OBSERVATION_MODIFIER", 385, 390], ["pneumonia", "OBSERVATION", 391, 400], ["disease", "OBSERVATION", 475, 482], ["empyema", "OBSERVATION", 500, 507]]], ["The majority (about 64%) of episodes of pneumococcal/lobar pneumonia and empyema occurred in children under 5 years old, peaking at 4 to 5 years old.", [["lobar", "ANATOMY", 53, 58], ["pneumococcal/lobar pneumonia", "DISEASE", 40, 68], ["empyema", "DISEASE", 73, 80], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["pneumococcal", "SPECIES", 40, 52], ["pneumococcal/lobar pneumonia", "PROBLEM", 40, 68], ["empyema", "PROBLEM", 73, 80], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["pneumococcal", "OBSERVATION_MODIFIER", 40, 52], ["lobar", "OBSERVATION_MODIFIER", 53, 58], ["pneumonia", "OBSERVATION", 59, 68], ["empyema", "OBSERVATION", 73, 80]]], ["Children with empyema had a higher case fatality rate than those without (OR 118; 95% CI 28-492).DiscussionEvaluating the population-based incidence of pneumococcal pneumonia was difficult because the blood and pleural effusion culture yield rates of S. pneumoniae were very low in these cases [20] .", [["blood", "ANATOMY", 201, 206], ["pleural effusion", "ANATOMY", 211, 227], ["empyema", "DISEASE", 14, 21], ["pneumonia", "DISEASE", 165, 174], ["pleural effusion", "DISEASE", 211, 227], ["Children", "ORGANISM", 0, 8], ["pneumococcal", "ORGANISM", 152, 164], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["pleural", "PATHOLOGICAL_FORMATION", 211, 218], ["S. pneumoniae", "ORGANISM", 251, 264], ["Children", "SPECIES", 0, 8], ["S. pneumoniae", "SPECIES", 251, 264], ["pneumococcal", "SPECIES", 152, 164], ["S. pneumoniae", "SPECIES", 251, 264], ["empyema", "PROBLEM", 14, 21], ["CI", "TEST", 86, 88], ["pneumococcal pneumonia", "PROBLEM", 152, 174], ["the blood", "TEST", 197, 206], ["pleural effusion culture", "TEST", 211, 235], ["S. pneumoniae", "PROBLEM", 251, 264], ["empyema", "OBSERVATION", 14, 21], ["pneumococcal", "OBSERVATION_MODIFIER", 152, 164], ["pneumonia", "OBSERVATION", 165, 174], ["pleural", "ANATOMY", 211, 218], ["effusion", "OBSERVATION", 219, 227]]], ["A rapid diagnostic tool, the urine pneumococcal antigen test (Binax NOW, Binax, USA), was introduced to Taiwan in 2000.", [["urine", "ANATOMY", 29, 34], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["pneumococcal", "SPECIES", 35, 47], ["the urine pneumococcal antigen test", "TEST", 25, 60]]], ["This test is reported to be useful for diagnosing pneumococcal pneumonia cases due to its high specificity, though it has also reported to have a 15% false-positive rate in younger children [15, 16] .", [["pneumonia", "DISEASE", 63, 72], ["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["pneumococcal", "SPECIES", 50, 62], ["This test", "TEST", 0, 9], ["pneumococcal pneumonia cases", "PROBLEM", 50, 78], ["pneumonia", "OBSERVATION", 63, 72]]], ["Since this test was introduced, there has been a significant increase in the annual population-based incidence of pneumococcal/lobar pneumonia.", [["pneumococcal/lobar pneumonia", "DISEASE", 114, 142], ["pneumococcal", "SPECIES", 114, 126], ["this test", "TEST", 6, 15], ["the annual population", "PROBLEM", 73, 94], ["pneumococcal/lobar pneumonia", "PROBLEM", 114, 142], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["annual", "OBSERVATION_MODIFIER", 77, 83], ["population", "OBSERVATION_MODIFIER", 84, 94], ["pneumococcal", "OBSERVATION_MODIFIER", 114, 126], ["lobar", "OBSERVATION_MODIFIER", 127, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["We were not sure whether this increasing trend is due to this better and more convenient diagnostic tool.DiscussionIn a previous nationwide population study, we reported the incidence of pneumonia to be the greatest in children younger than 1 year old in Taiwan [21] .", [["pneumonia", "DISEASE", 187, 196], ["children", "ORGANISM", 219, 227], ["children", "SPECIES", 219, 227], ["a previous nationwide population study", "TEST", 118, 156], ["pneumonia", "PROBLEM", 187, 196], ["pneumonia", "OBSERVATION", 187, 196]]], ["The current study, however, found incidence of pneumococcal/lobar pneumonia to reach a peak between the ages of 4 and 5 years old.", [["lobar", "ANATOMY", 60, 65], ["pneumonia", "DISEASE", 66, 75], ["pneumococcal", "SPECIES", 47, 59], ["The current study", "TEST", 0, 17], ["pneumococcal/lobar pneumonia", "PROBLEM", 47, 75], ["pneumococcal", "OBSERVATION", 47, 59], ["lobar", "OBSERVATION_MODIFIER", 60, 65], ["pneumonia", "OBSERVATION", 66, 75], ["peak", "OBSERVATION_MODIFIER", 87, 91]]], ["The age distribution pattern of empyema cases was similar to that of pneumococcal/lobar pneumonia.", [["empyema", "DISEASE", 32, 39], ["pneumonia", "DISEASE", 88, 97], ["pneumococcal", "SPECIES", 69, 81], ["empyema cases", "PROBLEM", 32, 45], ["pneumococcal/lobar pneumonia", "PROBLEM", 69, 97], ["empyema", "OBSERVATION", 32, 39], ["pneumococcal", "OBSERVATION_MODIFIER", 69, 81], ["lobar", "OBSERVATION_MODIFIER", 82, 87], ["pneumonia", "OBSERVATION", 88, 97]]], ["The difference in age distribution may be due to the greater number of virus etiologies causing pneumonia in younger children [14, 17] as well as the higher colonization rates of pneumococci in kindergarteners [13] .", [["pneumonia", "DISEASE", 96, 105], ["pneumococci", "DISEASE", 179, 190], ["children", "ORGANISM", 117, 125], ["children", "SPECIES", 117, 125], ["virus etiologies", "PROBLEM", 71, 87], ["pneumonia", "PROBLEM", 96, 105], ["pneumococci in kindergarteners", "PROBLEM", 179, 209], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["may be due to", "UNCERTAINTY", 35, 48], ["greater", "OBSERVATION_MODIFIER", 53, 60], ["virus", "OBSERVATION", 71, 76], ["pneumonia", "OBSERVATION", 96, 105], ["higher", "OBSERVATION_MODIFIER", 150, 156], ["colonization", "OBSERVATION_MODIFIER", 157, 169], ["pneumococci", "OBSERVATION", 179, 190]]], ["One 1998 study reported pneumococcal carriage rate to be 19.9% in northern Taiwan population and the isolation rate to be higher in children aged between Fig. 4 The annual population-based incidence of empyema in children under 2, 2-5, and 5-18 years old from 1997 to 2004 in Taiwan Fig. 5 The age-specific incidence of empyema from 1997 to 2004 in Taiwan 2 and 5 years [13] .", [["empyema", "DISEASE", 202, 209], ["empyema", "DISEASE", 320, 327], ["pneumococcal", "ORGANISM", 24, 36], ["children", "ORGANISM", 132, 140], ["children", "ORGANISM", 213, 221], ["children", "SPECIES", 132, 140], ["children", "SPECIES", 213, 221], ["pneumococcal", "SPECIES", 24, 36], ["pneumococcal carriage rate", "PROBLEM", 24, 50], ["the isolation rate", "TREATMENT", 97, 115], ["empyema", "PROBLEM", 202, 209], ["empyema", "PROBLEM", 320, 327], ["annual", "OBSERVATION_MODIFIER", 165, 171], ["population", "OBSERVATION_MODIFIER", 172, 182], ["incidence", "OBSERVATION_MODIFIER", 189, 198], ["empyema", "OBSERVATION", 202, 209], ["empyema", "OBSERVATION", 320, 327]]], ["Therefore, it is reasonable to hypothesize that high pneumococcus colonization rate may contribute to peak in incidence of lobar/pneumococcal pneumonia and empyema in this age group.", [["lobar", "ANATOMY", 123, 128], ["pneumonia", "DISEASE", 142, 151], ["empyema", "DISEASE", 156, 163], ["pneumococcal", "SPECIES", 129, 141], ["high pneumococcus colonization rate", "PROBLEM", 48, 83], ["lobar/pneumococcal pneumonia", "PROBLEM", 123, 151], ["empyema", "PROBLEM", 156, 163], ["lobar", "OBSERVATION_MODIFIER", 123, 128], ["pneumococcal", "OBSERVATION_MODIFIER", 129, 141], ["pneumonia", "OBSERVATION", 142, 151], ["empyema", "OBSERVATION", 156, 163]]], ["Furthermore, this population might benefit from a universal pneumococcal vaccination program since seven-valent conjugated vaccine can cover about 70% of IPD cases in this age group in Taiwan [12] .DiscussionThe seasonal distribution of pneumococcal/lobar pneumonia was prominent in winter and spring seasons in Taiwan in this 8-year study.", [["IPD", "DISEASE", 154, 157], ["pneumonia", "DISEASE", 256, 265], ["pneumococcal", "ORGANISM", 237, 249], ["pneumococcal", "SPECIES", 60, 72], ["pneumococcal", "SPECIES", 237, 249], ["a universal pneumococcal vaccination program", "TREATMENT", 48, 92], ["seven-valent conjugated vaccine", "TREATMENT", 99, 130], ["pneumococcal/lobar pneumonia", "PROBLEM", 237, 265], ["pneumococcal", "OBSERVATION_MODIFIER", 237, 249], ["lobar", "OBSERVATION_MODIFIER", 250, 255], ["pneumonia", "OBSERVATION", 256, 265], ["prominent", "OBSERVATION_MODIFIER", 270, 279]]], ["This seasonal distribution is similar to that of influenza because the viral surveillance of Taiwan Centers for Disease Control between 2002 and 2004 demonstrated that influenza A and influenza B viruses had a obvious seasonal variation, with peak incidence from the fifth to 14th week every year during our study period in Taiwan [6] , and it was compatible to the peak pneumococcal/lobar pneumonia incidence in the spring (February to April) in this study.", [["influenza", "DISEASE", 49, 58], ["influenza A", "DISEASE", 168, 179], ["influenza B", "DISEASE", 184, 195], ["pneumonia", "DISEASE", 390, 399], ["influenza A", "ORGANISM", 168, 179], ["influenza B viruses", "ORGANISM", 184, 203], ["influenza B viruses", "SPECIES", 184, 203], ["pneumococcal", "SPECIES", 371, 383], ["influenza", "PROBLEM", 49, 58], ["Disease Control", "TREATMENT", 112, 127], ["influenza", "PROBLEM", 168, 177], ["influenza B viruses", "PROBLEM", 184, 203], ["the peak pneumococcal/lobar pneumonia", "PROBLEM", 362, 399], ["this study", "TEST", 447, 457], ["peak", "OBSERVATION_MODIFIER", 366, 370], ["pneumococcal", "OBSERVATION", 371, 383], ["lobar", "OBSERVATION_MODIFIER", 384, 389], ["pneumonia", "OBSERVATION", 390, 399]]], ["It suggests that both are seasonal diseases and may be interrelated in Taiwan.DiscussionIn our previous study [21] , the nadir of hospitalized pneumonia occurred in the summer of 2003, so did lobar/ pneumococcal pneumonia in this study.", [["pneumonia", "DISEASE", 143, 152], ["pneumonia", "DISEASE", 212, 221], ["pneumococcal", "SPECIES", 199, 211], ["seasonal diseases", "PROBLEM", 26, 43], ["our previous study", "TEST", 91, 109], ["hospitalized pneumonia", "PROBLEM", 130, 152], ["lobar/ pneumococcal pneumonia", "PROBLEM", 192, 221], ["this study", "TEST", 225, 235], ["seasonal diseases", "OBSERVATION", 26, 43], ["may be", "UNCERTAINTY", 48, 54], ["pneumonia", "OBSERVATION", 143, 152], ["lobar", "OBSERVATION", 192, 197], ["pneumococcal", "OBSERVATION_MODIFIER", 199, 211], ["pneumonia", "OBSERVATION", 212, 221]]], ["The incidence decrease in the summer of 2003 may be related to SARS outbreak [5] , which kept people away from hospitals for fear of nosocomial SARS infections.", [["SARS", "DISEASE", 63, 67], ["SARS infections", "DISEASE", 144, 159], ["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100], ["SARS outbreak", "PROBLEM", 63, 76], ["nosocomial SARS infections", "PROBLEM", 133, 159], ["incidence", "OBSERVATION_MODIFIER", 4, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22]]], ["In addition, the hygiene campaign for SARS may have universally reduced the transmission of infections and thus decreased the incidence or episodes of pneumonia of all causes.DiscussionThis study found that annual population-based incidence of empyema among children under 5 increased year by year, reaching a peak in 2002 (from 4.94 to 15.55 episodes per 100,000 children-year).", [["SARS", "DISEASE", 38, 42], ["infections", "DISEASE", 92, 102], ["pneumonia", "DISEASE", 151, 160], ["empyema", "DISEASE", 244, 251], ["children", "ORGANISM", 258, 266], ["children", "SPECIES", 258, 266], ["children", "SPECIES", 364, 372], ["the hygiene campaign", "TREATMENT", 13, 33], ["SARS", "PROBLEM", 38, 42], ["infections", "PROBLEM", 92, 102], ["pneumonia", "PROBLEM", 151, 160], ["all causes", "PROBLEM", 164, 174], ["This study", "TEST", 185, 195], ["annual population", "PROBLEM", 207, 224], ["empyema", "PROBLEM", 244, 251], ["infections", "OBSERVATION", 92, 102], ["pneumonia", "OBSERVATION", 151, 160], ["empyema", "OBSERVATION", 244, 251]]], ["From 1995 to 2002, one medical center in Taiwan also reported an increase in percentage of pneumococcal pneumonia complicated with necrotizing pneumonia and/or empyema (from 25% to 70%) [10] .", [["pneumonia", "DISEASE", 104, 113], ["pneumonia", "DISEASE", 143, 152], ["empyema", "DISEASE", 160, 167], ["pneumococcal", "SPECIES", 91, 103], ["pneumococcal pneumonia", "PROBLEM", 91, 113], ["necrotizing pneumonia", "PROBLEM", 131, 152], ["empyema", "PROBLEM", 160, 167], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["percentage", "OBSERVATION_MODIFIER", 77, 87], ["pneumococcal", "OBSERVATION_MODIFIER", 91, 103], ["pneumonia", "OBSERVATION", 104, 113], ["necrotizing", "OBSERVATION_MODIFIER", 131, 142], ["pneumonia", "OBSERVATION", 143, 152], ["empyema", "OBSERVATION", 160, 167]]], ["In our study, the rate (34%) of requiring intensive care was relatively high, which could be explained by some less severe cases who were admitted to intensive care unit for just close monitoring of vital signs.", [["our study", "TEST", 3, 12], ["the rate", "TEST", 14, 22], ["intensive care", "TREATMENT", 42, 56], ["vital signs", "TEST", 199, 210]]], ["According to another study of pediatric empyema receiving thoracoscopic management in Taiwan, 32.7% of cases also required the preoperative intensive care [7] , which was similar to our results.DiscussionOne of the major limitations of the study is that it only presents data based on ICD-9 coding and we could not provide actual patient clinical data and microbiologic data that would be important in determining the true incidence of disease and its clinical outcome and the possible impact of vaccine on disease burden.", [["empyema", "DISEASE", 40, 47], ["patient", "ORGANISM", 330, 337], ["patient", "SPECIES", 330, 337], ["pediatric empyema", "TREATMENT", 30, 47], ["thoracoscopic management", "TREATMENT", 58, 82], ["the study", "TEST", 236, 245], ["ICD", "TREATMENT", 285, 288], ["microbiologic data", "TEST", 356, 374], ["disease", "PROBLEM", 436, 443], ["disease burden", "PROBLEM", 507, 521], ["empyema", "OBSERVATION", 40, 47], ["thoracoscopic", "OBSERVATION", 58, 71], ["disease", "OBSERVATION", 436, 443]]], ["The other weak point of this study is that patients with ICD-9 codes for pneumococcal pneumonia and those for lobar pneumonia were combined, and we have to clarify that all patients with lobar pneumonia do not have pneumococcal disease.", [["pneumococcal pneumonia", "DISEASE", 73, 95], ["pneumonia", "DISEASE", 116, 125], ["lobar pneumonia", "DISEASE", 187, 202], ["pneumococcal disease", "DISEASE", 215, 235], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 173, 181], ["pneumococcal", "SPECIES", 73, 85], ["pneumococcal", "SPECIES", 215, 227], ["this study", "TEST", 24, 34], ["ICD", "TREATMENT", 57, 60], ["pneumococcal pneumonia", "PROBLEM", 73, 95], ["lobar pneumonia", "PROBLEM", 110, 125], ["lobar pneumonia", "PROBLEM", 187, 202], ["pneumococcal disease", "PROBLEM", 215, 235], ["weak", "OBSERVATION_MODIFIER", 10, 14], ["pneumococcal", "OBSERVATION_MODIFIER", 73, 85], ["pneumonia", "OBSERVATION", 86, 95], ["lobar", "OBSERVATION_MODIFIER", 110, 115], ["pneumonia", "OBSERVATION", 116, 125], ["lobar", "OBSERVATION_MODIFIER", 187, 192], ["pneumonia", "OBSERVATION", 193, 202], ["pneumococcal", "OBSERVATION_MODIFIER", 215, 227], ["disease", "OBSERVATION", 228, 235]]], ["For the purpose of clinical data and microbiologic data, a prospective cohort study to investigate the etiology of lobar pneumonia and serotypes of pneumococci in Taiwan is mandatory in the near future.DiscussionIn summary, this study found the population-based incidences of pneumococcal/lobar pneumonia and empyema among children 5 years old or younger in Taiwan to be 44.9 and 10.5 episodes per 100,000 children-year, respectively.", [["lobar", "ANATOMY", 115, 120], ["lobar pneumonia", "DISEASE", 115, 130], ["pneumococci", "DISEASE", 148, 159], ["pneumococcal/lobar pneumonia", "DISEASE", 276, 304], ["empyema", "DISEASE", 309, 316], ["children", "ORGANISM", 323, 331], ["children", "SPECIES", 323, 331], ["children", "SPECIES", 406, 414], ["pneumococcal", "SPECIES", 276, 288], ["clinical data", "TEST", 19, 32], ["microbiologic data", "TEST", 37, 55], ["a prospective cohort study", "TEST", 57, 83], ["lobar pneumonia", "PROBLEM", 115, 130], ["serotypes", "PROBLEM", 135, 144], ["pneumococci", "PROBLEM", 148, 159], ["this study", "TEST", 224, 234], ["pneumococcal/lobar pneumonia", "PROBLEM", 276, 304], ["empyema", "PROBLEM", 309, 316], ["lobar", "OBSERVATION_MODIFIER", 115, 120], ["pneumonia", "OBSERVATION", 121, 130], ["pneumococci", "OBSERVATION", 148, 159], ["pneumococcal", "OBSERVATION_MODIFIER", 276, 288], ["lobar", "OBSERVATION_MODIFIER", 289, 294], ["pneumonia", "OBSERVATION", 295, 304], ["empyema", "OBSERVATION", 309, 316]]], ["The morbidity and case fatality rates of children with pneumococcal/lobar pneumonia were significantly higher because of empyema complications.", [["pneumococcal/lobar pneumonia", "DISEASE", 55, 83], ["empyema", "DISEASE", 121, 128], ["children", "ORGANISM", 41, 49], ["empyema", "PATHOLOGICAL_FORMATION", 121, 128], ["children", "SPECIES", 41, 49], ["pneumococcal", "SPECIES", 55, 67], ["pneumococcal/lobar pneumonia", "PROBLEM", 55, 83], ["empyema complications", "PROBLEM", 121, 142], ["morbidity", "OBSERVATION", 4, 13], ["lobar", "ANATOMY", 68, 73], ["pneumonia", "OBSERVATION", 74, 83], ["empyema", "OBSERVATION", 121, 128]]], ["To date, Taiwan has no universal PCV inoculation program for younger children, a population that this study finds most susceptible to pneumococcal pneumonia and empyema.", [["pneumonia", "DISEASE", 147, 156], ["empyema", "DISEASE", 161, 168], ["children", "ORGANISM", 69, 77], ["pneumococcal", "ORGANISM", 134, 146], ["children", "SPECIES", 69, 77], ["pneumococcal", "SPECIES", 134, 146], ["this study", "TEST", 97, 107], ["pneumococcal pneumonia", "PROBLEM", 134, 156], ["empyema", "PROBLEM", 161, 168], ["pneumococcal", "OBSERVATION_MODIFIER", 134, 146], ["pneumonia", "OBSERVATION", 147, 156], ["empyema", "OBSERVATION", 161, 168]]], ["A universal inoculation of PCV may be able to provide maximum protection from this disease and prevent most episodes of pneumococcal/lobar pneumonia and empyema across the region in the future.", [["lobar", "ANATOMY", 133, 138], ["pneumonia", "DISEASE", 139, 148], ["empyema", "DISEASE", 153, 160], ["pneumococcal", "SPECIES", 120, 132], ["A universal inoculation of PCV", "TREATMENT", 0, 30], ["maximum protection", "TREATMENT", 54, 72], ["this disease", "PROBLEM", 78, 90], ["pneumococcal/lobar pneumonia", "PROBLEM", 120, 148], ["empyema", "PROBLEM", 153, 160], ["pneumococcal", "OBSERVATION_MODIFIER", 120, 132], ["lobar", "OBSERVATION_MODIFIER", 133, 138], ["pneumonia", "OBSERVATION", 139, 148], ["empyema", "OBSERVATION", 153, 160]]]], "PMC7222942": [["IntroductionImmunizing pregnant women to protect the mother, fetus and infant from infection has increasingly been used over the last decade [1].", [["fetus", "ANATOMY", 61, 66], ["infection", "DISEASE", 83, 92], ["women", "ORGANISM", 32, 37], ["fetus", "ANATOMICAL_SYSTEM", 61, 66], ["women", "SPECIES", 32, 37], ["infant", "SPECIES", 71, 77], ["infection", "PROBLEM", 83, 92], ["infection", "OBSERVATION", 83, 92]]], ["Maternal antibodies are transferred from mother to infant during pregnancy through transplacental transport [2] or after delivery via breastfeeding [3] and provide protection against infections in early life.IntroductionThe transplacental transport is regulated by the neonatal Fc receptor with a gradual increase in the amount of transported maternal antibodies from mother to infant as the pregnancy proceeds [4].", [["infections", "DISEASE", 183, 193], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 278, 289], ["Maternal antibodies", "PROTEIN", 0, 19], ["neonatal Fc receptor", "PROTEIN", 269, 289], ["maternal antibodies", "PROTEIN", 343, 362], ["infant", "SPECIES", 51, 57], ["infant", "SPECIES", 378, 384], ["Maternal antibodies", "PROBLEM", 0, 19], ["delivery via breastfeeding", "TREATMENT", 121, 147], ["infections", "PROBLEM", 183, 193], ["transported maternal antibodies", "TREATMENT", 331, 362], ["gradual", "OBSERVATION_MODIFIER", 297, 304], ["increase", "OBSERVATION_MODIFIER", 305, 313]]], ["The placental transport system is highly selective for IgG antibodies and essentially excludes the transport of other major immunoglobulin classes including IgE, IgM and IgA.", [["placental", "ANATOMY", 4, 13], ["placental", "ORGAN", 4, 13], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 55, 69], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 124, 138], ["IgE", "GENE_OR_GENE_PRODUCT", 157, 160], ["IgM", "GENE_OR_GENE_PRODUCT", 162, 165], ["IgA", "GENE_OR_GENE_PRODUCT", 170, 173], ["IgG antibodies", "PROTEIN", 55, 69], ["immunoglobulin classes", "PROTEIN", 124, 146], ["IgE", "PROTEIN", 157, 160], ["IgM", "PROTEIN", 162, 165], ["IgA", "PROTEIN", 170, 173], ["The placental transport system", "TEST", 0, 30], ["IgG antibodies", "TEST", 55, 69], ["IgE", "TEST", 157, 160]]], ["Within the IgG antibodies, preferential transport of IgG isotype 1 is noted, leading to a more efficient transport of antibodies elicited by vaccines containing protein antigens compared with vaccines containing polysaccharide antigens (eliciting IgG2 isotype antibodies) [5].", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 11, 25], ["IgG isotype 1", "GENE_OR_GENE_PRODUCT", 53, 66], ["polysaccharide antigens", "GENE_OR_GENE_PRODUCT", 212, 235], ["IgG2", "GENE_OR_GENE_PRODUCT", 247, 251], ["IgG antibodies", "PROTEIN", 11, 25], ["IgG isotype 1", "PROTEIN", 53, 66], ["antibodies", "PROTEIN", 118, 128], ["protein antigens", "PROTEIN", 161, 177], ["polysaccharide antigens", "PROTEIN", 212, 235], ["IgG2 isotype antibodies", "PROTEIN", 247, 270], ["the IgG antibodies", "TEST", 7, 25], ["IgG isotype", "TEST", 53, 64], ["protein antigens", "PROBLEM", 161, 177], ["vaccines", "TREATMENT", 192, 200], ["polysaccharide antigens", "TEST", 212, 235], ["IgG2 isotype antibodies", "TEST", 247, 270], ["IgG isotype", "OBSERVATION", 53, 64]]], ["Some chronic maternal infections like malaria and HIV can cause an impaired transplacental transport [6, 7].IntroductionSecretory IgA antibodies are secreted into the colostrum and breast milk and are ingested by the neonate during breastfeeding providing mucosal immunity to the newborn.", [["colostrum", "ANATOMY", 167, 176], ["breast milk", "ANATOMY", 181, 192], ["mucosal", "ANATOMY", 256, 263], ["maternal infections", "DISEASE", 13, 32], ["malaria", "DISEASE", 38, 45], ["HIV", "DISEASE", 50, 53], ["HIV", "ORGANISM", 50, 53], ["IgA antibodies", "GENE_OR_GENE_PRODUCT", 130, 144], ["colostrum", "ORGANISM_SUBSTANCE", 167, 176], ["breast milk", "ORGANISM_SUBSTANCE", 181, 192], ["neonate", "ORGANISM", 217, 224], ["mucosal", "MULTI-TISSUE_STRUCTURE", 256, 263], ["IntroductionSecretory IgA antibodies", "PROTEIN", 108, 144], ["HIV", "SPECIES", 50, 53], ["colostrum", "SPECIES", 167, 176], ["HIV", "SPECIES", 50, 53], ["Some chronic maternal infections", "PROBLEM", 0, 32], ["malaria", "PROBLEM", 38, 45], ["HIV", "PROBLEM", 50, 53], ["an impaired transplacental transport", "PROBLEM", 64, 100], ["IntroductionSecretory IgA antibodies", "TEST", 108, 144], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["infections", "OBSERVATION", 22, 32], ["malaria", "OBSERVATION", 38, 45], ["impaired", "OBSERVATION", 67, 75], ["breast", "ANATOMY", 181, 187]]], ["After maternal vaccination, an increased amount of disease-specific maternal antibodies is observed in the breast milk up to several weeks postpartum [3, 8, 9].", [["breast milk", "ANATOMY", 107, 118], ["breast milk", "ORGANISM_SUBSTANCE", 107, 118], ["maternal antibodies", "PROTEIN", 68, 87], ["maternal vaccination", "PROBLEM", 6, 26], ["an increased amount of disease", "PROBLEM", 28, 58], ["specific maternal antibodies", "PROBLEM", 59, 87], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["amount", "OBSERVATION_MODIFIER", 41, 47], ["disease", "OBSERVATION", 51, 58], ["breast", "ANATOMY", 107, 113]]], ["These maternal antibodies provide mucosal immunity through neutralization and prevention of adherence of toxins and virulence factors in the respiratory and gastrointestinal tract [10].", [["mucosal", "ANATOMY", 34, 41], ["respiratory", "ANATOMY", 141, 152], ["gastrointestinal tract", "ANATOMY", 157, 179], ["respiratory and gastrointestinal tract", "DISEASE", 141, 179], ["mucosal", "MULTI-TISSUE_STRUCTURE", 34, 41], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 157, 179], ["maternal antibodies", "PROTEIN", 6, 25], ["virulence factors", "PROTEIN", 116, 133], ["These maternal antibodies", "TREATMENT", 0, 25], ["mucosal immunity through neutralization", "TREATMENT", 34, 73], ["toxins", "PROBLEM", 105, 111], ["virulence factors in the respiratory and gastrointestinal tract", "PROBLEM", 116, 179], ["respiratory", "ANATOMY", 141, 152], ["gastrointestinal tract", "ANATOMY", 157, 179]]], ["However, whether these antibodies can be transported across the upper respiratory mucosa and the intestinal epithelial barrier into the circulation is unknown.IntroductionThe amount of maternal antibodies transferred to the neonate through both the placenta and breast milk depends on the timing of vaccination during pregnancy [11], the placental function and on the concentration of maternal antibodies in the pregnant women [12].", [["upper respiratory mucosa", "ANATOMY", 64, 88], ["intestinal epithelial", "ANATOMY", 97, 118], ["placenta", "ANATOMY", 249, 257], ["breast milk", "ANATOMY", 262, 273], ["placental", "ANATOMY", 338, 347], ["upper respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 64, 88], ["intestinal epithelial barrier", "TISSUE", 97, 126], ["neonate", "ORGANISM", 224, 231], ["placenta", "TISSUE", 249, 257], ["breast milk", "ORGANISM_SUBSTANCE", 262, 273], ["placental", "ORGAN", 338, 347], ["women", "ORGANISM", 421, 426], ["antibodies", "PROTEIN", 23, 33], ["maternal antibodies", "PROTEIN", 185, 204], ["maternal antibodies", "PROTEIN", 385, 404], ["women", "SPECIES", 421, 426], ["these antibodies", "PROBLEM", 17, 33], ["maternal antibodies", "PROBLEM", 185, 204], ["the placenta and breast milk", "TREATMENT", 245, 273], ["vaccination during pregnancy", "TREATMENT", 299, 327], ["the placental function", "PROBLEM", 334, 356], ["the concentration of maternal antibodies", "TREATMENT", 364, 404], ["upper", "ANATOMY_MODIFIER", 64, 69], ["respiratory mucosa", "ANATOMY", 70, 88], ["intestinal", "ANATOMY", 97, 107], ["epithelial", "ANATOMY_MODIFIER", 108, 118], ["circulation", "ANATOMY", 136, 147], ["amount", "OBSERVATION_MODIFIER", 175, 181], ["placenta", "ANATOMY", 249, 257], ["breast", "ANATOMY", 262, 268]]], ["The latter depends on the vaccination status of the women or the time since last vaccination or disease [13].", [["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["disease", "PROBLEM", 96, 103]]], ["In order to transfer the maximum amount of maternal antibodies to the fetus, the concentration of antibodies in the maternal blood should be high during pregnancy.", [["fetus", "ANATOMY", 70, 75], ["blood", "ANATOMY", 125, 130], ["fetus", "ORGANISM", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["maternal antibodies", "PROTEIN", 43, 62], ["antibodies", "PROTEIN", 98, 108], ["maternal antibodies", "TREATMENT", 43, 62], ["the concentration of antibodies", "TREATMENT", 77, 108], ["the maternal blood", "TEST", 112, 130]]], ["Therefore, for some infectious diseases, increasing the maternal antibody level induced by vaccination during pregnancy is currently the only option to offer passive protection to the newborn immediately after birth [2, 14].IntroductionMaternal antibodies wane exponentially during the first weeks or months of life and the rate of decay is consistent regardless of the amount of antibodies received at birth [15].", [["infectious diseases", "DISEASE", 20, 39], ["Maternal antibodies", "PROTEIN", 236, 255], ["antibodies", "PROTEIN", 380, 390], ["some infectious diseases", "PROBLEM", 15, 39], ["the maternal antibody level", "PROBLEM", 52, 79], ["passive protection", "TREATMENT", 158, 176], ["infectious", "OBSERVATION", 20, 30]]], ["Therefore, infants starting with a higher level of maternal antibodies at birth will still have a longer persistence of these antibodies until the start of the infant\u2019s own primary immunization schedule [13, 16].IntroductionHigh concentrations of vaccine-induced maternal antibodies are known to interfere with the infant\u2019s humoral immune response with an inhibition of the antibody generation after their own vaccination and lower antibody titers as a consequence [17].", [["infants", "ORGANISM", 11, 18], ["maternal antibodies", "PROTEIN", 51, 70], ["antibodies", "PROTEIN", 126, 136], ["maternal antibodies", "PROTEIN", 263, 282], ["infants", "SPECIES", 11, 18], ["infant", "SPECIES", 160, 166], ["infant", "SPECIES", 315, 321], ["a higher level of maternal antibodies", "TREATMENT", 33, 70], ["these antibodies", "PROBLEM", 120, 136], ["primary immunization schedule", "TREATMENT", 173, 202], ["vaccine", "TREATMENT", 247, 254], ["maternal antibodies", "PROBLEM", 263, 282], ["the antibody generation", "TREATMENT", 370, 393], ["their own vaccination", "TEST", 400, 421], ["lower antibody titers", "PROBLEM", 426, 447]]], ["However, this interference effect is mostly a temporary effect which mainly affects humoral immune responses after primary vaccination and to a lesser extent after booster vaccination [5].", [["a temporary effect", "PROBLEM", 44, 62], ["primary vaccination", "TREATMENT", 115, 134], ["temporary effect", "OBSERVATION_MODIFIER", 46, 62]]], ["Whether high concentrations of maternal antibodies also affect cellular immune responses in infants is not completely clear yet and needs further investigation [18].", [["cellular", "ANATOMY", 63, 71], ["cellular", "CELL", 63, 71], ["infants", "ORGANISM", 92, 99], ["maternal antibodies", "PROTEIN", 31, 50], ["infants", "SPECIES", 92, 99], ["high concentrations of maternal antibodies", "PROBLEM", 8, 50], ["further investigation", "TEST", 138, 159]]], ["Also, the clinical consequences, if any, of this blunting can vary depending on the vaccine and the disease [19].IntroductionDuring recent infectious disease outbreaks (influenza, pertussis, Zika\u2026) and for some other infectious diseases (CMV, GBS\u2026), pregnant women are increasingly identified as an important target for vaccination.", [["infectious disease outbreaks", "DISEASE", 139, 167], ["influenza, pertussis", "DISEASE", 169, 189], ["infectious diseases", "DISEASE", 217, 236], ["CMV, GBS\u2026", "DISEASE", 238, 247], ["CMV", "ORGANISM", 238, 241], ["women", "ORGANISM", 259, 264], ["women", "SPECIES", 259, 264], ["CMV", "SPECIES", 238, 241], ["this blunting", "PROBLEM", 44, 57], ["the disease", "PROBLEM", 96, 107], ["recent infectious disease outbreaks", "PROBLEM", 132, 167], ["influenza", "PROBLEM", 169, 178], ["pertussis", "PROBLEM", 180, 189], ["some other infectious diseases", "PROBLEM", 206, 236], ["CMV", "PROBLEM", 238, 241], ["blunting", "OBSERVATION", 49, 57], ["infectious", "OBSERVATION_MODIFIER", 139, 149], ["infectious", "OBSERVATION", 217, 227]]], ["For some of these diseases, vaccines are already on the market, and recommended during pregnancy.", [["these diseases", "PROBLEM", 12, 26], ["vaccines", "TREATMENT", 28, 36], ["diseases", "OBSERVATION", 18, 26]]], ["For others, vaccines are currently under development; furthermore, some are even specifically designed to be administered during pregnancy.", [["vaccines", "TREATMENT", 12, 20]]], ["Therefore, in this review, we focused on three vaccines that are currently recommended during pregnancy and also on some other vaccines that are currently under development and that can be used during pregnancy in the future.Tetanus ::: Existing maternal vaccination recommendationsMaternal and neonatal tetanus (MNT) is an important cause of maternal and neonatal morbidity and mortality.", [["Tetanus", "DISEASE", 225, 232], ["tetanus", "DISEASE", 304, 311], ["three vaccines", "TREATMENT", 41, 55], ["some other vaccines", "TREATMENT", 116, 135], ["Existing maternal vaccination recommendations", "TREATMENT", 237, 282], ["maternal and neonatal morbidity", "PROBLEM", 343, 374]]], ["MNT is often fatal and characterized by muscular rigidity and spasms and without medical care; case fatality ratio (CFR) is close to 100%.", [["muscular", "ANATOMY", 40, 48], ["muscular rigidity", "DISEASE", 40, 57], ["spasms", "DISEASE", 62, 68], ["muscular", "ORGAN", 40, 48], ["muscular rigidity", "PROBLEM", 40, 57], ["spasms", "PROBLEM", 62, 68], ["medical care", "TREATMENT", 81, 93], ["fatal", "OBSERVATION", 13, 18], ["muscular rigidity", "OBSERVATION", 40, 57]]], ["Maternal tetanus, defined as tetanus during pregnancy or within 6 weeks after delivery, is linked to miscarriages, abortion and unhygienic delivery conditions, whereas neonatal tetanus is secondary and a consequence of poor postpartum cord care practices [20, 21].Tetanus ::: Existing maternal vaccination recommendationsNeonatal tetanus was estimated to be responsible for over half a million of deaths globally in the early 1980s.", [["cord", "ANATOMY", 235, 239], ["tetanus", "DISEASE", 9, 16], ["tetanus", "DISEASE", 29, 36], ["miscarriages", "DISEASE", 101, 113], ["abortion", "DISEASE", 115, 123], ["tetanus", "DISEASE", 177, 184], ["Tetanus", "DISEASE", 264, 271], ["Neonatal tetanus", "DISEASE", 321, 337], ["deaths", "DISEASE", 397, 403], ["cord", "ORGAN", 235, 239], ["Maternal tetanus", "PROBLEM", 0, 16], ["delivery", "TREATMENT", 78, 86], ["miscarriages", "PROBLEM", 101, 113], ["abortion", "PROBLEM", 115, 123], ["unhygienic delivery conditions", "PROBLEM", 128, 158], ["neonatal tetanus", "PROBLEM", 168, 184], ["Existing maternal vaccination recommendations", "TREATMENT", 276, 321], ["Neonatal tetanus", "TREATMENT", 321, 337]]], ["In 1988, the WHO estimated that 787,000 newborns died due to neonatal tetanus corresponding with a global incidence of approximately 6.7 deaths per 1000 live births.", [["tetanus", "DISEASE", 70, 77], ["deaths", "DISEASE", 137, 143], ["newborns", "ORGANISM", 40, 48], ["neonatal tetanus", "PROBLEM", 61, 77]]], ["In low- and middle-income countries, the overall incidence was even higher with 50 to 110 deaths per 1000 live births due to neonatal tetanus [20, 22].Tetanus ::: Existing maternal vaccination recommendationsTherefore, the World Health Assembly launched the Maternal and Neonatal Tetanus Elimination Program (MNTE) in 1989.", [["deaths", "DISEASE", 90, 96], ["neonatal tetanus", "DISEASE", 125, 141], ["Tetanus", "DISEASE", 151, 158], ["Tetanus", "DISEASE", 280, 287], ["neonatal tetanus", "PROBLEM", 125, 141], ["Existing maternal vaccination recommendations", "TREATMENT", 163, 208], ["low", "OBSERVATION_MODIFIER", 3, 6], ["middle", "ANATOMY_MODIFIER", 12, 18]]], ["The goal of this program is to eliminate MNT through the promotion of birth hygiene, surveillance and maternal immunization with tetanus toxoid.", [["tetanus toxoid", "DISEASE", 129, 143], ["tetanus toxoid", "ORGANISM", 129, 143], ["birth hygiene", "TREATMENT", 70, 83], ["surveillance", "TEST", 85, 97], ["maternal immunization", "TREATMENT", 102, 123], ["tetanus toxoid", "TREATMENT", 129, 143]]], ["WHO recommends that unimmunized pregnant women or pregnant women without documentation of previous tetanus vaccination should receive two doses of tetanus toxoid (TT) at least 4 weeks apart.", [["tetanus", "DISEASE", 99, 106], ["tetanus toxoid", "CHEMICAL", 147, 161], ["women", "ORGANISM", 41, 46], ["women", "ORGANISM", 59, 64], ["tetanus toxoid", "ORGANISM", 147, 161], ["women", "SPECIES", 41, 46], ["women", "SPECIES", 59, 64], ["previous tetanus vaccination", "TREATMENT", 90, 118], ["tetanus toxoid (TT)", "TREATMENT", 147, 166]]], ["The first dose should be given as early as possible during pregnancy and the last dose should be given at least 2 weeks prior to delivery.", [["delivery", "TREATMENT", 129, 137]]], ["A total of 5 doses are considered sufficient for life-long immunity so further doses should be given during subsequent pregnancies or at intervals of at least 1 year [23].Tetanus ::: Existing maternal vaccination recommendationsFollowing the launch of this program and with an increasing coverage of minimum two doses of TT in pregnant women, the incidence of MNT declined substantially.", [["Tetanus", "DISEASE", 171, 178], ["TT", "CHEMICAL", 321, 323], ["women", "ORGANISM", 336, 341], ["women", "SPECIES", 336, 341], ["A total of 5 doses", "TREATMENT", 0, 18], ["life-long immunity", "TREATMENT", 49, 67], ["further doses", "TREATMENT", 71, 84], ["Existing maternal vaccination recommendations", "TREATMENT", 183, 228], ["this program", "TREATMENT", 252, 264], ["an increasing coverage", "TREATMENT", 274, 296], ["TT in pregnant women", "TREATMENT", 321, 341]]], ["According to the WHO, 34,019 newborns died from tetanus in 2015 which corresponds with a 96% reduction in burden of tetanus-related mortality compared with the early 1980s.", [["tetanus", "DISEASE", 48, 55], ["tetanus", "DISEASE", 116, 123], ["newborns", "ORGANISM", 29, 37], ["tetanus", "PROBLEM", 48, 55], ["tetanus", "PROBLEM", 116, 123]]], ["In March 2018, elimination was even achieved by 41 countries [20].Tetanus ::: Existing maternal vaccination recommendationsExtensive and longtime research showed that TT has an extensive safety profile in pregnant women [24].", [["Tetanus", "DISEASE", 66, 73], ["TT", "CHEMICAL", 167, 169], ["women", "ORGANISM", 214, 219], ["women", "SPECIES", 214, 219], ["Existing maternal vaccination recommendations", "TREATMENT", 78, 123], ["extensive", "OBSERVATION_MODIFIER", 177, 186]]], ["It has also been shown that TT administered to pregnant women is efficient and effective for protection against maternal and neonatal tetanus.", [["TT", "CHEMICAL", 28, 30], ["tetanus", "DISEASE", 134, 141], ["TT", "SIMPLE_CHEMICAL", 28, 30], ["women", "ORGANISM", 56, 61], ["women", "SPECIES", 56, 61], ["TT", "TREATMENT", 28, 30], ["protection", "TREATMENT", 93, 103], ["maternal and neonatal tetanus", "PROBLEM", 112, 141]]], ["A recent systematic review shows a decrease in mortality from neonatal tetanus by 94% in infants from women that have been vaccinated in pregnancy with at least 2 doses of TT [25].Pertussis ::: Existing maternal vaccination recommendationsDespite the availability of successful universal pertussis vaccination programs (85% global DTP3 coverage in 2017) [26], the disease remains an important public health problem with an estimated 89,000 deaths yearly [27].", [["tetanus", "DISEASE", 71, 78], ["Pertussis", "DISEASE", 180, 189], ["deaths", "DISEASE", 440, 446], ["infants", "ORGANISM", 89, 96], ["women", "ORGANISM", 102, 107], ["infants", "SPECIES", 89, 96], ["women", "SPECIES", 102, 107], ["A recent systematic review", "TEST", 0, 26], ["a decrease in mortality", "PROBLEM", 33, 56], ["neonatal tetanus", "TREATMENT", 62, 78], ["Existing maternal vaccination recommendations", "TREATMENT", 194, 239], ["successful universal pertussis vaccination programs", "TREATMENT", 267, 318], ["global DTP3 coverage", "TREATMENT", 324, 344], ["the disease", "PROBLEM", 360, 371], ["decrease", "OBSERVATION_MODIFIER", 35, 43]]], ["During recent years, some countries with high vaccination coverage experienced a rise in the incidence of pertussis with the highest incidence, disease burden and case fatality rate in infants below 1 year of age.", [["pertussis", "DISEASE", 106, 115], ["infants", "ORGANISM", 185, 192], ["infants", "SPECIES", 185, 192], ["pertussis", "SPECIES", 106, 115], ["high vaccination coverage", "TREATMENT", 41, 66], ["pertussis", "PROBLEM", 106, 115], ["disease burden", "PROBLEM", 144, 158]]], ["These infants are too young to be protected by the currently available vaccines and vaccination schedules since infant pertussis vaccination does not start before the age of 6 weeks, resulting in a susceptibility gap for pertussis infection in infants [28].", [["pertussis", "CHEMICAL", 119, 128], ["pertussis infection", "DISEASE", 221, 240], ["infants", "ORGANISM", 6, 13], ["infant pertussis", "ORGANISM", 112, 128], ["infants", "ORGANISM", 244, 251], ["infants", "SPECIES", 6, 13], ["infants", "SPECIES", 244, 251], ["vaccines", "TREATMENT", 71, 79], ["vaccination schedules", "TREATMENT", 84, 105], ["infant pertussis vaccination", "TREATMENT", 112, 140], ["a susceptibility gap", "PROBLEM", 196, 216], ["pertussis infection", "PROBLEM", 221, 240]]], ["As a result of the resurgence of pertussis disease and to better protect these vulnerable infants, national advisory bodies from both industrialized and developing countries have recommended immunization with a tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine for all pregnant women in the second or third trimester of pregnancy [29, 30].", [["pertussis disease", "DISEASE", 33, 50], ["tetanus", "DISEASE", 211, 218], ["diphtheria", "DISEASE", 220, 230], ["acellular pertussis", "CHEMICAL", 232, 251], ["infants", "ORGANISM", 90, 97], ["acellular pertussis", "ORGANISM", 232, 251], ["women", "ORGANISM", 289, 294], ["infants", "SPECIES", 90, 97], ["women", "SPECIES", 289, 294], ["pertussis", "SPECIES", 33, 42], ["pertussis disease", "PROBLEM", 33, 50], ["immunization", "TREATMENT", 191, 203], ["a tetanus, diphtheria", "TREATMENT", 209, 230], ["acellular pertussis (aP) (Tdap) vaccine", "TREATMENT", 232, 271]]], ["Many studies have reported the safety of maternal Tdap vaccination concluding that the current strategy of maternal pertussis vaccination is a safe strategy for mother, fetus and infant [31, 32].Pertussis ::: Existing maternal vaccination recommendationsProtection against pertussis disease is dependent on both the humoral and cellular immune response.", [["fetus", "ANATOMY", 169, 174], ["cellular", "ANATOMY", 328, 336], ["pertussis", "CHEMICAL", 116, 125], ["Pertussis", "DISEASE", 195, 204], ["pertussis disease", "DISEASE", 273, 290], ["fetus", "ORGANISM_SUBDIVISION", 169, 174], ["cellular", "CELL", 328, 336], ["infant", "SPECIES", 179, 185], ["pertussis", "SPECIES", 273, 282], ["Many studies", "TEST", 0, 12], ["maternal Tdap vaccination", "TREATMENT", 41, 66], ["maternal pertussis vaccination", "TREATMENT", 107, 137], ["Existing maternal vaccination recommendations", "TREATMENT", 209, 254], ["Protection", "TREATMENT", 254, 264], ["pertussis disease", "PROBLEM", 273, 290], ["humoral", "ANATOMY", 316, 323], ["cellular immune response", "OBSERVATION", 328, 352]]], ["Vaccinating pregnant women with an aP-containing vaccine induces similar humoral immune responses compared with non-pregnant women [33, 34].", [["women", "ORGANISM", 21, 26], ["women", "ORGANISM", 125, 130], ["women", "SPECIES", 21, 26], ["women", "SPECIES", 125, 130], ["an aP-containing vaccine", "TREATMENT", 32, 56]]], ["Overall, pertussis-specific antibodies wane quite rapidly with already a significant decline in antibody titers 1 year after maternal Tdap vaccination [34, 35].", [["pertussis-specific antibodies", "PROTEIN", 9, 38], ["pertussis", "PROBLEM", 9, 18], ["a significant decline in antibody titers", "PROBLEM", 71, 111], ["maternal Tdap vaccination", "TREATMENT", 125, 150], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["decline", "OBSERVATION", 85, 92]]], ["This observation supports the recommendation for repeated booster vaccinations in successive pregnancies.", [["repeated booster vaccinations", "TREATMENT", 49, 78], ["successive pregnancies", "PROBLEM", 82, 104]]], ["In the case of cellular immune responses, maternal Tdap vaccination stimulates significantly weaker proliferative and IFN-\u03b3 responses in pregnant compared with non-pregnant women [34], but the vaccination is still immunogenic and induces a sufficient amount of maternal antibodies in women.", [["cellular", "ANATOMY", 15, 23], ["cellular", "CELL", 15, 23], ["Tdap", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 118, 123], ["women", "ORGANISM", 173, 178], ["women", "ORGANISM", 284, 289], ["IFN", "PROTEIN", 118, 121], ["maternal antibodies", "PROTEIN", 261, 280], ["women", "SPECIES", 173, 178], ["women", "SPECIES", 284, 289], ["maternal Tdap vaccination", "TEST", 42, 67], ["significantly weaker proliferative", "PROBLEM", 79, 113], ["IFN", "TEST", 118, 121], ["immunogenic", "PROBLEM", 214, 225], ["maternal antibodies in women", "PROBLEM", 261, 289]]], ["These antibodies can be transported actively across the placenta to the fetus to protect the offspring in the first weeks of life.", [["placenta", "ANATOMY", 56, 64], ["fetus", "ANATOMY", 72, 77], ["placenta", "ORGAN", 56, 64], ["fetus", "ORGAN", 72, 77], ["antibodies", "PROTEIN", 6, 16]]], ["Recent studies show that maternal Tdap vaccination, administered in the second or third trimester of pregnancy, prevents pertussis in at least 9 out of 10 infants below 6 months of age [36\u201338].Pertussis ::: Existing maternal vaccination recommendationsRegarding the optimal timing of pertussis vaccination in pregnancy, different considerations should be carefully taken into account including safety, vaccine effectiveness, uptake and timing of antenatal care visits [39].", [["Tdap", "CHEMICAL", 34, 38], ["pertussis", "DISEASE", 121, 130], ["Pertussis", "DISEASE", 193, 202], ["Tdap", "GENE_OR_GENE_PRODUCT", 34, 38], ["infants", "ORGANISM", 155, 162], ["infants", "SPECIES", 155, 162], ["pertussis", "SPECIES", 284, 293], ["Recent studies", "TEST", 0, 14], ["maternal Tdap vaccination", "TREATMENT", 25, 50], ["pertussis", "PROBLEM", 121, 130], ["Existing maternal vaccination recommendations", "TREATMENT", 207, 252], ["pertussis vaccination", "TREATMENT", 284, 305], ["safety, vaccine effectiveness", "TREATMENT", 394, 423]]], ["However, recent data show that vaccination earlier in pregnancy, even second rather than third trimester vaccination, is the best option since this timing offers the necessary time to develop and transport maternal antibodies towards the unborn child.", [["maternal antibodies", "PROTEIN", 206, 225], ["child", "SPECIES", 245, 250], ["vaccination", "TREATMENT", 31, 42], ["third trimester vaccination", "TREATMENT", 89, 116]]], ["An Australian study reported higher pertussis-specific antibody titers in cord blood of infants born to women immunized at 28\u201332 weeks of gestation compared with women immunized between 33 and 36 weeks of gestation suggesting that vaccination earlier in the third trimester is more effective than later in pregnancy [40].", [["cord blood", "ANATOMY", 74, 84], ["cord blood", "ORGANISM_SUBSTANCE", 74, 84], ["infants", "ORGANISM", 88, 95], ["women", "ORGANISM", 104, 109], ["women", "ORGANISM", 162, 167], ["infants", "SPECIES", 88, 95], ["women", "SPECIES", 104, 109], ["women", "SPECIES", 162, 167], ["An Australian study", "TEST", 0, 19], ["higher pertussis", "PROBLEM", 29, 45], ["specific antibody titers", "TEST", 46, 70], ["cord blood", "TEST", 74, 84], ["vaccination", "TREATMENT", 231, 242], ["cord", "ANATOMY", 74, 78]]], ["More recently, a Swiss study found that second trimester immunization was associated with significantly higher titers in cord blood of term born infants compared with third trimester immunization [41].", [["cord blood", "ANATOMY", 121, 131], ["cord blood", "ORGANISM_SUBSTANCE", 121, 131], ["infants", "ORGANISM", 145, 152], ["infants", "SPECIES", 145, 152], ["a Swiss study", "TEST", 15, 28], ["second trimester immunization", "TREATMENT", 40, 69], ["significantly higher titers in cord blood", "PROBLEM", 90, 131], ["third trimester immunization", "TREATMENT", 167, 195], ["cord", "ANATOMY", 121, 125]]], ["The same effect was seen in the cord of preterm born infants, even when they were born before 33 weeks of gestation [11], a time point where transplacental transport is considered to be suboptimal.Pertussis ::: Existing maternal vaccination recommendationsBlunting or interference of the infant immune response is currently one of the areas of investigation of the maternal pertussis vaccination strategy.", [["cord", "ANATOMY", 32, 36], ["Pertussis", "DISEASE", 197, 206], ["cord", "ORGAN", 32, 36], ["infants", "ORGANISM", 53, 60], ["infant", "ORGANISM", 288, 294], ["infants", "SPECIES", 53, 60], ["infant", "SPECIES", 288, 294], ["transplacental transport", "TEST", 141, 165], ["Existing maternal vaccination recommendations", "TREATMENT", 211, 256], ["Blunting", "PROBLEM", 256, 264], ["the maternal pertussis vaccination strategy", "TREATMENT", 361, 404], ["cord", "ANATOMY", 32, 36], ["interference", "OBSERVATION_MODIFIER", 268, 280], ["immune response", "OBSERVATION", 295, 310]]], ["In the 1990s, blunting of naturally acquired maternal pertussis antibodies with the infant\u2019s humoral immune response to whole cell pertussis (wP), yet not to aP vaccines, was already described [42].", [["whole cell", "ANATOMY", 120, 130], ["whole cell pertussis", "ORGANISM", 120, 140], ["maternal pertussis antibodies", "PROTEIN", 45, 74], ["infant", "SPECIES", 84, 90], ["blunting of naturally acquired maternal pertussis antibodies", "PROBLEM", 14, 74], ["whole cell pertussis", "PROBLEM", 120, 140], ["aP vaccines", "TREATMENT", 158, 169], ["blunting", "OBSERVATION_MODIFIER", 14, 22]]], ["On the other hand, it has been shown that the presence of vaccine-induced passive maternal antibodies may blunt the infant immune response to childhood aP vaccination.", [["passive maternal antibodies", "PROTEIN", 74, 101], ["infant", "SPECIES", 116, 122], ["vaccine", "TREATMENT", 58, 65], ["passive maternal antibodies", "PROBLEM", 74, 101], ["childhood aP vaccination", "TREATMENT", 142, 166]]], ["However, this interference effect is highly variable for different aP-containing vaccines and even in different studies on the same aP-containing vaccine [2, 14, 33, 43\u201347].", [["different aP-containing vaccines", "TREATMENT", 57, 89]]], ["More recently, also blunting of the infant immune response to childhood wP-containing vaccines in the presence of vaccine-induced maternal antibodies has been shown [48].", [["wP", "CHEMICAL", 72, 74], ["infant", "ORGANISM", 36, 42], ["wP", "SIMPLE_CHEMICAL", 72, 74], ["maternal antibodies", "PROTEIN", 130, 149], ["infant", "SPECIES", 36, 42], ["childhood wP", "TREATMENT", 62, 74], ["vaccines", "TREATMENT", 86, 94], ["vaccine", "TREATMENT", 114, 121], ["maternal antibodies", "PROBLEM", 130, 149], ["blunting", "OBSERVATION_MODIFIER", 20, 28]]], ["Besides blunting of the infant humoral immune responses to the same vaccine antigens as the ones included in the Tdap vaccine, also blunting of vaccine antigens conjugated to the diphtheria toxoid variant (CRM) or TT has also been demonstrated, for example, blunting of the pneumococcal immune response, mainly after primary immunization [47, 49].", [["diphtheria toxoid", "CHEMICAL", 179, 196], ["diphtheria toxoid variant", "GENE_OR_GENE_PRODUCT", 179, 204], ["pneumococcal", "ORGANISM", 274, 286], ["vaccine antigens", "PROTEIN", 68, 84], ["vaccine antigens", "PROTEIN", 144, 160], ["diphtheria toxoid variant", "PROTEIN", 179, 204], ["CRM", "PROTEIN", 206, 209], ["infant", "SPECIES", 24, 30], ["pneumococcal", "SPECIES", 274, 286], ["blunting of the infant humoral immune responses", "PROBLEM", 8, 55], ["the same vaccine antigens", "TREATMENT", 59, 84], ["the Tdap vaccine", "TREATMENT", 109, 125], ["blunting of vaccine antigens", "PROBLEM", 132, 160], ["the diphtheria toxoid variant", "PROBLEM", 175, 204], ["TT", "PROBLEM", 214, 216], ["blunting of the pneumococcal immune response", "PROBLEM", 258, 302], ["blunting", "OBSERVATION_MODIFIER", 8, 16], ["blunting", "OBSERVATION_MODIFIER", 132, 140], ["blunting", "OBSERVATION_MODIFIER", 258, 266], ["pneumococcal immune response", "OBSERVATION", 274, 302]]], ["Up until now, no clinical evidence of blunting has been shown [50].", [["blunting", "PROBLEM", 38, 46], ["blunting", "OBSERVATION", 38, 46]]], ["But, ongoing surveillance in older, vaccinated infants and toddlers is still essential to understand the longer-term impact and possible significance of these immunological findings.Influenza ::: Existing maternal vaccination recommendationsInfluenza infection affects all age groups and causes mild to severe illness.", [["Influenza", "DISEASE", 182, 191], ["Influenza infection", "DISEASE", 241, 260], ["illness", "DISEASE", 310, 317], ["infants", "ORGANISM", 47, 54], ["infants", "SPECIES", 47, 54], ["Influenza", "SPECIES", 182, 191], ["Influenza", "PROBLEM", 182, 191], ["Existing maternal vaccination recommendations", "TREATMENT", 196, 241], ["Influenza infection", "PROBLEM", 241, 260], ["mild to severe illness", "PROBLEM", 295, 317], ["infection", "OBSERVATION", 251, 260], ["mild", "OBSERVATION_MODIFIER", 295, 299], ["severe", "OBSERVATION_MODIFIER", 303, 309], ["illness", "OBSERVATION", 310, 317]]], ["The World Health Organization (WHO) estimates that during normal seasonal epidemics, 5\u201315% of the population is infected, with 3 to 5 million cases of severe illness and up to 650,000 influenza-associated deaths annually.", [["illness", "DISEASE", 158, 165], ["influenza", "DISEASE", 184, 193], ["deaths", "DISEASE", 205, 211], ["normal seasonal epidemics", "PROBLEM", 58, 83], ["infected", "PROBLEM", 112, 120], ["severe illness", "PROBLEM", 151, 165], ["influenza", "PROBLEM", 184, 193], ["infected", "OBSERVATION", 112, 120], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["illness", "OBSERVATION", 158, 165]]], ["Pregnant women are at increased risk of influenza-associated complications and are recognized as a priority group for seasonal and pandemic influenza vaccination.", [["influenza", "DISEASE", 40, 49], ["influenza", "DISEASE", 140, 149], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["influenza-associated complications", "PROBLEM", 40, 74], ["seasonal and pandemic influenza vaccination", "PROBLEM", 118, 161], ["influenza", "OBSERVATION", 40, 49], ["complications", "OBSERVATION", 61, 74]]], ["During recent seasonal influenza episodes, pregnant women had a significantly higher risk of hospitalization [51] compared with non-pregnant women.", [["influenza episodes", "DISEASE", 23, 41], ["women", "ORGANISM", 52, 57], ["women", "ORGANISM", 141, 146], ["women", "SPECIES", 52, 57], ["women", "SPECIES", 141, 146], ["recent seasonal influenza episodes", "PROBLEM", 7, 41], ["seasonal", "OBSERVATION_MODIFIER", 14, 22], ["influenza", "OBSERVATION", 23, 32]]], ["The disease severity increased with each trimester and was the highest for pregnant women with medical co-morbidities, e.g. metabolic disorders and chronic lung diseases [52].", [["lung", "ANATOMY", 156, 160], ["metabolic disorders", "DISEASE", 124, 143], ["chronic lung diseases", "DISEASE", 148, 169], ["women", "ORGANISM", 84, 89], ["lung", "ORGAN", 156, 160], ["women", "SPECIES", 84, 89], ["The disease severity", "PROBLEM", 0, 20], ["medical co-morbidities", "PROBLEM", 95, 117], ["metabolic disorders", "PROBLEM", 124, 143], ["chronic lung diseases", "PROBLEM", 148, 169], ["disease", "OBSERVATION", 4, 11], ["severity", "OBSERVATION_MODIFIER", 12, 20], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["lung", "ANATOMY", 156, 160], ["diseases", "OBSERVATION", 161, 169]]], ["Besides, influenza infection during pregnancy is associated with an increased risk of preterm delivery and small for gestational age for infants [53, 54].", [["influenza infection", "DISEASE", 9, 28], ["infants", "ORGANISM", 137, 144], ["infants", "SPECIES", 137, 144], ["influenza infection", "PROBLEM", 9, 28], ["preterm delivery", "PROBLEM", 86, 102], ["influenza", "OBSERVATION_MODIFIER", 9, 18], ["infection", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["preterm", "OBSERVATION", 86, 93], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["Additionally, infants under 6 months of age are at high risk of severe influenza and associated complications with high rates of influenza-associated hospitalizations and even mortality [55].", [["influenza", "DISEASE", 71, 80], ["influenza", "DISEASE", 129, 138], ["infants", "ORGANISM", 14, 21], ["infants", "SPECIES", 14, 21], ["severe influenza", "PROBLEM", 64, 80], ["associated complications", "PROBLEM", 85, 109], ["influenza", "PROBLEM", 129, 138], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["influenza", "OBSERVATION", 71, 80]]], ["However, currently, there is no influenza vaccine approved in any country for use in infants below 6 months of age.", [["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 85, 92], ["influenza vaccine", "TREATMENT", 32, 49], ["no", "UNCERTAINTY", 29, 31], ["influenza", "OBSERVATION", 32, 41]]], ["So, protection of infants during the first months of life can only be achieved by influenza vaccination during pregnancy [56].", [["infants", "ORGANISM", 18, 25], ["infants", "SPECIES", 18, 25], ["influenza vaccination", "TREATMENT", 82, 103]]], ["Several national and international institutions, e.g. the WHO and the Center for Disease Control and Prevention (CDC), recommend that every pregnant women should be vaccinated with one dose of an inactivated influenza vaccine during any trimester of pregnancy before the start of the flu season [57, 58].", [["influenza", "DISEASE", 208, 217], ["women", "ORGANISM", 149, 154], ["women", "SPECIES", 149, 154], ["Disease Control", "TREATMENT", 81, 96], ["an inactivated influenza vaccine", "TREATMENT", 193, 225]]], ["In 2012, the WHO stated that pregnant women should be prioritized above other groups for influenza vaccination in countries considering the initiation or expansion of their programs for seasonal influenza vaccination [59].Influenza ::: Existing maternal vaccination recommendationsSeveral studies on the safety of maternal influenza vaccination showed that the inactivated influenza vaccine is well tolerated in pregnant women without unexpected side effects in the fetus and infant [53, 60].", [["fetus", "ANATOMY", 466, 471], ["influenza", "DISEASE", 89, 98], ["influenza", "DISEASE", 195, 204], ["Influenza", "DISEASE", 222, 231], ["influenza", "DISEASE", 373, 382], ["women", "ORGANISM", 38, 43], ["women", "ORGANISM", 421, 426], ["fetus", "ORGANISM", 466, 471], ["women", "SPECIES", 38, 43], ["Influenza", "SPECIES", 222, 231], ["women", "SPECIES", 421, 426], ["infant", "SPECIES", 476, 482], ["influenza vaccination", "TREATMENT", 89, 110], ["expansion of their programs", "TREATMENT", 154, 181], ["seasonal influenza vaccination", "PROBLEM", 186, 216], ["Influenza", "PROBLEM", 222, 231], ["Existing maternal vaccination recommendations", "TREATMENT", 236, 281], ["Several studies", "TEST", 281, 296], ["maternal influenza vaccination", "TREATMENT", 314, 344], ["the inactivated influenza vaccine", "TREATMENT", 357, 390]]], ["Regarding the immunogenicity of the strategy, some studies report a slightly lower immune response to vaccination and significant differences in seroconversion rates in pregnant versus non-pregnant women while other studies report comparable immunogenicity [61, 62].", [["women", "ORGANISM", 198, 203], ["women", "SPECIES", 198, 203], ["some studies", "TEST", 46, 58], ["a slightly lower immune response", "PROBLEM", 66, 98], ["vaccination", "TREATMENT", 102, 113], ["significant differences", "PROBLEM", 118, 141], ["seroconversion rates", "TEST", 145, 165], ["other studies", "TEST", 210, 223]]], ["Yet, in general, pregnant women mount a good immune response to influenza vaccination with a significant increase in antibody titers to all vaccine strains and a significantly higher seroconversion rate in influenza-vaccinated compared with placebo-vaccinated pregnant women [63, 64].", [["influenza", "DISEASE", 64, 73], ["women", "ORGANISM", 26, 31], ["women", "ORGANISM", 269, 274], ["women", "SPECIES", 26, 31], ["women", "SPECIES", 269, 274], ["influenza vaccination", "TREATMENT", 64, 85], ["a significant increase in antibody titers", "PROBLEM", 91, 132], ["all vaccine strains", "TREATMENT", 136, 155], ["a significantly higher seroconversion rate", "PROBLEM", 160, 202], ["influenza", "PROBLEM", 206, 215], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["antibody titers", "OBSERVATION", 117, 132]]], ["After influenza vaccination during pregnancy, effective transplacental antibody transfer is seen with a correlation between maternal and cord blood antibody titers at delivery [65].Influenza ::: Existing maternal vaccination recommendationsFor the moment, no consensus has been reached on the timing of influenza vaccination during pregnancy.", [["cord blood", "ANATOMY", 137, 147], ["Influenza", "DISEASE", 181, 190], ["influenza", "DISEASE", 303, 312], ["cord blood", "ORGANISM_SUBSTANCE", 137, 147], ["Influenza", "SPECIES", 181, 190], ["influenza vaccination", "TREATMENT", 6, 27], ["pregnancy", "PROBLEM", 35, 44], ["effective transplacental antibody transfer", "TREATMENT", 46, 88], ["maternal and cord blood antibody titers", "TEST", 124, 163], ["Influenza", "PROBLEM", 181, 190], ["Existing maternal vaccination recommendations", "TREATMENT", 195, 240], ["influenza vaccination", "TREATMENT", 303, 324], ["cord", "ANATOMY", 137, 141]]], ["A recently published systematic review and meta-analysis found that vaccinating women later in pregnancy, at least 15 days before delivery, results in higher influenza-specific maternal antibody concentrations at birth and thus transfer of more antibodies to the unborn child.", [["women", "ORGANISM", 80, 85], ["antibodies", "PROTEIN", 245, 255], ["women", "SPECIES", 80, 85], ["child", "SPECIES", 270, 275], ["meta-analysis", "TEST", 43, 56], ["delivery", "TREATMENT", 130, 138], ["higher influenza-specific maternal antibody concentrations", "PROBLEM", 151, 209]]], ["On the other hand, vaccinating earlier in pregnancy will provide protection against influenza during a longer proportion of the pregnancy, which is beneficial for the pregnant women, but may increase the probability that protection does not last until delivery and that consequently protection is not transferred to the offspring [66].", [["influenza", "DISEASE", 84, 93], ["women", "ORGANISM", 176, 181], ["women", "SPECIES", 176, 181], ["protection", "TREATMENT", 65, 75], ["influenza", "PROBLEM", 84, 93], ["delivery", "TREATMENT", 252, 260]]], ["Additionally, safety data on influenza vaccination during the first trimester of pregnancy are lacking.Influenza ::: Existing maternal vaccination recommendationsMaternal influenza vaccination protects both pregnant women and newborns against the disease.", [["Influenza", "DISEASE", 103, 112], ["women", "ORGANISM", 216, 221], ["newborns", "ORGANISM", 226, 234], ["Influenza", "SPECIES", 103, 112], ["women", "SPECIES", 216, 221], ["influenza vaccination", "TREATMENT", 29, 50], ["pregnancy", "PROBLEM", 81, 90], ["Influenza", "PROBLEM", 103, 112], ["Existing maternal vaccination recommendations", "TREATMENT", 117, 162], ["Maternal influenza vaccination", "TREATMENT", 162, 192], ["the disease", "PROBLEM", 243, 254], ["influenza", "OBSERVATION", 171, 180], ["disease", "OBSERVATION", 247, 254]]], ["Up until now, it is hard to estimate the exact effectiveness of the strategy since studies are conducted in places with different epidemiological background, use influenza vaccines with different composition and are inconsistent in measuring end points as there are laboratory-confirmed influenza, influenza like illness or respiratory infection symptoms\u2026 However, several observational studies and clinical trials already demonstrated that maternal influenza vaccination is effective in preventing laboratory-confirmed influenza in pregnant women [67].", [["respiratory", "ANATOMY", 324, 335], ["influenza", "DISEASE", 287, 296], ["influenza like illness", "DISEASE", 298, 320], ["respiratory infection", "DISEASE", 324, 345], ["influenza", "DISEASE", 450, 459], ["influenza", "DISEASE", 520, 529], ["women", "ORGANISM", 542, 547], ["women", "SPECIES", 542, 547], ["studies", "TEST", 83, 90], ["influenza vaccines", "TREATMENT", 162, 180], ["influenza", "PROBLEM", 287, 296], ["influenza", "PROBLEM", 298, 307], ["respiratory infection symptoms", "PROBLEM", 324, 354], ["several observational studies", "TEST", 365, 394], ["clinical trials", "TEST", 399, 414], ["maternal influenza vaccination", "TREATMENT", 441, 471], ["influenza", "PROBLEM", 520, 529], ["respiratory", "ANATOMY", 324, 335], ["infection", "OBSERVATION", 336, 345]]], ["The duration of passive protection against influenza in the infants depends on the maternal level of antibodies, the amount of antibodies transferred from mother to infant and on how quickly these passively acquired antibodies wane during the first months of life.", [["influenza", "DISEASE", 43, 52], ["infants", "ORGANISM", 60, 67], ["antibodies", "PROTEIN", 101, 111], ["antibodies", "PROTEIN", 127, 137], ["antibodies", "PROTEIN", 216, 226], ["infants", "SPECIES", 60, 67], ["infant", "SPECIES", 165, 171], ["passive protection", "TREATMENT", 16, 34], ["influenza", "PROBLEM", 43, 52]]], ["Studies in South Africa and Bangladesh describe a half-life of vaccine-induced maternal influenza antibodies in the infant of 42\u201350 days corresponding with a protection of approximately 2\u20133 months [64, 65].Maternal vaccination recommendations for future vaccinesGiven the far-reaching potential of maternal immunization for both women and offspring, several new vaccines specifically designed for use in pregnancy are currently under development.", [["influenza antibodies", "DISEASE", 88, 108], ["women", "ORGANISM", 329, 334], ["maternal influenza antibodies", "PROTEIN", 79, 108], ["infant", "SPECIES", 116, 122], ["women", "SPECIES", 329, 334], ["vaccine", "TREATMENT", 63, 70], ["maternal influenza antibodies", "PROBLEM", 79, 108], ["Maternal vaccination recommendations", "TREATMENT", 206, 242], ["future vaccines", "TREATMENT", 247, 262], ["maternal immunization", "TREATMENT", 298, 319], ["several new vaccines", "TREATMENT", 350, 370], ["influenza", "OBSERVATION", 88, 97]]], ["These maternal vaccines have the potential to change the epidemiology of several infectious diseases in pregnant women and their infants and may improve global maternal and neonatal health [68].Maternal vaccination recommendations for future vaccinesUp until now, the strategy of maternal immunization is not used to its full potential in many places.", [["infectious diseases", "DISEASE", 81, 100], ["women", "ORGANISM", 113, 118], ["infants", "ORGANISM", 129, 136], ["women", "SPECIES", 113, 118], ["infants", "SPECIES", 129, 136], ["These maternal vaccines", "TREATMENT", 0, 23], ["several infectious diseases", "PROBLEM", 73, 100], ["Maternal vaccination recommendations", "TREATMENT", 194, 230], ["future vaccines", "TREATMENT", 235, 250], ["maternal immunization", "TREATMENT", 280, 301], ["several", "OBSERVATION_MODIFIER", 73, 80], ["infectious", "OBSERVATION", 81, 91]]], ["Accelerating access to maternal immunization and the development of new maternal vaccines is key.", [["maternal immunization", "TREATMENT", 23, 44], ["new maternal vaccines", "TREATMENT", 68, 89], ["new", "OBSERVATION_MODIFIER", 68, 71]]], ["Therefore, several international bodies are bringing together stakeholders from around the world to create a pathway to enable informed decision-making and rapid launch of maternal vaccines.", [["maternal vaccines", "TREATMENT", 172, 189]]], ["Here, we highlight a few vaccines that are currently in the pipeline.Maternal vaccination recommendations for future vaccinesA first focus for a new vaccine is on respiratory syncytial virus (RSV).", [["respiratory syncytial virus", "DISEASE", 163, 190], ["respiratory syncytial virus", "ORGANISM", 163, 190], ["RSV", "ORGANISM", 192, 195], ["respiratory syncytial virus", "SPECIES", 163, 190], ["respiratory syncytial virus", "SPECIES", 163, 190], ["RSV", "SPECIES", 192, 195], ["a few vaccines", "TREATMENT", 19, 33], ["Maternal vaccination recommendations", "TREATMENT", 69, 105], ["future vaccinesA", "TREATMENT", 110, 126], ["a new vaccine", "TREATMENT", 143, 156], ["respiratory syncytial virus", "PROBLEM", 163, 190]]], ["RSV causes a significant global respiratory disease burden, especially in young infants.", [["respiratory", "ANATOMY", 32, 43], ["RSV", "DISEASE", 0, 3], ["respiratory disease", "DISEASE", 32, 51], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 80, 87], ["infants", "SPECIES", 80, 87], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["a significant global respiratory disease burden", "PROBLEM", 11, 58], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["global", "OBSERVATION_MODIFIER", 25, 31], ["respiratory disease", "OBSERVATION", 32, 51]]], ["Of the more than 30 million RSV childhood cases worldwide, the disease causes 1.4 million hospitalizations in the first year of life and 120,000 deaths before 5 years of age each year [69].", [["deaths", "DISEASE", 145, 151], ["RSV", "ORGANISM", 28, 31], ["RSV", "SPECIES", 28, 31], ["the disease", "PROBLEM", 59, 70]]], ["Currently, vaccination of pregnant women is considered as the most plausible strategy to protect these infants against RSV.", [["RSV", "DISEASE", 119, 122], ["women", "ORGANISM", 35, 40], ["infants", "ORGANISM", 103, 110], ["RSV", "ORGANISM", 119, 122], ["women", "SPECIES", 35, 40], ["infants", "SPECIES", 103, 110], ["RSV", "SPECIES", 119, 122], ["RSV", "PROBLEM", 119, 122]]], ["Several maternal vaccines are currently under various stages of development and could be available within a few years [70].", [["Several maternal vaccines", "TREATMENT", 0, 25]]], ["One of these vaccines, the RSV F nanoparticle vaccine (Novavax\u00ae), was already tested in 4636 pregnant women in an international phase 3 clinical trial.", [["RSV F nanoparticle", "CHEMICAL", 27, 45], ["RSV", "ORGANISM", 27, 30], ["Novavax\u00ae", "SIMPLE_CHEMICAL", 55, 63], ["women", "ORGANISM", 102, 107], ["women", "SPECIES", 102, 107], ["RSV", "SPECIES", 27, 30], ["these vaccines", "TREATMENT", 7, 21], ["the RSV F nanoparticle vaccine (Novavax\u00ae)", "TREATMENT", 23, 64]]], ["Despite the fact that the primary outcomes of the study were not met, the candidate vaccine showed no significant safety issues in pregnant women and their offspring, a good immunogenicity and seroresponse rate in pregnant women, an efficient transplacental antibody transfer with high concentrations of RSV antibodies in the infants at birth and a progressively greater efficacy against severe outcomes of RSV infection in young infants [71].Maternal vaccination recommendations for future vaccinesAnother target for maternal immunization is Group B Streptococcus (GBS).", [["RSV infection", "DISEASE", 407, 420], ["GBS", "DISEASE", 566, 569], ["women", "ORGANISM", 140, 145], ["women", "ORGANISM", 223, 228], ["RSV", "ORGANISM", 304, 307], ["infants", "ORGANISM", 326, 333], ["RSV", "ORGANISM", 407, 410], ["Group B Streptococcus", "ORGANISM", 543, 564], ["RSV antibodies", "PROTEIN", 304, 318], ["women", "SPECIES", 140, 145], ["women", "SPECIES", 223, 228], ["infants", "SPECIES", 326, 333], ["infants", "SPECIES", 430, 437], ["RSV", "SPECIES", 304, 307], ["RSV", "SPECIES", 407, 410], ["the study", "TEST", 46, 55], ["the candidate vaccine", "TREATMENT", 70, 91], ["significant safety issues", "PROBLEM", 102, 127], ["seroresponse rate in pregnant women", "PROBLEM", 193, 228], ["an efficient transplacental antibody transfer", "TREATMENT", 230, 275], ["RSV antibodies", "PROBLEM", 304, 318], ["RSV infection", "PROBLEM", 407, 420], ["Maternal vaccination recommendations", "TREATMENT", 443, 479], ["future vaccines", "TREATMENT", 484, 499], ["maternal immunization", "TREATMENT", 518, 539], ["Group B Streptococcus (GBS", "TEST", 543, 569], ["no", "UNCERTAINTY", 99, 101], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["RSV antibodies", "OBSERVATION", 304, 318], ["RSV infection", "OBSERVATION", 407, 420]]], ["GBS can be found in the vagina or lower gastrointestinal tract of about 10\u201340% of women of reproductive age and is a leading cause of neonatal and infant invasive bacterial disease, often leading to death or neurological sequelae.", [["vagina", "ANATOMY", 24, 30], ["lower gastrointestinal tract", "ANATOMY", 34, 62], ["neurological", "ANATOMY", 208, 220], ["GBS", "DISEASE", 0, 3], ["bacterial disease", "DISEASE", 163, 180], ["death", "DISEASE", 199, 204], ["neurological sequelae", "DISEASE", 208, 229], ["vagina", "ORGAN", 24, 30], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 34, 56], ["tract", "ORGANISM_SUBDIVISION", 57, 62], ["women", "ORGANISM", 82, 87], ["women", "SPECIES", 82, 87], ["infant", "SPECIES", 147, 153], ["GBS", "PROBLEM", 0, 3], ["lower gastrointestinal tract", "PROBLEM", 34, 62], ["neonatal and infant invasive bacterial disease", "PROBLEM", 134, 180], ["death", "PROBLEM", 199, 204], ["neurological sequelae", "PROBLEM", 208, 229], ["vagina", "ANATOMY", 24, 30], ["lower", "ANATOMY_MODIFIER", 34, 39], ["gastrointestinal tract", "ANATOMY", 40, 62], ["invasive", "OBSERVATION_MODIFIER", 154, 162], ["bacterial disease", "OBSERVATION", 163, 180]]], ["GBS infections during pregnancy can lead to stillbirth and premature delivery, puerperal sepsis and other maternal morbidities [72].", [["GBS infections", "DISEASE", 0, 14], ["stillbirth", "DISEASE", 44, 54], ["sepsis", "DISEASE", 89, 95], ["maternal morbidities", "DISEASE", 106, 126], ["GBS infections", "PROBLEM", 0, 14], ["stillbirth", "PROBLEM", 44, 54], ["premature delivery", "PROBLEM", 59, 77], ["puerperal sepsis", "PROBLEM", 79, 95], ["other maternal morbidities", "PROBLEM", 100, 126], ["infections", "OBSERVATION", 4, 14]]], ["Recently, the WHO drafted a \u201cGroup B Streptococcus Vaccine Development Technology Roadmap\u201d with priorities for development, testing, licensure and global availability of GBS vaccines [73].", [["a \u201cGroup B Streptococcus Vaccine", "TREATMENT", 26, 58], ["testing", "TEST", 124, 131], ["GBS vaccines", "TREATMENT", 170, 182]]], ["For the moment, several companies have vaccine candidates against GBS in their pipelines.", [["GBS", "DISEASE", 66, 69], ["vaccine candidates", "TREATMENT", 39, 57], ["GBS", "PROBLEM", 66, 69]]], ["But these vaccines are only in phase 1 or phase 2 clinical trials yet and additional research is needed to get these vaccines on the market [74\u201376].Maternal vaccination recommendations for future vaccinesFinally, vaccine development against cytomegalovirus (CMV) is also proceeding with potential use of the vaccine both before and during pregnancy to benefit both mother and neonate.", [["cytomegalovirus (CMV)", "DISEASE", 241, 262], ["cytomegalovirus", "ORGANISM", 241, 256], ["CMV", "ORGANISM", 258, 261], ["cytomegalovirus", "SPECIES", 241, 256], ["CMV", "SPECIES", 258, 261], ["these vaccines", "TREATMENT", 4, 18], ["these vaccines", "TREATMENT", 111, 125], ["Maternal vaccination recommendations", "TREATMENT", 148, 184], ["future vaccines", "TREATMENT", 189, 204], ["vaccine", "TREATMENT", 213, 220], ["cytomegalovirus", "PROBLEM", 241, 256], ["the vaccine", "TREATMENT", 304, 315]]], ["CMV infection is a major public health priority which causes substantial long-term morbidity, particularly sensorineural hearing loss in newborns [77].", [["CMV infection", "DISEASE", 0, 13], ["sensorineural hearing loss", "DISEASE", 107, 133], ["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["CMV infection", "PROBLEM", 0, 13], ["substantial long-term morbidity", "PROBLEM", 61, 92], ["sensorineural hearing loss in newborns", "PROBLEM", 107, 145], ["infection", "OBSERVATION", 4, 13], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["long-term", "OBSERVATION_MODIFIER", 73, 82], ["morbidity", "OBSERVATION", 83, 92], ["sensorineural hearing loss", "OBSERVATION", 107, 133]]], ["Up until now, progress towards the development of a CMV vaccine has been limited due to an incomplete understanding of the correlates of protective immunity for the fetus.", [["fetus", "ANATOMY", 165, 170], ["CMV", "ORGANISM", 52, 55], ["fetus", "ORGANISM", 165, 170], ["CMV", "SPECIES", 52, 55], ["a CMV vaccine", "TREATMENT", 50, 63]]], ["Additional research within this field in the near future is crucial [78].Maternal vaccination recommendations for future vaccinesAdditional vaccines that can offer protection against other infectious agents including Zika, Ebola, and herpes simplex are only in the developmental phase but certainly have the potential to be successful when being developed and on the market [79].ConclusionImmunizing pregnant women to protect the mother, fetus and infant from infection has increasingly been used over the last decade.", [["fetus", "ANATOMY", 438, 443], ["Zika, Ebola, and herpes simplex", "DISEASE", 217, 248], ["infection", "DISEASE", 460, 469], ["Zika", "ORGANISM", 217, 221], ["Ebola", "ORGANISM", 223, 228], ["herpes simplex", "ORGANISM", 234, 248], ["women", "ORGANISM", 409, 414], ["fetus", "ANATOMICAL_SYSTEM", 438, 443], ["infant", "ORGANISM", 448, 454], ["Ebola", "SPECIES", 223, 228], ["herpes simplex", "SPECIES", 234, 248], ["women", "SPECIES", 409, 414], ["infant", "SPECIES", 448, 454], ["Maternal vaccination recommendations", "TREATMENT", 73, 109], ["future vaccines", "TREATMENT", 114, 129], ["Additional vaccines", "TREATMENT", 129, 148], ["protection", "TREATMENT", 164, 174], ["Zika", "PROBLEM", 217, 221], ["Ebola", "PROBLEM", 223, 228], ["herpes simplex", "PROBLEM", 234, 248], ["infection", "PROBLEM", 460, 469], ["infection", "OBSERVATION", 460, 469]]], ["Currently, vaccines against three diseases, tetanus, pertussis and influenza, are broadly recommended to be safely used during pregnancy.", [["tetanus", "DISEASE", 44, 51], ["pertussis", "DISEASE", 53, 62], ["influenza", "DISEASE", 67, 76], ["vaccines", "TREATMENT", 11, 19], ["three diseases", "PROBLEM", 28, 42], ["tetanus", "PROBLEM", 44, 51], ["pertussis", "PROBLEM", 53, 62], ["influenza", "PROBLEM", 67, 76]]], ["Other vaccines specifically designed for use during pregnancy, e.g. RSV, GBS, and CMV, are in various stages of development.ConclusionSome other vaccines can be considered to reduce a personal risk of a woman and her offspring in case of travelling during pregnancy or potential close contact to a source of infection.", [["GBS", "DISEASE", 73, 76], ["infection", "DISEASE", 308, 317], ["RSV", "ORGANISM", 68, 71], ["CMV", "ORGANISM", 82, 85], ["woman", "ORGANISM", 203, 208], ["woman", "SPECIES", 203, 208], ["RSV", "SPECIES", 68, 71], ["CMV", "SPECIES", 82, 85], ["Other vaccines", "TREATMENT", 0, 14], ["pregnancy", "PROBLEM", 52, 61], ["RSV", "PROBLEM", 68, 71], ["GBS", "TEST", 73, 76], ["CMV", "PROBLEM", 82, 85], ["ConclusionSome other vaccines", "TREATMENT", 124, 153], ["infection", "PROBLEM", 308, 317], ["CMV", "OBSERVATION", 82, 85], ["infection", "OBSERVATION", 308, 317]]], ["In that case, as a general rule, all inactivated and toxoid-based vaccines are considered to be safe to use during pregnancy.", [["toxoid-based vaccines", "TREATMENT", 53, 74]]], ["Due to a theoretical teratogenic risk, live-attenuated vaccines should be avoided in pregnancy.", [["a theoretical teratogenic risk", "PROBLEM", 7, 37], ["live-attenuated vaccines", "TREATMENT", 39, 63]]], ["However, if accidental vaccination occurs, termination of the pregnancy is not advised [80].", [["accidental vaccination", "PROBLEM", 12, 34]]]], "dd35e7a51c3ab7872de124789936b4bf6c513e44": [["Coronavirus disease 19 (COVID-19) is causing severe pneumonia leading to acute respiratory distress syndrome, a condition where prone ventilation for > 12 hours/day has proven beneficial [1] .", [["respiratory", "ANATOMY", 79, 90], ["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 24, 32], ["pneumonia", "DISEASE", 52, 61], ["acute respiratory distress syndrome", "DISEASE", 73, 108], ["COVID-19", "ORGANISM", 24, 32], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 24, 29], ["severe pneumonia", "PROBLEM", 45, 61], ["acute respiratory distress syndrome", "PROBLEM", 73, 108], ["prone ventilation", "TREATMENT", 128, 145], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["pneumonia", "OBSERVATION", 52, 61], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory distress", "OBSERVATION", 79, 99]]], ["Transthoracic echocardiography (TTE) to assess COVID-19-related cardiac complications [2] is very challenging on patients in the prone position.", [["cardiac", "ANATOMY", 64, 71], ["cardiac complications", "DISEASE", 64, 85], ["cardiac", "ORGAN", 64, 71], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Transthoracic echocardiography", "TEST", 0, 30], ["TTE", "TEST", 32, 35], ["COVID", "TEST", 47, 52], ["cardiac complications", "PROBLEM", 64, 85], ["cardiac", "ANATOMY", 64, 71], ["complications", "OBSERVATION", 72, 85], ["very", "OBSERVATION_MODIFIER", 93, 97], ["challenging", "OBSERVATION", 98, 109]]], ["The aim of this study was to examine the feasibility of an innovative use of a transesophageal echocardiography (TEE) probe to perform TTE's on patients with COVID-19 who were invasively ventilated in the prone position.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["this study", "TEST", 11, 21], ["a transesophageal echocardiography", "TEST", 77, 111], ["TEE", "TEST", 113, 116], ["TTE", "TEST", 135, 138], ["COVID", "TEST", 158, 163], ["ventilated", "OBSERVATION", 187, 197]]]]}